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The Harvey-Ras-like tumor suppressor (HRASLS) enzymes are a homologous group of 
proteins belonging to the H-rev107 gene family that are part of a larger papain-like N1pC/P60 
superfamily of vertebrate thiol proteases. Five HRASLS enzymes have been identified in humans, 
with three (Hrasls1,3,5) conserved in rodents. Some HRASLS enzymes have been characterized 
as class II tumor suppressors, but recent studies have focused on their roles in phospholipid 
metabolism. HRASLS enzymes share sequence homology with lecithin:retinol acyltransferases 
(LRATs), including a conserved NCEHFV motif in the C-terminal region that is critical for 
acylation and de-acylation reactions. All members of this enzyme family display varying levels of 
O-transacylase, N-transacylase, and phospholipase A1/2 activity in vitro. However, the 
biochemical function of these enzymes has not been fully explored. I tested the effect of 
overexpressing Hrasls1 in HEK-293 cells, and found a specific increase in total cardiolipin content 
that had not previously been reported. Thus, the aim of this thesis was to investigate a novel role 
for HRASLS1 in phospholipid and, more specifically, cardiolipin metabolism. The first objective 
of this thesis was to define the biochemical function of HRASLS1 in the context of cellular 
phospholipid metabolism. Endogenous HRASLS1 was found to localize to the endoplasmic 
reticulum. Evidence from crude lysates from HEK-293 overexpressing cells, and reticulocyte 
lysates, suggested that HRASLS1 functions as a phosphatidylcholine (PC): monolysocardiolipin 
(MLCL) transacylase in the synthesis of CL. The second objective of this thesis was to investigate 
the effects of Hrasls1 overexpression on cellular phospholipid content and composition in vivo, 
and related effects on mitochondrial physiology. HEK-293 cells overexpressing HRASLS1 had an 
~62% higher content of cardiolipin as compared to controls, but no significant increases in any 
other major phospholipid classes. Interestingly, mitochondrial respiration was impaired in these 
cells, although mitochondrial DNA content was not different, indicating that total mitochondria 
had not decreased. Overexpression of HRASLS1 in HEK-293 cells significantly up-regulated the 
mRNA expression of multiple genes involved in phospholipid biosynthesis, suggesting that 
Hrasls1 overexpression may also indirectly alter cardiolipin metabolism through cell signaling 
that could target transcriptional regulation. HRASLS1 has been demonstrated previously to 
synthesize N-acylphosphatidylethanolamines (NAPEs) in vitro, which increases the down-stream 
synthesis of bioactive N-acylethanolamines (NAEs). However, treatment of cells with 
oleoylethanolamine (OEA), stearoylethanolamine (SEA), or palmitoylethanolamine (PEA) did not 
 vi 
significantly increase cardiolipin content in HEK-293 cells. This suggested either that NAEs do 
not play a significant role in modulating the cardiolipin biosynthetic effects of HRASLS1, or that 
an NAE other than OEA, SEA, or PEA may be involved in mediating the induction of phospholipid 
metabolizing genes in Hrasls1-overexpressing HEK-293 cells. The final objective of this thesis 
was to assess the ability of OEA, one of the most abundant cellular NAEs, to modulate cardiolipin 
content and composition in a model of cellular cardiolipin deficiency. This work was performed 
in parallel with the studies on OEA, SEA, and PEA in HEK-293 cells, and therefore the negative 
results of that work did not inform the choice of NAE species. Cultured B-lymphocytes from an 
individual with Barth Syndrome (BTHS) were utilized as a study model. BTHS is a rare, X-linked 
genetic disorder that stems from mutations in Tafazzin, a cardiolipin fatty acid remodeling enzyme. 
Due to their inability to remodel the fatty acyl chains on cardiolipin following de novo synthesis, 
patients with BTHS have decreased cardiolipin content, which leads to a disease state, including 
heart failure, growth delay, and cyclic neutropenia. BTHS B-lymphocytes treated with 1 M OEA 
exhibited a partial rescue of characteristic growth and cardiolipin deficiencies. This was surprising, 
given that: 1) OEA did not increase cardiolipin in HEK-293 cells, and 2) that a final collaborative 
characterization study found that HEK-293 cells overexpressing Hrasls1 had significantly 
decreased OEA and PEA levels relative to control. Of interest, that study also found that Hrasls1 
overexpression may raise levels of linoleoylethanolamine (LEA), strongly suggesting that future 
studies should examine this target NAE in the context of both cardiolipin synthesis and BTHS 
treatment. Thus, HRASLS1 is a microsomal PC:MLCL transacylase that increases cardiolipin in 
cells. Study of this enzyme and related pathways may provide novel therapeutic targets for 






Thank you to my supervisor, Dr. Robin Duncan, for taking a chance on me when no one else 
would. Robin, your teachings have helped shape me into the scientist I am today, and have made 
me a better person in the process. Thank you for your encouragement and your trust, but most of 
all for your patience. The hundreds of ‘little’ and ‘big’ conversations we have had in your office 
have meant the world to me, and I will surely miss them. I hope you enjoyed reading my 
discussions over the last six years. 
 
Thank you to the members of my thesis committee, Dr. Ken Stark, Dr. Joe Quadrilatero, Dr. Moira 
Glerum, and Dr. Grant Hatch for your helpful insights and interesting discussions on my thesis 
research. A special thank you to Dr. Ken Stark, who has served on every committee and as a 
reference for every scholarship since I started graduate school, six years ago.  
 
Thank you to the many lab mates and members of the Physiology department I have had the honour 
of working with throughout my time at Waterloo. You have all made my time here an absolute 
pleasure. I would like to especially thank the close friends I have gained throughout graduate 
school; to Emily Mardian who became like a sister, and is a great friend and confidant; to Phil 
Marvyn who insisted the lab should always be a fun place to be, even when things weren’t going 
our way; to Juan Jose Aristizabal Henao for always being willing to run ‘just one more 
experiment’; to Darin Bloemberg who pushed me to be a better scientist, just so I could prove him 
wrong; to Ash Hashemi who showed me the beautiful simplicity of chicken and rice; and to Katy 
Moes who taught me to ‘cherish’ good times with good friends. 
 
Thank you to Adam and Lois Galbraith, and Lynn Elwood. Your positivity in the face of Barth 
Syndrome truly helped to show me the importance of my research on making a difference in the 
lives of others, and provided meaningful motivation throughout my PhD.  
 
Of course, I would be remiss if I did not thank Chris Lange. Chris, thank you for all your help in 
making every figure in every one of my manuscripts and posters beautiful, even when it meant 
taking time from your own busy schedule.  
 
Thank you to the Natural Sciences and Engineering Research Council of Canada (NSERC), the 
Barth Syndrome Foundation and the Canada Foundation for Innovation for providing financial 
assistance and funding for the research projects in this thesis. 
 
The biggest thank you goes to my family, who has given me unwavering love and support 
throughout my entire life. Dad, thank you for teaching me the meaning of hard work, and how to 
live life with integrity. Mom, thank you for teaching me to be a more compassionate and 
understanding person. Thank you both for convincing me that I’m on the right path, and to keep 
doing what I love. I would not be where I am today without your love and guidance. Meghan, 
thank you for keeping me in line, even though you’re younger than I am. I’m very proud of you, 
and I am very lucky to have you as a sister. Thank you to Nana, for your love and support. Finally, 
I would like to thank Tamar Dobner for her love, encouragement, and tremendous support. T, 





This thesis is dedicated to my family. To my parents Paul and Ronit Bradley, to my sister 
Meghan, and to my nana Anne.  
  
 ix 
Table of Contents 
Examining Committee Membership ..........................................................................................................ii 
Author’s Declaration ................................................................................................................................. iii 
Statement of Contributions ........................................................................................................................ iv 
Abstract ........................................................................................................................................................ v 
Acknowledgements ....................................................................................................................................vii 
Dedication ................................................................................................................................................. viii 
Table of Contents ........................................................................................................................................ ix 
List of Figures ............................................................................................................................................. xi 
List of Tables ............................................................................................................................................ xiii 
List of Abbreviations ................................................................................................................................ xiv 
Chapter One: General Introduction .......................................................................................................... 1 
Chapter Two: Biochemical Foundations ................................................................................................... 5 
Harvey-Ras-like suppressor (HRASLS) enzymes ...................................................................................... 5 
HRASLS1 ............................................................................................................................................. 8 
HRASLS2 ............................................................................................................................................. 9 
HRASLS3 ............................................................................................................................................. 9 
HRASLS4 ............................................................................................................................................. 9 
HRASLS5 ........................................................................................................................................... 10 
O-Transacylase activity ........................................................................................................................... 10 
Phospholipase activity ............................................................................................................................. 12 
N-transacylase activity ........................................................................................................................ 15 
N-acylethanolamines (NAEs) and their synthesis from NAPEs ......................................................... 17 
Pathways of NAE degradation ............................................................................................................ 21 
Statement of the problem ......................................................................................................................... 21 
Kennedy Pathway of phospholipid and TAG synthesis ........................................................................... 22 
Cardiolipin .............................................................................................................................................. 25 
Tissue-specific molecular cardiolipin composition ................................................................................. 25 
Heart .................................................................................................................................................... 26 
Brain .................................................................................................................................................... 27 
Other tissues ........................................................................................................................................ 28 
Enzymes involved in cardiolipin acyl-chain remodeling ........................................................................ 29 
Tafazzin ............................................................................................................................................... 31 
Monolysocardiolipin-Acyltransferase 1 (MLCL-AT1) ...................................................................... 31 
alpha-Trifunctional Protein (αTFP) .................................................................................................... 32 
ALCAT1 ............................................................................................................................................. 32 
Chapter Three: Methods and Materials .................................................................................................. 43 
Materials ................................................................................................................................................. 43 
Animals .................................................................................................................................................... 43 
Cell Culture and Cell Counting............................................................................................................... 43 
RNA Extraction, Reverse Transcription (RT) and Real-Time (q) PCR ................................................... 44 
Cloning of Full-length HRASLS1 cDNA, HRASLS1-GFP, and generation of HRASLS1 adenovirus .... 48 
Generation of HRASLS1 Recombinant Protein from Reticulocyte Lysates ............................................ 49 
Protein Extraction and Immunoblot Analysis ......................................................................................... 49 
 x 
Subcellular Fractionation ....................................................................................................................... 50 
Lipid Extraction, Thin Layer Chromatography (TLC), and Gas Chromatography (GC) ...................... 52 
In-vitro Acyl-CoA:Lysophospholipid Acyltransferase Enzyme Assays ................................................... 53 
High-Resolution Mitochondrial Respirometry ........................................................................................ 54 
Metabolic Radiolabelling Experiments in NAE-treated cells ................................................................. 56 
NAE treatment of HEK-293 cells or B-lymphocytes ............................................................................... 56 
N-acylethanolamine and 1-AG and 2-AG sample extractions and liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) analysis ........................................................................................................ 56 
Statistical Analysis .................................................................................................................................. 57 
Chapter Four: Thesis Study I – Cellular and biochemical characterization of HRASLS1 ................ 58 
Introduction and Study Rationale............................................................................................................ 58 
Objectives and Hypotheses ...................................................................................................................... 60 
Study Design ............................................................................................................................................ 61 
Results ..................................................................................................................................................... 62 
Discussion ............................................................................................................................................... 71 
Conclusion ............................................................................................................................................... 75 
Chapter Five: Thesis Study II – Investigation of the in vivo role of HRASLS1 in cardiolipin 
metabolism.................................................................................................................................................. 76 
Introduction and Study Rationale............................................................................................................ 76 
Objectives and Hypotheses ...................................................................................................................... 77 
Study Design ............................................................................................................................................ 79 
Results ..................................................................................................................................................... 80 
Discussion ............................................................................................................................................... 91 
Conclusion ............................................................................................................................................... 97 
Chapter Six: Thesis Study III – Effects of OEA on CL metabolism and proliferation of cultured B-
Lymphocytes from an Individual with Barth Syndrome ....................................................................... 98 
Introduction and Study Rationale............................................................................................................ 98 
Study Design ............................................................................................................................................ 99 
Objectives and Hypotheses .................................................................................................................... 100 
Results ................................................................................................................................................... 102 
Discussion ............................................................................................................................................. 110 
Conclusion ............................................................................................................................................. 114 
Chapter Seven: Thesis Summary, Integrated Discussion, and Future Perspectives ......................... 115 
Thesis Summary ..................................................................................................................................... 115 
Integrated Discussion and Future Perspectives .................................................................................... 119 
References ................................................................................................................................................. 124 
Appendices................................................................................................................................................ 146 
Appendix A: Schematic of determining relative protein concentrations in protein generated from the 
TnT Coupled Reticulocyte Lysate System........................................................................................... 146 
Appendix B: Sequence alignment of Hrasls1 long and short transcript variants ................................. 147 
Appendix C: Metabolic label of HEK-293 cells with [14C] palmitate and treatment with NAE ........... 153 
Appendix D: List of buffers and components ........................................................................................ 154 
Appendix E: CL in HEK-293 cells as expressed as a percentage of total cellular PL ......................... 156 
Appendix E: Relative percent of fatty acid content in HEK-293 cells overexpressing control or 




List of Figures 
Figure 1: Example schematic of a glycerophospholipid structure. ................................................. 2 
Figure 2: Sequence alignment of human HRASLS and LRAT amino acid sequences. ................. 6 
Figure 3: The catalytic mechanism of HRASLS enzymes. ............................................................ 7 
Figure 4: PC O-transacylase/O-acyltransferase activity of HRASLS enzymes. .......................... 11 
Figure 5: Schematic of phospholipase A1/2 activity .................................................................... 13 
Figure 6: Illustration of N-transacylase activity ........................................................................... 15 
Figure 7: Illustration of the phosphodiesterase-transacylation pathway of NAE synthesis. ........ 18 
Figure 8: The Kennedy Pathway of glycerophospholipid and triacylglycerol synthesis.............. 24 
Figure 9: Enzymes involved in cardiolipin remodeling ................................................................ 33 
Figure 10: Schematic of the study design of Thesis Study I......................................................... 61 
Figure 11: Hrasls1 is highly expressed in the brain and heart. ..................................................... 67 
Figure 12: HRASLS1 localizes predominately to the endoplasmic reticulum. ............................ 68 
Figure 13: Post-nuclear crude cell lysates derived from HEK293 cells infected with adenoviral 
Hrasls1 or control adenovirus for 48 hours have both acyl-CoA-dependent LPI, MLCL, and 
DLCL acyltransferase, and also as a di-oleoyl PC:MLCL transacylase. ...................................... 69 
Figure 14: Preliminary testing of acyl-CoA-dependent MLCL O-acyltransferase activity and 
PC:MLCL O-transacylase activity of reticulocyte lysates overexpressing HRASLS1 or empty 
vector (control).............................................................................................................................. 70 
Figure 15: Schematic of the study design of Thesis Study II ....................................................... 79 
Figure 16: Adenoviral overexpression of HRASLS1 in HEK-293 cells increases cellular content 
of cardiolipin. ................................................................................................................................ 85 
Figure 17: Adenoviral overexpression of HRASLS1 in HEK-293 cells significantly reduces 
mitochondrial respiration, but does not alter H2O2 production or mtDNA content...................... 86 
Figure 18: HRASLS1 overexpression in HEK-293 cells significantly increases the expression of 
genes involved in phospholipid synthesis and remodeling. .......................................................... 87 
Figure 19: HRASLS1 overexpression in HEK-293 cells significantly increases the mRNA 
expression of PPAR and TRPV1................................................................................................ 88 
Figure 20: NAE treatment does not increase endogenous CL content in HEK-293 cells. ........... 89 
Figure 21: Adenoviral overexpression of HRASLS1 in HEK-293 cells significantly reduces PEA 
and OEA content. .......................................................................................................................... 90 
Figure 22: Schematic of the study design of Thesis Study III ...................................................... 99 
Figure 23: OEA treatment partially rescues CL content in BTHS-derived B-lymphocytes....... 105 
Figure 24: Fatty acyl profiles of CL isolated from healthy control B-lymphocytes and BTHS B-
lymphocytes with or without OEA treatment. ............................................................................ 106 
Figure 25: OEA treatment partially rescues the growth deficit observed in BTHS B-lymphocytes
..................................................................................................................................................... 107 
Figure 26: Expression of phospholipid biosynthetic genes in vehicle-treated healthy control and 
BTHS B-lymphocytes. ................................................................................................................ 108 
Figure 27: Expression of phospholipid biosynthetic genes in healthy control and BTHS B-
lymphocytes treated with 1 M OEA. ........................................................................................ 109 
 
Appendix Figure 1: Schematic to determine relative protein concentrations from reticulocyte 
lysates. ......................................................................................................................................... 146 
Appendix Figure 2: Protein alignment of long and short Hrasls1 transcript variants ................ 147 
Appendix Figure 3: Nucleotide alignment of long and short Hrasls1 transcript variants. ......... 148 
 xii 
Appendix Figure 4: Metabolic treatment of HEK-293 cells with [14C] palmitate and NAE does 
not significantly increase [14C]cardiolipin content. .................................................................... 153 
Appendix Figure 5: CL as a percentage of total cellular PL in HEK-293 cells overexpressing 
control or HRASLS1................................................................................................................... 156 
Appendix Figure 6: HRASLS1 overexpression in HEK-293 cells does not significantly alter 




List of Tables 
Table 1: Sequence homology of human HRASLS enzymes ........................................................ 10 
Table 2: Summary of the most abundant fatty acyl species found in cardiolipin in mammalian 
tissues ............................................................................................................................................ 29 
Table 3: Influence of dietary intervention on cardiolipin content and fatty acyl profile. ............. 38 
Table 4: List of primer sequences used for semi-quantitative gene expression experiments ....... 46 
Table 5: List of human primer sequences used in qPCR experiments ......................................... 47 
Table 6: Summary of key findings and novel contributions ....................................................... 118 
  
 xiv 
List of Abbreviations 
 
1, 2-DAG – 1, 2-diacylglcyerol 
1-AG – 1-arachidonylglycerol 
2-AG – 2-arachidonylglycerol 
TFP – -trifunctional protein 
ACSL4 – acyl-CoA synthase long chain family member 4 
AEA – anandamide 
AGPAT – acylglycerophosphate acyltransferase 
ALA – -linolenic acid 
ALCAT1 – acyl-CoA:lysocardiolipin acyltransferase 1  
AdPLA – adipose-specific phospholipase A2  
BD – basal diet 
BTHS – Barth Syndrome 
CB1 – cannabinoid receptor of the central type  
CB2 – cannabinoid receptor of the peripheral type  
CCCP – carbonyl cyanide m-chlorophenyl hydrazone 
CDP-DAG – cytidine diphosphate diacylglycerol  
CDS – phosphatidate cytidylyltransferase  
CL – cardiolipin  
CL-ND – cardiolipin nanodisk  
CLS – cardiolipin synthase 
Ca-NAT – calcium-dependent N-acyltransferase  
Co-IP – co-immunoprecipitation  
DAG – diacylglycerol  
DGAT – diacylglycerol acyltransferase 
DHA – docosahexaenoic acid 
DHEA – docosahexaenoyl ethanolamine  
DLCL – dilysocardiolipin 
DTT – dithiothreitol  
ER – endoplasmic reticulum 
ERT – enzyme replacement therapy 
ETC – electron transport chain 
FAAH – fatty acid amide hydrolase 
FBS – fetal bovine serum  
FISH – fluorescent in situ hybridization  
GC – gas chromatography 
GDE1 – glycerophosphodiester phosphodiesterase 1  
GFP – green fluorescent protein 
GP-NAE – glycerophospho-N-palmitoyl ethanolamine  
GPAT – glycerol-3-phosphate acyltransferase  
GPR119 – G-protein coupled receptor 119 
GPR55 – G-protein coupled receptor 55 
HCO – hydrogenated coconut oil  
HEK-293 – human embryonic kidney 293 cells 
HRASLS – Harvey-ras like suppressor 
 xv 
HUFA – highly unsaturated fatty acid 
IFU – infectious units 
iNAT – calcium-independent N-acyltransferase 
LEA – linoleoylethanolamine 
LPA – lysophosphatidic acid 
LPAAT – lysophosphatidic acid acyltransferase 
LPC – lysophosphatidylcholine 
LPE – lysophosphatidylethanolamine  
LPG – lysophosphatidylglycerol  
LPI – lysophosphatidylinositol  
LPS – lysophosphatidylserine  
LRAT – lecithin:retinol acyltransferase  
LRT – lipid replacement therapy  
LS-MS/MS – liquid chromatography tandem mass spectrometry 
MAM – mitochondrial-associated ER membranes 
MHC – major histocompatibility complex  
MLCL – monolysocardiolipin  
MLCL-AT1 – monolysocardiolipin acyltransferase  
MOI – multiplicity of infection  
MT-ND1 – NADH-ubiquinone oxidoreductase chain 1  
MT-TL1- mitochondrially encoded tRNA leucine 1  
MUFA – monounsaturated fatty acid 
MudPIT – multidimensional protein identification technology  
NAAA – N-acylethanolamine acid amidase  
NAE – N-acylethanolamine 
NAPE – N-acylphosphatidylethanolamine  
NAPE-PLD – N-acylphosphatidylethanolamine phospholipase D  
NPPE – N-palmitoyl phosphatidylethanolamine  
OEA – oleoylethanolamine  
P/G/M – pyruvate/glutamate/malate 
PA – phosphatidic acid 
PAP – phosphatidate phosphatase 
PC – phosphatidylcholine  
PDH – pyruvate dehydrogenase 
PE – phosphatidylethanolamine 
PEA – palmitoylethanolamine  
PG – phosphatidylglycerol  
PGP – phosphatidylglycerol phosphate  
PI – phosphatidylinositol  
PIP –phosphatidate phosphatase  
PLA/AT – phospholipases/acyltransferases 
PLA2GXVI – phospholipase A2 group XVI 
PLC – phospholipase C  
PLS3 – phospholipid scramblase 3 
PPAR - peroxisome proliferator-activated receptor alpha 
PS – phosphatidylserine  
 xvi 
PSS1- phosphatidylserine synthase 1  
PSS2 – phosphatidylserine synthase 2  
PTPN22 – protein tyrosine phosphatase, non-receptor type 22  
PUFA – polyunsaturated fatty acid 
rAAV – recombinant adeno-associated virus  
RARRES3 – retinoic acid receptor responder protein 3  
RIG1 – retinoic acid-inducible gene 1  
RLP1 – rat lecithin:retinol acyltransferase-like protein 1 
ROS – reactive oxygen species  
ROX – residual oxygen consumption 
RPMI – Roswell Park Memorial Institute medium 
RT-qPCR – real-time reverse transcriptase PCR 
SCD1 – stearoyl-CoA desaturase 1 
SEA – stearoylethanolamine  
SFA – saturated fatty acid 
SHIP1 - src homology 2 domain-containing inositol-5-phosphatase 1 
sPLA2 - group Ib secretory phospholipase A2  
sn – stereospecifically numbered 
SUIT – substrate uncoupled inhibitor titration  
TAG – triacylglycerol  
TAZ – tafazzin  
TAZ-KD – tafazzin knock-down mice 
TAZ-KO – tafazzin knockout mice 
TFP – trifunctional protein  
TIG3 - tazarotene-induced gene 3  
TLC – thin layer chromatography  
TMPD - N,N,N′,N′-tetramethyl-p-phenylenediamine 
TRPV1 – transient vanilloid receptor type 1 
UFA – unsaturated fatty acid 





 The maintenance of cellular homeostasis is dependent on the unique composition of 
biological membranes. The principal framework of all eukaryotic membranes is the lipid bilayer, 
a dynamic, semi-fluid membrane that is composed primarily of phospholipids. Phospholipids are 
amphipathic molecules comprised of both polar sections, i.e. a glycerol ‘backbone’, and a 
phosphate ‘head group’, and non-polar sections, i.e. fatty acyl ‘tails’ (see Figure 1 for a general 
schematic of phospholipid structure). The initial fatty acyl composition of de novo synthesized 
phospholipids is regulated by the specific glycerophosphate-acyltransferase and acyl-
glycerophosphate acyltransferase enzymes involved, which each have their own substrate 
specificities. Typically, however, phospholipids are remodeled to contain saturated fatty acids 
(SFA) esterified at the stereospecifically numbered 1st carbon (sn-1) position, and unsaturated fatty 
acids (UFA) esterified at the sn-2 position [1], although this can be variable depending on the 
individual phospholipid. The third carbon is esterified to a phosphate with a polar head group (R) 
attached. The type of polar head group will determine the class of phospholipid. For example, a 
choline head group or ethanolamine head group would result in classification of this phospholipid 
as phosphatidylcholine (PC), or phosphatidylethanolamine (PE), respectively. If no polar head 
group is attached (i.e. R=H, Figure 1), the phospholipid is a phosphatidic acid (PA). Thus, based 
on variation in the fatty acyl species, positional specificities, and polar head groups, the array of 






Figure 1: Example schematic of a glycerophospholipid structure. 
Glycerophospholipids contain a three-carbon glycerol backbone, with fatty acids present at the 
stereospecifically numbered 1st carbon position (sn-1), and sn-2 (2nd carbon) positions. In this 
example, the sn-1 position is esterified with C16:0, and the sn-2 position is esterified with C18:1n-
9. The third carbon is esterified to a phosphate with a polar head group (R) attached. As no polar 
head group is attached (i.e. R=H), the phospholipid is phosphatidic acid.  
 
Phospholipid composition in cellular membranes varies not only between different cell 
types [2-4], but also within different regions of a single cell membrane, and within different 
organelles from the same cell, and this diversity is critical for life [5, 6]. As the primary structural 
component of the lipid bilayer, phospholipids play important roles in cellular processes mediated 
by cell membranes, including the regulation of integral membrane protein function [7], cell-to-cell 
communication [8], and signal transduction cascades [9-11]. Plasma and organellar membranes 
have unique phospholipid compositions, which ultimately affect function. For example, the plasma 
membrane of most mammalian cells is primarily composed of phosphatidylcholine (PC), 
phosphatidylethanolamine (PE) [5, 12], the two most abundant classes of phospholipids in 
mammalian cells. The inner membrane of mitochondria, however, contains cardiolipin (CL), a 
phospholipid not present in the plasma membrane of mammalian cells [5]. The presence of CL in 
the inner mitochondrial membrane is critical for unique mitochondrial processes including 
oxidative phosphorylation [13], and loss of this phospholipid can lead to impaired mitochondrial 
respiration, mitochondrial degeneration, and ultimately, cell death [14]. 
Phospholipids are thought to be synthesized primarily in the endoplasmic reticulum (ER), 
where most known enzymes involved in the de novo biosynthesis of phospholipids reside [15]. 
However, growing evidence in the literature has now identified less-traditional sites of 
phospholipid synthesis and fatty acyl remodeling, including, but not limited to, the mitochondria 
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[3], the Golgi apparatus [16], and the mitochondria-associated ER membranes (MAM) [17]. The 
discovery of new enzymes involved in phospholipid metabolism is therefore anticipated in 
association with these findings. Additionally, the relatively recent molecular and biochemical re-
examination of several enzyme families has begun redefining the known function of enzymes that 
were not previously believed to be involved in phospholipid metabolism. This work has been 
facilitated by data from the human genome project, which allowed for the identification of proteins 
with sequence homology to known phospholipid metabolizing enzymes. Reporting of these roles 
is sporadic, and thus our understanding of phospholipid metabolism is currently incomplete. As 
such, the physiological and biochemical significance of many of these enzymes are unknown and 
warrant investigation. 
In the context of these regards, the overall aim of this thesis was to investigate a novel role 
for Harvey-Ras-like suppressor 1 (HRASLS1) and its downstream bio-derivatives in phospholipid 
metabolism. Thus, the first objective of this thesis was to define the cellular and biochemical 
functions of HRASLS1 in the context of phospholipid metabolism, and expand upon the current 
literature. Analysis of tissue and cellular localization, as well as detailed in vitro enzymological 
experiments were utilized to complete this objective. Through these experiments, a novel function 
for HRASLS1 in cardiolipin metabolism was discovered. Specifically, HRASLS1 can function as 
a phosphatidylcholine (PC): monolysocardiolipin (MLCL) transacylase in the synthesis of CL. 
The second objective of this thesis was to assess the ability of HRASLS1 to modulate cellular 
phospholipid content and composition in vivo. For this objective, I investigated alterations in gene 
expression, cellular lipid profiles, and mitochondrial function stemming from HRASLS1 
overexpression in cultured HEK-293 cells. The results of this work confirmed an in vivo role for 
HRASLS1 in cardiolipin metabolism. The final objective of this thesis was to assess the ability of 
N-acylethanolamines (NAE) to modulate cardiolipin content and composition in a model of 
cardiolipin deficiency. In addition to transacylase activity, HRASLS1 also has N-acyltransferase 
activity, which contributes to the production of downstream NAE bio-derivatives. Cultured B-
lymphocytes taken from an individual with Barth Syndrome (BTHS) were utilized as a study 
model. BTHS is a rare, X-linked genetic disorder that stems from mutations in Tafazzin, a 
cardiolipin fatty acid remodeling enzyme. Due to their inability to remodel the fatty acyl chains on 
cardiolipin following de novo synthesis, patients with BTHS have decreased cardiolipin content, 
which leads to a disease state. BTHS B-lymphocytes treated with 1 M of oleoylethanolamine 
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(OEA), a species of NAE, exhibited a partial rescue of characteristic growth and cardiolipin 
deficiencies. Thus, HRASLS1 and its downstream bioactive products, NAEs, represent a new 







Harvey-Ras-like suppressor (HRASLS) enzymes 
The Harvey-Ras-like tumor suppressor (HRASLS) enzymes are a homologous group of 
proteins that are a part of a larger papain-like N1pC/P60 superfamily of vertebrate thiol proteases 
[18, 19]. Belonging to the H-rev107 gene family, some HRASLS enzymes have been characterized 
as class II tumor suppressors [20], a class of enzymes that can reversibly down-regulate cellular 
growth, while themselves remaining unchanged or un-mutated during cancer [19-26]. To date, five 
HRASLS family members have been found in humans (HRASLS1-5) [24, 27-31], with three of 
these enzymes (HRASLS1, 3, 5) conserved in rodents as well [32-36]. The HRASLS gene family 
has been mapped to the human chromosomal region between 11q12.3 and 13.1 [28], with the 
exception of HRASLS1, which is localized to 3q28 → q29 [27]. In mice, the HRASLS gene family 
is mapped to chromosome 16 (Hrasls1) [37] and chromosome 19 (Hrasls3 and Hrasls5) [38, 39].  
Besides their described function as class II tumor suppressors, HRASLS enzymes are 
reported to play roles in myriad biological processes, yet, their physiological significance is not 
fully understood. A recent study has implicated HRASLS enzymes in peroxisome metabolism 
[40]. Uyama et al. (2017) observed that overexpression of HRASLS3 in HEK-293 cells was 
associated with peroxisomal dysfunction by either direct phospholipase activity of peroxisome 
membrane lipids, or by inhibiting the formation of nascent peroxisomes [40]. Alteration or loss of 
HRASLS enzymes has also been implicated in genetic disorders including Poland Syndrome, a 
rare disorder characterized by hypoplasia/aplasia of the pectoralis major muscle [41]. In 
monozygotic twins presenting with Poland Syndrome, loss of HRASLS2-5 due to a heterozygous 
deletion event was observed, likely signifying a role for these enzymes in the pathogenesis of this 
disorder.  
HRASLS enzymes share sequence homology with lecithin:retinol acyltransferases 
(LRATs) [18, 42], including a conserved NCEHFV motif in the C-terminal region that is critical 
for acylation and de-acylation reactions [36] (see Figure 2 for amino acid alignment of HRASLS 
and LRAT sequences).  
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Figure 2: Sequence alignment of human HRASLS and LRAT amino acid sequences.  
Figure adapted from Mardian et al. (2015) [19]. Sequence alignment was performed using 
ClustalOmega [43]. The NCEHFV motif (highlighted in yellow) is critical for acylation/de-
acylation activity, and the additional two sites in the catalytic triad are highlighted in blue and 
bolded. Conserved residues are highlighted in green, and homologous residues are highlighted in 
grey. The C-terminal hydrophobic transmembrane domain is underlined. 
 
The conserved cysteine residue found within the NCEHFV motif serves as an anchoring 
point for both acyltransferase and hydrolase reactions, and is part of a catalytic triad along with 
two histidine residues [18]. In this reaction, the first histidine residue acts to transiently acylate the 
cysteine residue by causing a nucleophilic attack by the anionic sulfur of the deprotonated cysteine 
Hs_HRASLS1      -----MVRASCRLGSARTPSP-------------ARRPPGVRASQSRGGAAGTVSAWRRW 42 
Hs_HRASLS2      ------------------------------------------------------------ 0 
Hs_HRASLS3      ------------------------------------------------------------ 0 
Hs_HRASLS4      ------------------------------------------------------------ 0 
Hs_HRASLS5      MGLSPGAEGEYALRLPRIPPPLPKPASRTAGTGPKDQPPALRRSAVPHSEES--VGFAA- 57 
Hs_LRAT         ------------------------------------------------------------ 0 
                                                                             
 
Hs_HRASLS1      CWRWPWRTAPSDGWRLPPGCLPGTDGVVPRPPAARSAA-ARPRETPGHTQLPPGARRRPR 101 
Hs_HRASLS2      ------------------------------------------------------------ 0 
Hs_HRASLS3      ------------------------------------------------------------ 0 
Hs_HRASLS4      ------------------------------------------------------------ 0 
Hs_HRASLS5      LVQLP-------AKQPPPGTLEQGRSIQQGEKAVVSLE-TTPSQKADWSSIP-------K 102 
Hs_LRAT         --------------------------MKNPMLEVVSLLLEKLLLISNFTLFSSGAAGEDK 34 
                                                                             
 
Hs_HRASLS1      LESEMAFNDCFSLNYPGNPCPGDLIEVFRPGYQHWALYLGDGYVINIAPVDGIPA-SFT- 159 
Hs_HRASLS2      ----------M-ALARPRPRLGDLIEISRFGYAHWAIYVGDGYVVHLAPASEIAGAGAA- 48 
Hs_HRASLS3      ----------M-RAPIPEPKPGDLIEIFRPFYRHWAIYVGDGYVVHLAPPSEVAGAGAA- 48 
Hs_HRASLS4      ----------M-ASPHQEPKPGDLIEIFRLGYEHWALYIGDGYVIHLAPPSEYPGAGSS- 48 
Hs_HRASLS5      PENEGKLIKQA-AEGKPRPRPGDLIEIFRIGYEHWAIYVEDDCVVHLAPPSEEFEVG--- 158 
Hs_LRAT         GRN--------SFYETSSFHRGDVLEVPRTHLTHYGIYLGDNRVAHMMPDILLALTDDMG 86 
                                     **::*: *    *:.:*: *. * :: *       .    
 
Hs_HRASLS1      S----------AKSVFSSKALVKMQLLKDVVGNDTYRINNKYDETY--PPLPVEEIIKRS 207 
Hs_HRASLS2      S----------VLSALTNKAIVKKELLSVVAGGDNYRVNNKHDDRY--TPLPSNKIVKRA 96 
Hs_HRASLS3      S----------VMSALTDKAIVKKELLYDVAGSDKYQVNNKHDDKY--SPLPCSKIIQRA 96 
Hs_HRASLS4      S----------VFSVLSNSAEVKRERLEDVVGGCCYRVNNSLDHEY--QPRPVEVIISSA 96 
Hs_HRASLS5      S----------ITSIFSNRAVVKYSRLEDVLHGCSWKVNNKLDGTY--LPLPVDKIIQRT 206 
Hs_LRAT         RTQKVVSNKRLILGVIVKVASIRVDTVEDFAYGANILVNH-LDESLQKKALLNEEVARRA 145 
                             . : . * :: . :  .  .    :*:  *          . :   : 
 
Hs_HRASLS1      EFVIGQEVAYNLLVNNCEHFVTLLRYGEGVSEQANRAISTVEFVTAAV---GVFSFLGLF 264 
Hs_HRASLS2      EELVGQELPYSLTSDNCEHFVNHLRYGVSRSDQVTGAVTTVGVAAGLL---AAASLVGIL 153 
Hs_HRASLS3      EELVGQEVLYKLTSENCEHFVNELRYGVARSDQVRDVIIAASVAGMGL---AAMSLIGVM 153 
Hs_HRASLS4      KEMVGQKMKYSIVSRNCEHFVTQLRYGKSRCKQVEKAKVEVGVATAL----GILVVAGCS 152 
Hs_HRASLS5      KKMVNKIVQYSLIEGNCEHFVNGLRYGVPRSQQVEHALMEGAKAAGAV---ISAVVDSIK 263 
Hs_LRAT         EKLLG-FTPYSLLWNNCEHFVTYCRYGTPISPQSDKFCETVKIIIRDQRSVLASAVLGLA 204 
                : ::.    *.:   ******.  ***   . *                      . .   
 
Hs_HRASLS1      PKG-QRAKYY---------------- 273 
Hs_HRASLS2      LARSKRERQ----------------- 162 
Hs_HRASLS3      FSRNKRQKQ----------------- 162 
Hs_HRASLS4      FAIRRYQKKATA-------------- 164 
Hs_HRASLS5      ------PKPITA-------------- 269 
Hs_LRAT         SIVCTGLVSYTTLPAIFIPFFLWMAG 230 
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residue on the sn-1 acyl chain of the phospholipid. This results in the formation of a thioester 
intermediate, while the second histidine acts to stabilize the correct imidazole ring of the first 
histidine [18, 36]. The intermediate is then cleaved into a lysophospholipid and an enzyme-fatty 
acyl intermediate. The enzyme-fatty acyl intermediate can transfer the fatty acyl to 
phosphatidylethanolamine, making N-acylphosphatidylethanolamines (NAPEs), or to a 
lysophospholipid, making phospholipid, or can hydrolyze the enzyme-acyl thioester bond to 
release a free fatty acid [19]. An illustration of this catalytic mechanism is found in Figure 3. 
 
Figure 3: The catalytic mechanism of HRASLS enzymes. 
Figure adapted from Mardian, Bradley and Duncan (2015) [19]. The conserved cysteine of 
HRASLS enzymes is acylated by the first histidine residue, resulting in the formation of a thioester 
intermediate. The thioester intermediate is hydrolyzed into an enzyme-fatty acyl intermediate, and 
a lysophospholipid. From here, the enzyme-fatty acyl intermediate can be further hydrolyzed into 
free fatty acids, NAPE, or phospholipids.  
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Similar to the mechanism employed by LRAT in de-acylating PC at the sn-1 position to 
esterify the fatty acyl species onto the hydroxyl group of all-trans retinol [40, 44] to form retinyl 
ester, mass spectrometry analysis has demonstrated that HRASLS family members predominantly 
utilize a fatty acyl from the sn-1 position of PC in the generation of glycerophospholipids [18]. 
Thus, in this context, HRASLS enzymes have been reported to play important roles in 
phospholipid metabolism [45], specifically due to their demonstrated in vitro abilities to act as 
both O- and N-acyltransferases, and as phospholipases [45]. While the HRASLS enzyme family 
is known by many names, their enzymatic functions in lipid metabolism have garnered a new 
name: PLA/ATs (phospholipases A1/2/acyltransferases) [26, 36, 46]. 
Since HRASLS enzymes can encode multiple complex enzymatic functions, an initial 
summary of each enzyme’s discovery and characterization is summarized below. Following these 
summaries, a comprehensive review of the major enzymatic functions of HRASLS enzymes 




HRASLS1, originally known as A-C1, and also known as PLA/AT1, was initially cloned 
and characterized in mice in 1999 by Akiyama and colleagues, and in humans in 2001 by Ito et al. 
[27]. HRASLS1 was discovered through comparative display between two murine cell lines: 
embryonic fibroblast C3H10T1/2 and chondrogenic ATDC5 [33]. The murine Hrasls1 gene 
encodes for a protein that is 167 amino acids in length and shows 46% homology with a rat gene 
known as H-rev107, now known as HRASLS3 [33]. Akiyama et al. determined that murine 
Hrasls1 is ubiquitously expressed, albeit most highly in skeletal muscle, heart, brain, and bone 
marrow [33], a finding that has been corroborated by the work of Hussain et al. (2016) [47]. 
However, this expression profile varies slightly in humans, as the content of HRASLS1 is 
relatively low in most tissues other than the testes, skeletal muscle, and heart [27, 45]. 
Chromosomal mapping by fluorescent in situ hybridization (FISH) analysis found that the human 
HRASLS1 gene localizes to 3q28 → q29 [33]. Subcellular analysis indicated that HRASLS1 
localizes to the cytoplasm, and the peri-nuclear region of transfected COS-7 cells, with no 




HRASLS2 was initially cloned from SW40 human colon cancer cells and characterized in 
2008 [28]. Shyu et al. demonstrated that HRASLS2, also known as PLA/AT2, is highly expressed 
in the gastrointestinal system, specifically in the small intestine, but also shows expression in the 
kidney and trachea as well [28]. The coding region of HRASLS2 encodes for an 18 kDa protein 
that is comprised of 162 amino acids, and shares 47 and 69% protein sequence homology with 
HRASLS1 and HRASLS3, respectively [28]. Wildtype HRASLS2 protein transfected into HtTA 
cells preferentially localizes in a perinuclear pattern with some expression in the cytoplasm as 
well, whereas both C- and N-truncated HRASLS2 protein are found equally between the 
cytoplasm and the nucleus [28]. Like other HRASLS enzymes, HRASLS2 has been observed to 
exhibit anti-Ras activity, as well as growth inhibitory activity in cancer cells [28]. In 2012, the 
crystal structure of HRASLS2 was solved by Golczak and colleagues, demonstrating that this 
enzyme contains three -helices, and four antiparallel -sheets [18].  
 
HRASLS3 
HRASLS3 was the first member of the HRASLS enzyme family to be cloned and 
characterized [32]. Also known as H-rev107, and adipose-specific phospholipase A2 (AdPLA) 
[48], Hrasls3 was identified through subtractive hybridization in H-ras transformed rat fibroblasts 
[32]. Human HRASLS3 shares 46% protein sequence homology with human HRASLS1. This 
enzyme, like other members of the HRASLS family, has been reported to suppress growth in 
cancer cell lines [20, 25, 32], and is thus identified as a class II tumour suppressor. Further analysis 
of HRASLS3 demonstrated that although it is found in all tissues examined thus far, it is expressed 
at highest levels in adipocytes [48]. The crystal structure of HRASLS3 was published at the same 
time as HRASLS2 by the same group, and indicated that like HRASLS2, HRASLS3 contains three 
-helices, and four antiparallel -sheets [18].  
 
HRASLS4 
HRASLS4 was identified on three separate occasions and classified under three alternative 
names: tazarotene-induced gene 3 (TIG3) [29], retinoid-inducible gene 1 (RIG1) [30], and retinoic 
acid receptor responder 3 (RARRES3) [24]. HRASLS4 shares high sequence homology with 
HRASLS3/AdPLA, and inhibits H-Ras-mediated signaling [28, 49, 50], and also shares 48% 
protein sequence homology with HRASLS1. Interestingly, while HRASLS4 is anchored to both 
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the endoplasmic reticulum and the Golgi apparatus, the anti-cancer effects of this protein are 
limited to effects mediated within the Golgi, as only Golgi-targeted HRASLS4 induces apoptosis 
in cancer cells [49]. The NMR structure of HRASLS4 was published in 2015 by Wei et al., 
indicating that the overall structure of the N-terminal domain of HRASLS4 is very similar to that 
of HRASLS3 [51]. However, HRASLS4 has less flexible C- and N-terminal domains than that of 
HRASLS3, which may result in functional differences between the two enzymes [51]. 
 
HRASLS5  
Originally named rat LRAT-like protein (RLP1) for similarities in its sequence homology 
to LRAT, HRASLS5 was discovered in 2007 as part of an effort to identify enzymes involved in 
the generation of NAPEs [31]. HRASLS5 shares 45% protein sequence homology with 
HRASLS1. Studied in rats, this enzyme shows highest expression in testes [31, 34] and is proposed 
to play an important role in spermatogenesis in addition to its proposed role as a tumor suppressor 
[34]. However, the physiological significance of HRASLS5, and whether it does indeed possess 
anti-cancer activities similar to the other members of the HRASLS family, is still unknown [34]. 
Sequence homology between the human HRASLS enzymes is shown in Table 1. 

































48% 57% 51% - 56% 
HRASLS5 
(NP_001140200.1) 




 In the context of phospholipid metabolism, O-transacylase activity involves the transfer of 
an acyl group from a phospholipid to glycerol-3-phosphate or a lysophospholipid, in a process that 
is also referred to as O-acyltransferase activity [35, 45] (see Figure 4 for an illustration of 
transacylase/O-acyltransferase activity). The term O-transacylase is preferred over O-
acyltransferase, because it distinguishes the CoA-independent phospholipid-to-phospholipid 
transfer of a fatty acid from the Co-A-dependent activity of acyltransferase enzymes such as the 
lysophosphatidic acid acyltransferase enzymes (LPAATs). The HRASLS enzymes have all been 




Figure 4: PC O-transacylase/O-acyltransferase activity of HRASLS enzymes. 
HRASLS enzymes have the ability to produce phospholipids by functioning as lysophospholipid 
O-acyltransferases. In this example, HRASLS enzymes will derive a select fatty acyl group from 
the sn-1 or sn-2 position of PC for the incorporation into the sn-1 position of LPC, to produce PC. 
This activity is typically employed by HRASLS enzymes to form phospholipids with specific acyl 
compositions. 
 
 The specific O-transacylase activity of HRASLS1 was not described until 2011 when 
Shinohara et al. reported that human HRASLS1 has in vitro O-transacylation activity utilizing PC 
as an acyl donor and lysophosphatidylcholine (LPC) as an acyl acceptor [45]. Consistent with the 
enzymatic mechanisms proposed by Golczak et al. (2012) [18] in solving the structures of 
HRASLS2 and HRASLS3, HRASLS1 prefers esterolysis at the sn-1 position of PC, and 
esterification at the sn-1 position of LPC [45]. This role for HRASLS1 in acyl remodeling of PC 
operates in a CoA-independent manner, and requires dithiothreitol (DTT) and Nonidet P-40 for 
full enzymatic activity [45]. The O-transacylase activity of HRASLS1 is approximately 8-fold 
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higher than its N-transacylase activity, and approximately 5-fold higher than its PLA1/2 activity, 
indicating that in vitro, HRASLS1 predominately acts as an O-transacylase [45]. 
 The in vitro O-transacylase activities of human HRASLS2, HRASLS3, and HRASLS4 
were first reported in 2009 by Uyama et al. [46], and later also reported in the Shinohara study 
[45]. Like HRASLS1, HRASLS2 prefers to esterify fatty acyls at the sn-1 rather than the sn-2 
position. HRASLS2 used 1-hydroxy-2-[14C] palmitoyl-LPC as an acyl acceptor, although it also 
utilized 1-[14C] palmitoyl-2-hydroxy-LPC to a lesser extent, demonstrating 2.4 – 4.7-fold lower 
activity with the latter [46]. Similarly, both HRASLS3 and HRASLS4 show higher in vitro LPC 
O-transacylase activity when using 1-hydroxy-2-[14C] palmitoyl LPC, although these enzymes 
show higher phospholipase A1/2 activity than O-transacylase activity [46]. In vitro O-transacylase 
activity of HRASLS5 was reported in the Shinohara study [45]. In line with the other HRASLS 
family members, HRASLS5 prefers 1-hydroxy-2-[14C] palmitoyl LPC to 1-[14C] palmitoyl-2-
hydroxy- LPC (~2.5-fold higher activity), although the authors found that HRASLS5 also has 
higher in vitro phospholipase activity than O-transacylase activity [45].  
 
Phospholipase activity 
 All of the HRASLS enzymes have been reported to possess varying degrees of Ca2+–
independent phospholipase A1/2 activity [31, 45, 46]. The catalytic activity of HRASLS enzymes 
(Figure 3) results in cleavage of a fatty acyl chain from a phospholipid at either the sn-1 position 
or at the sn-2 position that is coupled with the formation of a fatty acyl-enzyme intermediate 
complex, and the release of a lysophospholipid.  If the fatty acyl group is released from the catalytic 
cleft, rather than transferred to a new phospholipid through the O- or N-transacylase activities of 
the enzyme, then the enzyme is displaying phospholipase activity. This is characterized as 
phospholipase A1 activity if the fatty acyl released was generated from the sn-1 position, and 
phospholipase A2 activity if the fatty acyl released from the sn-2 position. An example of 




Figure 5: Schematic of phospholipase A1/2 activity 
HRASLS enzymes have phospholipase activity. In this example, HRASLS enzymes are able to 
hydrolyze fatty acids from either the sn-1 (top figure), or sn-2 (bottom figure) positions of 
phospholipids. These fatty acids are released, resulting in the production of a lysophospholipid.  
 
 The phospholipase A1/2 activity of HRASLS1 was first described in 2011, through a study 
identifying a role for this enzyme in phospholipid metabolism [45]. Optimal PLA1/2 activity of 
HRASLS is dependent on several factors including optimal pH (around 8-9), the presence of 
EDTA (approximately 1 mM), and the absence of Ca2+ [45]. In addition, catalytic activity of 
HRASLS1 as a phospholipase requires the presence of DTT and Nonidet-P40, similar to the 
requirement for these compounds for O- or N- transacylase activities [45]. Although HRASLS1 
can catalyze the hydrolysis of acyl groups from both the sn-1 and sn-2 positions of PC, it much 
prefers to act as a PLA1, showing ~56% higher activity when acting as a PLA1 versus acting as a 
PLA2 [45]. HRASLS1 shows phospholipase activity with both PC and PE. However, it does not 
show phospholipase activity with either 1-[14C] palmitoyl-2-hydroxy-LPC or 1-hydroxy-2-[14C] 
palmitoyl-LPC, indicating activity as a PLA1/2 but not a PLB [45]. When compared to other 
members of the HRASLS family, HRASLS1 has modest PLA1/2 activity, and instead prefers to 
act as a PC O-transacylase in vitro [45].  
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 HRASLS2 has also been reported to have Ca2+–independent PLA1/2 activity. Like 
HRASLS1, HRASLS2 requires the presence of DTT and Nonidet P-40 for optimal PLA1/2 
activity, and functions best at pH 8-9 [46]. HRASLS2 shows a striking preference for PLA1 
activity to PLA2 activity, as PLA1 activity for this enzyme was 4.4 – 27.6-fold higher than PLA2 
activity depending on the substrate [46]. However, much like HRASLS1, HRASLS2 prefers O-
transacylase activity in vitro over PLA1/2 or N-transacylase activity [45]. 
HRASLS3 was initially described as an in vitro N-acyltransferase by Jin et al. (2007) [31]. 
However, a thorough characterization of this enzyme in vitro and in adipose tissue found that 
phospholipase activity is the predominant function of this enzyme, which is responsible for 80% 
of adipocyte phospholipase activity [52]. As a result, HRASLS3 was renamed adipose-specific 
phospholipase A2 (AdPLA), and given the gene name PLA2 Group XVI (PLA2GXVI) [48, 52]. 
Later studies by others confirmed these findings [35, 45]. HRASLS3 has been shown to be critical 
for the development of obesity, and to be a regulator of lipolysis in mice [48, 52]. However, the 
PLA1/2 preference of HRASLS3/AdPLA is debated. While it is agreed that the major enzymatic 
activity of HRASLS3 is as a phospholipase, a study performed by Uyama et al. (2009) [46] 
suggests that HRASLS3 has predominant PLA1 activity, whereas the Duncan study (2008) 
indicates that PLA2 is slightly dominates as the major phospholipase activity of this enzyme [48]. 
As well, the Uyama study showed PLA activity with PC and PE as substrates [26], which was 
furthered by the Duncan study, which demonstrated that HRASLS3 has PLA activity with 
phosphatidylserine (PS) and phosphatidylinositol (PI), but not phosphatidic acid (PA) [48]. 
Relative to the other HRASLS enzymes, HRASLS3 has the greatest in vitro PLA1/2 activity [45].  
Like HRASLS3, HRASLS4 acts primarily as a Ca2+–independent phospholipase A1/2 in 
vitro, although it has only weak O- and N-transacylase activity [46]. HRASLS4 preferentially 
hydrolyses fatty acids from the sn-1 position of PC and PE, and similar to HRASLS1, 2, and 5, it 
functions optimally between pH 8-9, and requires DTT and Nonidet P-40 for maximal catalytic 
activity [46]. Although HRASLS5 primarily functions as an N-transacylase, it does also have 
phospholipase A1/2 activity [36]. Whereas most HRASLS enzymes prefer sn-1 hydrolysis, as 
indicated by preferential PLA1 activity in phospholipase assays, initial investigation indicated that 
HRASLS5 does not show a clear preference for use of fatty acyl groups from either the sn-1 or sn-





 N-transacylase activity describes the transfer of a fatty acyl group from the sn-1 or sn-2 
position of a phospholipid, to the amino group of the PE polar head group (see Figure 6 for an 
illustration of N-transacylase activity) [35]. Most studies utilize PC as an acyl donor [26, 35, 40, 
45, 46, 53], but other phospholipids and lysophospholipids can also be utilized as acyl donors 
including 1-acyl-LPC, PE, and CL [54]. These reactions are catalyzed by three groups of enzymes: 
Ca2+–dependent N-transacylases (Ca-NATs), Ca2+–independent N-transacylases (iNATs), and 
HRASLS enzymes, which are also largely Ca2+–independent, but constitute a separate group [55].  
 
 
Figure 6: Illustration of N-transacylase activity 
HRASLS enzymes can function as N-transacylases in the synthesis of NAPE. In this example, the 
HRASLS enzyme cleaves a fatty acid from the sn-1 position of PC for selective esterification onto 
the nitrogen of the ethanolamine polar head group of PE. During this reaction, 
lysophosphatidylcholine is released, and a molecule of NAPE is produced. The species of NAPE 
will depend on which fatty acid is esterified onto the ethanolamine head group. NAPE serve as 
precursors for the synthesis of NAE.  
 
The result of HRASLS-mediated N-transacylase activity is the production of a molecule of 
NAPE. Many different species of NAPE can be produced, with the molecular species of N-
acylethanolamine depending on the fatty acyl species extracted from the donor 
glycerophospholipid [54]. Unlike O-acyltransferase activity, where fatty acyl-CoA can be utilized, 
the synthesis of NAPE is dependent on acyl species derived from existing glycerophospholipids 
[54]. Since glycerophospholipids tend to have a saturated fatty acyl in the sn-1 position, and an 
unsaturated fatty acyl in sn-2 position, the N-acylethanolamine group produced by transacylation 
will, to some extent, be influenced by the positional-preference of the N-transacylase enzyme. The 
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species of NAPE produced in cells can affect cellular function, since NAPE are important 
precursors to biologically active signaling molecules known as N-acylethanolamines (NAEs).  
 The observation that HRASLS1 exhibits PE N-acylation activity has been determined by 
in vitro PE N-transacylation activity assays, as well as metabolic labeling experiments in intact 
cells [35, 36, 45, 53]. In the 2011 study by Shinohara and colleagues, purified human HRASLS1 
was found to have N-transacylase activity when utilizing PE as an acyl acceptor and [14C] PC as 
an acyl donor [45]. While this activity was relatively modest (~0.08 mol [14C] NPPE/min/mg 
protein) as compared to the sn-1 O-transacylase activity of this enzyme using 1-hydroxy-2-
[14C]16:0-LPC as an acyl acceptor (~1.2 mol PC/min/mg protein), it is comparable to the in vitro 
PC phospholipase (~0.15 mol 16:0/min/mg protein) and sn-2 O-transacylase activities (~0.10 
mol [14C] PC/min/mg protein using 1-[14C16:0]-2-hydroxy-LPC as an acyl acceptor) [45]. In 
experiments where [14C] palmitate was used to metabolically label COS-7 cells, stable 
overexpression of HRASLS1 caused an ~100-fold increase in the formation of [14C] N-palmitoyl-
PE (NPPE), as compared to controls, indicating the ability of HRASLS1 to synthesize NAPE in 
vivo as well [45]. Further studies investigating the in vitro N-transacylase ability of HRASLS1 
found that it has approximately 1.6-fold higher activity in vitro as an N-transacylase than as a 
phospholipase [35], and that overexpression of this enzyme in COS-7 cells increases levels of total 
endogenous NAPE [35]. 
 In comparison to HRASLS3 and HRASLS4, Uyama et al. (2009) found that only 
HRASLS2 had detectable in vitro N-acyltransferase activity resulting in the formation of [14C] 
NPPE (~0.10 mol [14C] NPPE/min/mg protein) when utilizing 1,2-[14C] dipalmitoyl-PC as an 
acyl donor and PE as an acyl acceptor, and found virtually no activity with HRASLS3 or 
HRASLS4 [46]. The subsequent Shinohara study found comparable levels of N-acyltransferase 
activity for HRASLS2 (~0.10 mol [14C] NPPE/min/mg protein) by utilizing the same conditions 
[45]. A more recent study performed by Uyama and colleagues characterized HRASLS2 activity 
in vitro as predominately N-acyltransferase, as compared to its ability to act as a phospholipase 
(~5.6-fold higher activity) [35]. In addition, transient expression of HRASLS2 in COS-7 cells 
resulted in an accumulation in total NAPE species, while knockdown of HRASLS2 caused a 
significant drop in N-transacylase activity and NAPE levels [35], indicating a role for HRASLS2 
in NAPE production in vivo.  
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 The N-transacylase activity of HRASLS3 was first reported in 2007 by Jin et al., who 
identified that this enzyme exhibits in vitro N-transacylase activity [31]. However, the N-
transacylase abilities of HRASLS3 are the lowest amongst the other HRASLS family members 
[35, 45, 46].  In comparison to its ability to act as a phospholipase, HRASLS3 has exceedingly 
low in vitro N-transacylase activity [35]. When assayed in vitro, the ratio of N-transacylase activity 
to phospholipase A1/2 activity of HRASLS3 is a trivial 0.1 [35].  
Although HRASLS4 displays limited N-acyltransferase activity in vitro [46], 
overexpression of HRASLS4 in COS-7 cells increases cellular NAPE content [35]. HRASLS4 has 
higher activity as an N-acyltransferase than as a phospholipase in vitro [35], but this is opposite in 
vivo [35, 45, 46] . HRASLS5 was originally identified as a Ca2+–dependent N-acyltransferase that 
synthesizes anandamide [31]. HRASLS5 possesses in vitro N-acyltransferase activity that 
predominates over both O-transacylase and phospholipase A1/2 activity [31]. This observation 
was supported by experiments performed in vivo, where overexpression of HRASLS5 in cultured 
cells was found to enrich cellular content of both NAPE and NAEs [31, 35, 36, 45]. HRASLS5 
has been suggested to be of importance in the production of anandamide due to its lack of 
preference in utilizing acyl chains from either the sn-1 or sn-2 positions of glycerophospholipids 
to produce NAPE and NAE [31]. While other HRASLS family members show preference for the 
sn-1 position, HRASLS5 will utilize fatty acyl chains from the sn-2 position equally well, and this 
site is more likely to be enriched in arachidonic acid required for N-arachidonoyl ethanolamine 
and downstream anandamide production. 
 
N-acylethanolamines (NAEs) and their synthesis from NAPEs 
 
 The generation of NAPE by Ca2+–dependent N-acyltransferases, along with HRASLS 
enzymes, is part of a larger pathway in the synthesis of NAEs, known as the phosphodiesterase-





Figure 7: Illustration of the phosphodiesterase-transacylation pathway of NAE synthesis.  
Figure adapted from Ueda et al. (2010) [54]. NAE are generated through the phosphodiesterase-
transacylation pathway. The majority of NAE are produced from NAPE-PLD-mediated hydrolysis 
of NAPE, which also results in the release of a molecule of PA. Alternatively, NAPE can be 
hydrolyzed by PLC into NAE-phosphate, which is then de-phosphorylated by either PTPN22 or 
SHIP1 to catalyze the formation of NAE. NAE can also be produced in a less direct, but also 
utilized pathway. In this alternative pathway, NAE can be produced by the hydrolysis of the sn-2 
acyl group in NAPE by the enzyme ABH4 or sPLA2, which results in the production of a molecule 
of lyso-NAPE. Lyso-NAPE can then be directly hydrolyzed into NAE by the enzyme lyso-PLD, 
or be converted into GP-NAPE by the hydrolysis of the sn-1 fatty acid on lyso-NAPE, which will 
generate a molecule of GP-NAPE. Once GP-NAPE is produced, NAE can be formed by the 
hydrolytic activity of the enzyme GDE1.  
 
Along with NAEs, NAPE molecules are themselves bioactive, accumulating in sites of 
inflammation following injurious events such as myocardial infarction [56, 57] and neural 
ischemia [58, 59]. However, NAPEs have been better characterized as important precursors to the 
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synthesis of NAEs. NAEs play diverse roles in a multitude of biological processes including, but 
not limited to nocioception [60], tumor growth suppression [61], apoptosis [62], and PPAR 
agonism [62]. Quantitatively, the most abundant NAEs are N-palmitoylethalomine (PEA), N-
oleoylethanolamine (OEA), N-stearoylethanolamine (SEA), and N-linoleoylethanolamine (LEA) 
[54]. Perhaps the most well-known NAE, however, is N-arachidonylethanolamine, better known 
as anandamide (AEA) [60]. NAEs including AEA signal through a host of receptors, including the 
cannabinoid receptor of the central and peripheral types (CB1 and CB2, respectively) [63], the 
transient vanilloid receptor type 1 (TRPV1) [64], G-protein-coupled receptors 55 [65] and 119 
[66] (GPR55 and GPR119), and peroxisome proliferator-activated receptor  (PPAR) [67, 68]. 
NAEs form a relatively minor component of membranes, and are synthesized on-demand, rather 
than stored in cells [54]. As such, their regulation is highly dependent on the enzymes involved in 
their synthesis and degradation [54]. 
The majority of NAEs are generated from NAPEs through the enzyme NAPE-
phospholipase D (NAPE-PLD) in a one-step reaction [69]. NAPE-PLD is a 46 kDa integral 
membrane protein, which acts as a phosphodiesterase of the phospholipase D type [70, 71]. As 
such, NAPE-PLD releases a molecule of NAPE and a molecule of phosphatidic acid following 
NAPE degradation, and is the only mammalian enzyme to directly hydrolyze NAE from NAPE 
[54].  Unlike HRASLS enzymes, with N-acyltransferase activity that is activated by Ca2+, NAPE-
PLD largely operates in a Ca2+–independent manner, as its activity is only minimally stimulated 
upon the introduction of Ca2+ [55]. Interestingly, although NAPE-PLD is the only known 
mammalian enzyme to directly hydrolyze NAPE into NAE, studies from NAPE-PLD-/- mice still 
show the formation of NAE, which suggested the existence of alternative NAPE degradation 
pathways [72]. As such, two multi-step pathways independent of NAPE-PLD have been 
discovered in the formation of NAEs from NAPE [73-76]. 
In one pathway independent of NAPE-PLD, a group Ib secretory PLA2 (sPLA2) 
hydrolyzes the fatty acyl group from the sn-2 position of a NAPE molecule, resulting in lyso-
NAPE [77]. Following this, lyso-NAPE can be either be further hydrolyzed into NAE by an 
enzyme known as lyso-PLD [77], or it can be converted into glycerophospho-N-acylethanolamide 
(GP-NAE) by the hydrolysis of the sn-1 acyl group by the enzyme ABH4 [73]. The molecule of 
GP-NAE can then be hydrolyzed by the enzyme glycerophosphodiester phosphodiesterase 1 
(GDE1) [78], resulting in the release of glycerol-3-phosphate and a molecule of NAE.  
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In a separate pathway that is independent of NAPE-PLD-mediated NAE synthesis, NAPE 
can be hydrolyzed into diacylglycerol (DAG) and NAE-phosphate by phospholipase C (PLC) 
activity [79]. However, the enzyme responsible for the PLC activity observed in this pathway has 
not yet been characterized [55]. Following the generation of NAE-phosphate, two separate 
phosphatases can mediate the hydrolysis of NAE-phosphate into NAE and phosphoric acid [55]. 
The first phosphatase identified is known as protein tyrosine phosphatase, non-receptor type 22 
(PTPN22) [80]. PTPN22 had been previously cloned and characterized in cultured RAW264.7 
murine macrophages, whereby its stable overexpression caused doubling in endogenous 
anandamide content [80]. As well, investigations on PTPN22-deficient mice have shown that 
PTPN22 is at least partially responsible for the cleavage of anandamide-phosphate into 
anandamide [55, 75]. Thus, a role for PTPN22 in the formation of NAE from NAE-phosphate has 
been demonstrated, and studies are ongoing to investigate possible inhibitors of this enzyme [55]. 
The other known phosphatase is an enzyme known as src homology 2 domain-containing inositol-
5-phosphatase 1 (SHIP1), which was identified in 2005 [81].  SHIP1 activity is stimulated by 
lipopolysaccharide, and has been shown to cleave anandamide-phosphate into anandamide [75]. 
Interestingly, studies have indicated that the sPLA2/ABH4-mediated pathway seemingly occurs 
at a much faster rate (i.e. 6x faster) than the PLC/PTPN22/SHIP1-mediated pathway in brain 
homogenates, indicating that it may be favoured in vivo [55]. However, analysis of RAW264.7 
cells treated with lipopolysaccharide showed anandamide formation through only the 
PLC/PTPN22/SHIP1-mediated pathway [55].  Further characterization of NAE synthesis 
pathways independent of NAPE-PLD are warranted to appreciate their full physiological 
significance. 
Finally, there is recent evidence to suggest that the formation of NAE from NAPE can 
occur spontaneously within the cell [55] [82-84]. McCue and colleagues observed at high (150 
mM) concentrations of ethanolamine, anandamide was generated through the condensation of 
ethanolamine and arachidonyl-CoA [85]. The spontaneous formation of NAE through this method 
has been confirmed as the reverse reaction of the degradation of NAE through the enzyme fatty 
acid amide hydrolase (FAAH) [86-88], described below. However, due to the supra-physiological 
concentration of ethanolamine required for the spontaneous synthesis of anandamide, the 
physiological relevance of this reaction is unknown [55] 
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Pathways of NAE degradation  
 
 Perhaps the best characterized pathway of NAE degradation is mediated through FAAH, 
which hydrolyses NAE into ethanolamine and free fatty acid [89]. Although FAAH has highest 
affinity for anandamide, it is able to mediate the degradation of a number of NAE species including 
OEA, PEA, and LEA [82]. In humans, an isozyme of FAAH, termed FAAH-2 has also been shown 
to mediate the degradation of NAE [90]. However, FAAH-2 only shares 20% protein sequence 
homology with FAAH, and also differs in its cellular localization and physiological role [91].  
 Another enzyme responsible for the degradation of NAE is the protein N-
acylethanolamine-hydrolyzing acid amidase (NAAA), which was discovered in 1999 [92]. NAAA 
is a 31 kDa NAE-hydrolyzing enzyme that was first purified in rat lung [93], and then later cloned 
and characterized in humans [94]. NAAA shares no sequence homology with FAAH [94], and 
prefers the hydrolysis of PEA to anandamide [93]. NAAA functions similarly to a ceramide 
hydrolase by cleaving the amide bond of NAE to release ethanolamine and a free fatty acid [54, 
94]. 
 
Statement of the problem 
 
The aim of this thesis was to investigate a novel role for HRASLS1 and its downstream bio-
derivatives in phospholipid metabolism. Although Shinohara and colleagues have previously 
shown PC O-transacylase, PLA1/2, and N-transacylase activity [45], a full characterization of the 
ability of HRASLS1 to directly or indirectly synthesize additional phospholipids had not been 
tested. Specifically, a role for HRASLS1 in the metabolism of the mitochondrial phospholipid 
cardiolipin had not yet been investigated. Initial investigations indicated that overexpression of 
HRASLS1 in cells specifically increased the content of cardiolipin. The O-transacylase (i.e. PC 
transacylase) activity of HRASLS enzymes suggests that HRASLS1 could participate directly in 
cardiolipin remodeling, by transferring a fatty acyl chain from the sn-1 position of PC to MLCL 
or DLCL in a reaction similar to that catalyzed by the transacylase Tafazzin (TAZ). HRASLS1 
may also indirectly affect cardiolipin synthesis, through its role as an N-acyltransferase functioning 
in the synthesis of NAPEs and resultant NAEs [35]. Thus, a review of the phospholipid 
biosynthetic pathway and mechanisms of acyl remodeling follows. In addition, special attention is 
given to the biological importance and tissue- and enzymatic regulation of cardiolipin. 
 22 
Kennedy Pathway of phospholipid and TAG synthesis 
 
The de novo synthesis of phospholipids and triacylglycerol occurs in the Kennedy Pathway, 
initially described by Eugene Kennedy in 1956 [15]. Phospholipid and triacylglycerol (TAG) 
synthesis largely takes place in the endoplasmic reticulum, MAM, and the mitochondria [5]. The 
membranes of these organelles contain enzymes involved in glycerophospholipid synthesis 
including glycerol-3-phosphate acyltransferases (GPATs), and AGPATs/lysophosphatidic acid 
acyltransferases (LPAATs).  
In the initial step of this pathway, a fatty acyl-CoA is esterified to a molecule of glycerol-
3-phosphate by a member of the GPAT family of enzymes, producing a molecule of 
lysophosphatidic acid (LPA). To date, there have been four GPAT enzymes identified, the first 
two of which are mitochondrial [95, 96], and the latter two of which are microsomal [97, 98]. 
Following the production of a molecule of LPA, an AGPAT/LPAAT enzyme will esterify it with 
another fatty acyl chain, catalyzing the formation of phosphatidic acid (PA). Phosphatidic acid 
represents a unique branching point in the Kennedy Pathway. In one branch, PA can be 
dephosphorylated by a phosphatidate phosphatase (PAP) enzyme to yield 1, 2-diacylglycerol (1, 
2 – DAG), which can be used as a substrate to produce a molecule of TAG by one of two 
diacylglycerol acyltransferases (DGATs) [99, 100]. Alternatively, 1,2-DAG can be used as a 
substrate in either the CDP-choline pathway to produce the glycerophospholipid 
phosphatidylcholine (PC), or in the CDP-ethanolamine pathway to produce 
phosphatidylethanolamine (PE) [15]. Together, PC and PE jointly constitute 60-80% of 
glycerophospholipids found in eukaryotic cell membranes [5]. Among these, PC is the most 
abundant, representing anywhere from 45 – 55% of phospholipids in plasma membranes [5], while 
PE, which is typically enriched within the inner leaflet of membranes comprises 15-25% [5]. The 
synthesis of the glycerophospholipid phosphatidylserine (PS) can be achieved using either PC or 
PE as substrates, which are metabolized by either phosphatidylserine synthase 1 (PSS1) [101] or 
phosphatidylserine synthase 2 (PSS2) [102].  
If PA is used in the alternative branch of the Kennedy Pathway, glycerophospholipids that 
are typically enriched within the mitochondria can be synthesized. Once produced, PA can be 
converted into cytidine diphosphate diacylglycerol (CDP-DAG) by CDP-diacylglycerol synthase 
(CDS) [103]. CDP-DAG can then be combined with a molecule of inositol to produce the 
glycerophospholipid phosphatidylinositol. PI is an important signaling molecule that is 
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particularly enriched in the brain as compared to most other tissues [104-106]. Importantly, PI acts 
as a source of polyphosphorylated phosphoinositides (PIPs) that function in a multitude of brain 
signaling pathways including neurotransmission [107] and neuronal exocytosis [108], and have 
been implicated in regulating functional and structural plasticity [109-111]. Alternatively, CDP-
DAG can be converted into phosphatidylglycerol phosphate (PGP), which is dephosphorylated by 
a phosphatase to produce the glycerophospholipid phosphatidylglycerol (PG). 
Phosphatidylglycerol typically constitutes less than 1% of membrane glycerophospholipids, but 
importantly can be used as a precursor to the mitochondrial phospholipid cardiolipin. Cardiolipin 
is a dimeric phospholipid found almost exclusively in the inner mitochondrial membrane in 
eukaryotic cells, and is formed through the condensation of PG and CDP-DAG in a reaction 
catalyzed by the enzyme cardiolipin synthase (CLS) [112]. The mammalian synthesis of 
cardiolipin, known as the CDP-DG pathway, was initially discovered by Karl Hostetler in the 





Figure 8: The Kennedy Pathway of glycerophospholipid and triacylglycerol synthesis 
Phospholipids and triacylglycerol are produced de novo in the Kennedy Pathway. In this pathway, a molecule of glycerol-3-
phosphosphate is acylated at the sn-1 position by a member of the GPAT family to form lysoPA. Next, a member of the AGPAT/LPAAT 
family will acylate lysoPA at the sn-2 position to produce PA. PA represents a branching point in the pathway, where it can be 
dephosphorylated, and acylated to form 1,2-DAG that can serve as precursor to the synthesis of PC, PS, or PE. Alternatively, 1-2 DAG 
can be further acylated into TAG. In the other branch of the pathway, PA is converted into CDP-DAG by CDS enzymes. CDP-DAG 
then serves as a precursor to form either phosphatidylglycerol phosphate (PGP), or the phospholipid PI. Once PGP is formed, it can be 
de-phosphorylated into the phospholipid PG by PTPMT1. Finally, cardiolipin synthase is able to produce the mitochondrial phospholipid 




 Cardiolipin is structurally unique from other glycerophospholipids since it contains four, 
rather that two, fatty acyl side chains. These can vary in composition, and the molecular species 
of cardiolipin present in any particular tissue is highly specific [114, 115] and often conserved 
across related species [114, 116, 117]. The substrate specificities of known, and likely also of ‘as-
of-yet uncharacterized’ cardiolipin-remodeling enzymes are key in determining cardiolipin acyl 
moieties in any given tissue [118-122].  
 
Tissue-specific molecular cardiolipin composition 
In eukaryotes, cardiolipin is found predominately in the inner mitochondrial membrane 
where it is required for oxidative phosphorylation [13], and is critical in stabilizing electron 
transport chain (ETC) complexes [123]. A mitochondrial insult event, such as a loss of membrane 
potential, causes cardiolipin translocation to the outer mitochondrial membrane, catalyzed by the 
protein NDPK-D [124] and/or phospholipid scramblase 3 (PLS3) [125]. This externalization can 
serve as a target for mitochondrial-mediated apoptosis [126] and mitochondrial-specific autophagy 
(a process deemed mitophagy) [127, 128]. However, under normal conditions, the tissue content 
of cardiolipin in eukaryotes is specifically found in mitochondrial membranes. In contrast, 
prokaryotes, lack mitochondria as well as any other membrane-bound organelle, and cardiolipin is 
only found in the plasma membrane [129]. Interestingly, the presence of cardiolipin in the plasma 
membrane of prokaryotes, coupled with the absence of cardiolipin in any other eukaryotic structure 
besides mitochondria, helped give rise to the serial endosymbiont theory. This idea states that 
protoeukaryotic organisms took up an alpha-protobacterium, in an event that led to the evolution 
of eukaryotic organisms, which now contain a descendant of that protobacterium mitochondria 
[130].  
The total cardiolipin content of tissues varies in proportion with oxidative demand, 
reflecting the higher mitochondrial content. A number of studies have characterized the cardiolipin 
content of mammalian organs, and these are outlined below. In the heart, cardiolipin constitutes 
approximately 12-15% of the total phospholipid present [131], and is the third most abundant 
glycerophospholipid, following PC and PE [114, 132, 133]. In the kidneys, cardiolipin amounts to 
6-7% of total phospholipid [131]. The brain has a normalized energetic demand that is close to 
half that of cardiac muscle or kidney per unit mass, and similarly has a significantly lower 
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proportion of cardiolipin relative to total phospholipid content, accounting for only 1-2% [105]. 
Relative to total phospholipid, cardiolipin accounts for 2-3% by weight in lung, 5-6% in liver, and 
2-3% in testes [105]. The unique tissue-specific distribution of cardiolipin side chain composition 
is expanded below, and is summarized in Table 2. 
 
Heart 
Cardiolipin has been best described in heart, where it was first characterized, and from 
whence it derives its name [134]. Cardiac cardiolipin has a signature fatty acyl profile that is 
predominated by linoleic acid (18:2n-6). Approximately ~80% of cardiolipin molecules in heart 
are fully esterified with this acyl species at all four positions, forming tetra-linoleoyl cardiolipin 
[114]. This molecular specificity is highly conserved across mammals, with similar compositions 
observed in bovine, rodent, and human hearts [114, 116-118, 132, 133, 135-140]. Although this 
composition is relatively well preserved throughout many changing cellular conditions, alterations 
are reported. Lee et al. found an effect of aging on the composition of cardiolipin in rat hearts 
[116]. In that work, the authors reported that the linoleate content decreased approximately 34% 
between 12 and 24 months of age [116]. However, linoleate remained the major fatty acyl species 
in rat cardiac cardiolipin at all time points measured (4, 12, and 24 months of age). Furthermore, 
even at 24 months, 18:2n-6 was present at levels more than 10-fold higher than the next most 
abundant fatty acids, oleic acid (18:1n-9) and docosahexaenoic acid [116]. The predominance of 
linoleate in heart cardiolipin is also conserved during certain drug interventions that cause 
profound changes in other phospholipid species. Injection of rats with norepinephrine has been 
found to reduce the cardiac content of linoleate in phosphatidylcholine and 
phosphatidylethanolamine approximately in half, without affecting the amount of linoleate in 
cardiolipin [135]. While this treatment did lead to a small increase in the cardiolipin content of 
docosahexaenoic acid  (DHA), changes in other fatty acyl species were negligible, especially when 
compared to the total amount of linoleate present [135].  
Oleic acid is typically the next most abundant fatty acyl found in heart cardiolipin [114, 
116, 117]. Cardiolipin esterified with one oleic acid in place of a linoleic acid (18:2-18:2)-(18:2-
18:1) is the second most common molecular cardiolipin species detected in bovine, rodent, and 
human hearts [114, 116, 117, 135]. The third most abundant form of heart cardiolipin differs 
depending on the animal examined, although this may be reflective of differences in diet-induced 
cardiolipin remodeling rather than differences in host species, per se. In humans and rodents, 
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stearic acid (18:0) is commonly the third most abundant fatty acyl species esterified in cardiolipin 




Brain has an entirely different cardiolipin fatty acyl profile compared to heart, and there 
are species-specific differences in these profiles. In bovine [141] and human [115] brains, oleate 
is the most abundant fatty acyl within cardiolipin, accounting for ~54% and 32% of the total fatty 
acyl species, respectively. In rats, however, stearate is the most abundant, accounting for close to 
half of fatty acyl species in cardiolipin [142]. There is also species variation in which fatty acyl is 
the second most abundant within brain cardiolipin. In humans, stearate is often found in relative 
abundance, whereas in rodents, oleate predominates [115]. In contrast, linoleate typically accounts 
for <10% of total brain cardiolipin fatty acyl species [115]. 
The highly distinct profile of brain cardiolipin, and degree of difference compared to that 
of heart cardiolipin, has garnered speculation regarding biological significance. One hypothesis is 
that brain cardiolipin is composed of less unsaturated fatty acids than heart cardiolipin in order to 
help mitigate the effects of aging on lipid peroxidation [143]. Because of its proximity to molecular 
oxygen in mitochondria, cardiolipin is readily oxidized by reactive oxygen species (ROS) [143-
145]. Evidence has shown that the oxygenation of brain cardiolipin generates neuronal death 
signals [146, 147]. Thus, adopting a less unsaturated fatty acyl profile may render brain cardiolipin 
less likely to undergo peroxidation, and may promote the conservation of neurons that are non-
replicating and functionally irreplaceable. Conversely, a higher degree of cardiolipin unsaturation 
in heart may be necessary to achieve the very high rate of oxidative metabolism characteristic of 
that tissue [148-150].  
Alterations in the cardiolipin content or composition of brain may have pathological 
consequences [106, 136, 143, 151, 152]. Decreases in the total cardiolipin content of brain 
mitochondria have been reported in Parkinson’s Disease [127, 153], Alzheimer’s Disease [154], 
and in age-related dementia [154]. Changes in the fatty acyl composition of brain cardiolipin are 
also reported. Analysis of brains taken after death from individuals with Alzheimer’s Disease 
reveals an increased content of palmitate (16:0) in cardiolipin isolated from the frontal cortex, and 
a lower content of docosahexaenoate (22:6n-3) in cardiolipin isolated from the temporal cortex, 
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compared to brains from healthy controls [115]. Altered mitochondrial phospholipid composition 
has been shown to affect the capacity of mitochondria to perform oxidative phosphorylation. A 
study by Divakaran and Venkataraman (1977) examined the cardiolipin fatty acyl composition 
and oxidative phosphorylation capacity of mitochondria of Wistar rats fed a hydrogenated coconut 
oil (HCO)-supplemented diet or Wistar rats fed a safflower-oil supplemented diet [155]. Rats fed 
the HCO-diet had increases in cardiolipin oleic and palmitoleic acid content, which was associated 
with a decrease in the oxidative phosphorylative capacity of their liver mitochondria when using 
glutamate and malate as substrates, as compared to rats fed the safflower oil-supplemented diet, 
which had greater content of cardiolipin containing oleic and arachidonic acids, and had a greater 
capacity for oxidative phosphorylation. The observed decreases in capacity for oxidative 
phosphorylation in HCO-supplemented rats was hypothesized to be attributed to structural 
abnormalities in mitochondrial ultrastructure, due to an altered cardiolipin fatty acyl profile which 
may provide an unfavourable environment for the synthesis of high energy intermediates [155]. 
The specific composition of cardiolipin acyl chains has been studied to a degree, and a number of 
studies have built on the premise that mitochondria must contain a high degree of unsaturated 18 
carbon-rich cardiolipin needed for oxidative phosphorylation. It has been shown that mitochondria 
deficient in unsaturated 18 carbon-rich cardiolipin have impairments in the activity of ETC 
complexes including, but not limited to, complex IV (cytochrome c oxidase) [156], and complex 
II + III [157].  
Mitochondrial cardiolipin content has been studied in detail in neurons, and found to be 
proportionately higher in non-synaptic compared to synaptic mitochondria [158]. Interestingly, 
however, cardiolipin in non-synaptic mitochondria appears to be less resistant to aging-mediated 
changes, undergoing a decrease in total content with advancing age, while the cardiolipin content 
of synaptic mitochondria remains well preserved [158]. Conversely, in at least one model of 
Alzheimer’s Disease, synaptic mitochondria are shown to undergo a decline in most cardiolipin 
species, while it is the non-synaptic mitochondria that are well maintained [154].  
 
Other tissues 
The composition of liver cardiolipin is well conserved across species, with a high degree 
of similarity between rodents and bovines in fatty acyl profiles. Similar to heart, linoleate 
comprises more than two-thirds of the fatty acyl species in hepatic cardiolipin [142]. The next 
most abundant fatty acyl species in hepatic cardiolipin is oleate, which comprises ~19%, followed 
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by palmitate, which comprises ~6% [142, 159]. Markedly fewer studies have examined cardiolipin 
in lung, kidney, skeletal muscle, testes, and spleen, compared to heart, and brain. Linoleic acid is 
reported to be the predominant fatty acyl species in cardiolipin isolated from kidney (~61%) [142] 
and spleen (~49%) [142]. This profile is not seen in other tissues, which are often found with a 
more saturated cardiolipin profile.  Rodent lung and skeletal muscle are reported to have a greater 
content of saturated fatty acyl species, primarily stearate (~44% and ~40%, respectively) [142], 
whereas cardiolipin found in testes is predominated by palmitate (~55%) [142]. Additional studies 
on the cardiolipin content and composition of these and other tissues would fill an important gap 
in the primary literature. A summary of cardiolipin fatty acyl species by abundance in each tissue 
is shown in Table 2.  
 
Table 2: Summary of the most abundant fatty acyl species found in cardiolipin in 
mammalian tissues  
Organ Tissue 
source 





18:2n-6 >> 18:1n-9/20:4n-6 > 18.0 
18:2n-6 >> 18:1n-9 > 18:0/22:6n-3 









18:1n-9 >> 18:0 > 22:6n-3 
18:0 >> 18:1n-9 > 16:0 







18:2n-6 >> 18:1n-9 > 16:0 





18:0 >> 16:0 > 18:1n-9/18:2n-6 [142] 
Kidney 
 






18:0 >> 16:0 > 18:2n-6 





Rodent 18:2n-6 >> 18:0 > 18:1n-9 [142] 
Testes Rodent 16:0 >> 18:0 > 18:1n-9 [142] 
 
Enzymes involved in cardiolipin acyl-chain remodeling 
To date, four enzymes have been identified that can re-synthesize cardiolipin by acylating 
MLCL or DLCL. These enzymes play crucial roles in the remodeling of ‘immature’ or nascent 
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cardiolipin produced de novo in the Kennedy pathway to ‘mature’ cardiolipin that contains a 
profile of fatty acyl chains specific to, and functionally appropriate for, the tissue in which it is 
located. During the initial synthesis of cardiolipin, the enzyme CLS demonstrates a similar level 
of activity with substrates regardless of fatty acyl composition [161-163]. Cardiolipin synthesized 
de novo therefore tends to have the same essential composition as its major PG and CDP-
diacylglycerol precursors [161, 162, 164]. The biochemical characterization of human CLS found 
that de novo synthesis of nascent cardiolipin occurs at a high level with a number of PG species 
including dilinoleoyl (18:2n-6/18:2n-6)-PG and dioleoyl (18:1n-9/18:1n-9)-PG. CLS also had 
activity with 16:0/18:2n-6-PG, 16:0/18:1n-9-PG, dipalmitate (16:0/16:0)-PG, albeit to a lesser 
extent, where CLS activity was approximately halved with these PG species. In contrast, CLS had 
little-to-no activity relative to dilinoleoyl- and dioleoyl-PG with dimyristoyl-PG (14:0/14:0) [161]. 
Interestingly, CLS had similar activity with dimyristoyl-CDP-DAG, egg phosphatidylcholine, and 
dioleoyl-CDP-DAG, but substantially much less activity (~30%) with dipalmitoyl-CDP-DAG 
[161]. These glycerolipids are produced in earlier steps of the Kennedy Pathway using 
phosphatidic acid as the ultimate precursor. Since phosphatidic acid is acylated by 
glycerophosphate acyltransferases (GPATs) and acyl-glycerophosphate acyltransferases 
(AGPATs) that tend to prefer saturated and monounsaturated fatty acids [165], the remodeling 
process is critical to achieve the high degree of cardiolipin acyl chain specificity that is apparent 
in different tissues.  
Cardiolipin remodeling largely occurs via the Lands’ remodeling pathway [166, 167]. 
Remodeling of ‘immature’ cardiolipin is achieved through the joint action of phospholipases A1 
and A2, CoA-dependent acyltransferases, and O-transacylases. There are dozens of different 
known mammalian PLAs, and they vary widely in substrate specificity, with preferences for 
substrates based on glycerophospholipid species, fatty acyl side chain moieties, or both [168-171]. 
There are also over a dozen known acyl-CoA-dependent mammalian acyltransferases and acyl-
CoA-independent transacylases. These tend to show significant acyl donor and acyl acceptor 
substrate specificities [168, 170], recognizing only a narrow class of glycerophospholipids. A 
PLA2 will either cleave a fatty acid from one of the two sn-2 positions, resulting in the intermediate 
species MLCL, or it can cleave both fatty acids from the sn-2 positions, resulting in DLCL. 
Similarly, a PLA1 will act on either one or both of the sn-1 positions of cardiolipin. Re-acylation 
at one or both of these sites may be performed by an acyltransferase that utilizes fatty acyl-CoAs 
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as donor substrates, or a transacylase that cleaves and transfers a fatty acyl chain from another 
phospholipid such as phosphatidylcholine, generating reformed (i.e. fully acylated) cardiolipin and 
a lysophospholipid such as LPC (see Fig. 9 for an overview of cardiolipin remodeling). 
 
Tafazzin 
 The enzyme Tafazzin (encoded by the TAZ gene in humans) was first identified in 1996 
[172]. Tafazzin is a mitochondrial enzyme, found both on the outer- and inner-mitochondrial 
membranes [173]. It is most highly expressed in cardiac and skeletal muscle, with varying levels 
in other tissues [151], and has been shown to act predominantly as a linoleoyl transacylase in the 
remodeling of MLCL [118]. Although Tafazzin also exhibits some lesser activity with 
palmitoleoyl residues, it does not utilize oleoyl residues [118]. Tafazzin functions by deacylating 
linoleoyl residues from PC, which it then esterifies onto MLCL to produce linoleate-enriched 
cardiolipin [118]. Cardiolipin produced by Tafazzin usually contains linoleate at all sn-1 and sn-2 
positions [174]. Tafazzin can also catalyze the reverse reaction, esterifying LPC with acyl groups 
it derives from cardiolipin, PE, or PC, forming mature PC. However, the forward reaction is 
typically favoured in vivo [118]. This is supported by findings that knockdown of Tafazzin results 
in an overall decrease in the synthesis of tetra-linoleoyl cardiolipin, with accumulation of MLCL 
and linoleate-deficient cardiolipin species in cells [151]. Mutations in the TAZ gene also cause 
aberrant cardiolipin remodeling in humans [175-177], resulting in Barth Syndrome. This X-linked 
genetic disorder is characterized by a decrease in total cardiolipin and tetra-linoleoyl cardiolipin 
levels, and an accumulation of MLCL, resulting in skeletal- and cardiomyopathies, neutropenia, 
and frequently some degree of cognitive impairment [172, 177-180].  
 
Monolysocardiolipin-Acyltransferase 1 (MLCL-AT1) 
 MLCL-AT1 was first characterized by the laboratory of Grant Hatch in 1999 as a 
mitochondrial monolysocardiolipin acyltransferase enriched in the hearts of rats [181]. In 2003, 
the Hatch laboratory purified MLCL-AT1 from pig liver mitochondria and identified the protein 
sequence by mass spectrometry [182]. MLCL-AT1 is a 74 kDa protein that preferentially esterifies 
linoleoyl-CoA and oleoyl-CoA onto MLCL. Although it also utilizes palmitoyl-CoA, MLCL-AT1 
has 10-fold higher activity with unsaturated fatty acids, and no activity with any other 
lysophospholipid substrates, including DLCL. MLCL-AT1 activity has been found to increase 
during apoptosis in both cultured cells [183], and in rat hearts during heart failure [157], which 
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may reflect a compensatory mechanism employed to maintain homeostatic levels of cardiolipin 
that decline during apoptosis [184].  
 
alpha-Trifunctional Protein (αTFP) 
 In 2009, the human homolog of MLCL-AT1 was identified [119]. Human MLCL-AT1 is 
a 59 kDa acyl-CoA dependent enzyme that preferentially incorporates linoleate into MLCL in vivo 
[119]. Sequence analysis indicated that it is identical to the α-subunit of human trifunctional 
protein (TFP), which lacks the initial 227 N-terminal amino acids of the full-length protein. A 
detailed analysis of the cardiolipin-remodeling activity of αTFP has shown that it has the highest 
activity with linoleoyl-CoA, but can also utilize oleoyl-CoA and palmitoyl-CoA, similar to MLCL-
AT1 [120].  
 
ALCAT1 
 ALCAT1 is a 44 kDa acyl-CoA:lysocardiolipin acyltransferase that was characterized in 
2004 as an acyl-CoA dependent enzyme that can use both MLCL and DLCL as acyl acceptors 
[121], although it has shown activity with other anionic lysophospholipid acceptors as well, 
including LPI and LPG [185]. In vivo, ALCAT1 preferentially esterifies MLCL and DLCL with 
very long-chain highly unsaturated fatty acids (HUFA, 20 carbons, 3 double bonds), at the 
expense of 16-18 carbon saturated (SFA), monounsaturated (MUFA), and n-6- and n-3 
polyunsaturated fatty acids (n-6 PUFA, n-3 PUFA) [143]. This enzyme is predominantly expressed 
in the heart and liver and, importantly, has been found to localize to the MAM [143], which 
indicates participation in a cardiolipin-remodeling pathway that is distinct from the other known 
mitochondrial pathways [161]. Because ALCAT1 prefers HUFA, cardiolipin formed by this 
enzyme is highly unsaturated, and may be more prone to peroxidation [143]. ALCAT1 is therefore 
implicated in mitochondrial dysfunction [143]. A schematic of CL remodeling by ALCAT1, 





Figure 9: Enzymes involved in cardiolipin remodeling 
Cardiolipin produced during de novo synthesis must undergo acyl remodeling by one of four 
known enzymes in order for incorporation into the inner mitochondrial membrane. Tafazzin 
functions as a PC:MLCL transacylase by hydrolyzing a fatty acid from the sn-1 position of PC for 
incorporation into MLCL. This results in the production of a molecule of CL and a molecule of 
LPC. One enzyme, ALCAT1 can remodel CL from both MLCL and DLCL, and has the ability to 
incorporate fatty acyl-CoAs into either precursor molecule. Finally, two MLCL acyltransferases 
have been identified. Both MLCL-AT1 and TFP can esterify a fatty acid into MLCL for the 
remodeling of CL.  
 
Dietary regulation of cardiolipin acyl-chain profile  
 Differences in the dietary composition of fatty acids can influence body phospholipid fatty 
acyl profiles to the extent that functional consequences become evident, such as alterations in 
membrane fluidity [186-190]. Several studies have investigated the effects of modulating dietary 
fatty acid species on cardiolipin fatty acyl profiles, with outcomes examined most often in the heart 
and liver [133, 137, 138, 191]. Since a high degree of variability is evident between reported 
studies with regards to the methods used, source of fatty acids, and duration of treatment, the data 
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discussed here compare different dietary interventions only when performed within the same 
study. A summary of diet intervention on cardiolipin content and composition is given in Table 3.  
 
Dietary enrichment with saturated fatty acids (SFA) versus polyunsaturated fatty acids (PUFA)  
 In a study performed by Aoun et al. (2012), alterations in hepatic cardiolipin were observed 
when 6-week old Wistar rats were fed for 12 weeks on diets enriched in lard or fish oils, or fed a 
basal diet (BD) containing a mixture of olive oil, safflower oil, and lard, at either 5 or 30% total 
fat contents (w/w) [189]. The level of linoleate rose from ~50% to over 70% of fatty acyl species 
in hepatic cardiolipin when animals were fed a higher fat diet, regardless of the source. This 
increase was accounted for primarily by decreases in total monounsaturated fatty acid (MUFA) 
species (16:1n-7, 18:1n-9, and 18:1n-7) where the largest single change observed was an ~10% 
decrease in the proportion of palmitoleate (16:1n-7). Interestingly, the proportion of 22:6n-3 in 
hepatic cardiolipin was similar in rats across all dietary treatments, including the fish oil-enriched 
diet, when animals were fed fat at a 5% total fat level, indicating little effect of fish oil 
supplementation at low levels [189]. When the dietary content of fat was increased to 30%, the 
proportion of hepatic cardiolipin 22:6n-3 decreased in animals from all diet groups except for the 
fish oil-enriched diet, which stayed essentially the same. In animals fed BD, lard, or fish oil diets 
at a 5% total fat level, hepatic cardiolipin arachidonate content varied significantly from ~3% to 
2% to 1%, respectively. When animals were fed these same diets at a 30% fat level, the content of 
arachidonate made up a similar proportion of total hepatic cardiolipin fatty acyl species in BD and 
lard-enriched diets (~1.5 to 2%), whereas it represented a significantly lower proportion when 
animals were fed fish oil-enriched diets. Interestingly, the total content of saturated fatty acids in 
hepatic cardiolipin was not different across dietary groups, regardless of the percentage fat in the 
diet, and comprised ~8-10% of total fatty acyl species. 
Another study performed by Chicco et al. (2008) examined the effects on heart cardiolipin 
content and composition of spontaneous hypertensive heart failure prone rats (SHHR) (Mccfacp-/-) 
fed either a 20 kcal% lard diet, or a 20 kcal% high-linoleate safflower oil diet, compared to animals 
fed a control chow diet [138]. This strain of rats exhibits progressive cardiac hypertrophy leading 
to a distinct decrease in tetra-linoleoyl cardiolipin with advancing age. Dietary treatments were 
therefore initiated relatively late in life, at 18 months, and were continued until natural death 
occurred, with a mean duration of exposure to diets of approximately 5 months. In this study, 
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changes in cardiolipin composition between dietary groups were substantial. While the lard-
enriched diet had no significant effect relative to the low-fat chow diet on the proportion of tetra-
linoleoyl cardiolipin in rat hearts, which was close to 40% in both groups at death, the high-18:2n-
6 safflower-enriched diet resulted in a significant increase in cardiac tetra-linoleoyl cardiolipin 
species to ~80% of the total. Given the importance of maintaining tetra-linoleoyl cardiolipin in 
heart, this work suggests that dietary linoleic acid supplementation may have benefit for the 
maintenance of cardiac health in later life.    
 
Dietary enrichment with MUFA vs. PUFA  
 A study by Kramer and colleagues using 3-week old male Sprague-Dawley rats fed diets 
containing 20% (w/w) corn oil, 20% (w/w) soybean oil, or 20% (w/w) olive oil [137]. The most 
striking difference between these diets was in the relative contents of 18:2n-6 and 18:1n-9. The 
corn oil and soybean oil enriched diets contained ~60% and ~50% linoleic acid, respectively, but 
only ~24-25% oleic acid, whereas the olive oil-enriched diet contained over 75% oleic acid, but 
only ~7% linoleic acid. Over the course of a 16-week trial, rats fed the corn oil or soybean oil diets 
displayed significantly higher levels of cardiac cardiolipin linoleate (~85% of fatty acyl species) 
compared to rats fed the olive oil diet, where cardiac cardiolipin linoleate content was only ~52%. 
Not surprisingly, the difference in the proportionate content of fatty acyl species in cardiac 
cardiolipin in olive oil diet-fed rats was largely accounted for by enrichment with oleate. This 
study is important since it highlights the striking degree of influence that dietary fatty acyl 
composition can exert on cardiac cardiolipin profile. It also highlights that this change is possible 
either in animals at either a very young [137] or advanced age [138]. In addition, this study also 
emphasizes the apparent importance for a specific cardiolipin fatty acyl species in heart. The 
cardiac mitochondrial membranes of rats fed diets rich in oleic acid (i.e. olive oil) or alpha-
linolenic acids (i.e. soybean oil) over 16 weeks were more easily lysed, and generated a higher 
content of free fatty acids and lysophosphatidylcholine during lipid extraction than those fed diets 
high in linoleic acid (i.e. corn oil) [137]. These effects were positively correlated with heart lesions 
in male rats fed oils high in oleic acid and alpha-linolenic acid for an extended period of time 
[137].   
 
Dietary enrichment with n-3 PUFA vs. n-6 PUFA  
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 Perhaps the most intriguing dietary intervention studies are those that examine the effects 
of PUFAs on cardiolipin remodeling and content, since PUFAs have been shown to be important 
in maintaining cardiolipin function in oxidative metabolism [148-150], but there is still some 
debate as to whether n-6 PUFA is more effective than n-3 PUFA in supporting cardiolipin function. 
Swanson and Kinsella (1986) observed that Sprague-Dawley rats fed diets containing increasing 
percentages (5%, 10%, and 20%) of menhaden oil over 3 weeks had increasing levels of 22:6n-3 
(ranging from ~8% to ~21% of cardiac cardiolipin fatty acids) as well as increasing levels of 20:5n-
3 (ranging from an undetectable level to ~3.5%), but contents of 18:2n-6 and 20:4n-6 that 
decreased by ~one-third to one half [191]. This study observed the largest changes in heart 
cardiolipin composition with the 10% menhaden oil diet. Unlike changes observed with diets 
enriched by lard or n-6 PUFA, the changes in molecular cardiolipin species resulting from n-3 diet 
supplementation can happen quite rapidly and are evident within only a few weeks.  
In another report, the work of Pepe et al. (1999) reported little effect of a high n-6 PUFA 
diet relative to a high n-3 PUFA (fish oil supplemented) diet in preventing the age-related decline 
in cardiac cardiolipin linoleate levels in Wistar rats [192]. In fact, surprisingly, this study reported 
that increasing the n-6:n-3 PUFA ratio in rat cardiac mitochondria by feeding an n-6 PUFA 
enriched diet significantly attenuated the calcium-dependent activation of pyruvate dehydrogenase 
(PDH). This enzyme is important in driving the proton-motive force, which is required in oxidative 
phosphorylation, suggesting poorer function associated with the supplementation of n-6 PUFA in 
aging animals. Conversely, this study also reported that the function of pyruvate dehydrogenase 
was significantly augmented in rats fed an n-3-rich diet, where a higher n-3:n-6 ratio developed in 
their cardiac mitochondria membranes. In the same study, older rats (age 24 months) fed either 
standard, low fat reference, or n-6-rich diets, had significantly increased mitochondrial 
concentrations of calcium, and were more likely to reach calcium overload after 
ischemia/reperfusion as compared to rats fed n-3-rich diets [192]. The higher n-3:n-6 ratio in rats 
fed an n-3-rich diet was hypothesized to confer a cardioprotective effect compared to rats with 
higher n-6:n-3 ratios [192]. This study therefore suggests that n-3 PUFA in heart cardiolipin may 
play a beneficial role.  
However, this role clearly merits significant further investigation, since not all studies 
identify benefit associated with the diet-mediated enrichment of cardiac cardiolipin with n-3 
PUFA. In seven week-old Sprague-Dawley rats supplemented for 4 weeks, an approximate 2-fold 
 37 
higher linoleate content occurs in cardiac cardiolipin with 20% corn oil feeding relative to 20% 
sardine oil feeding [193]. Conversely, rats fed sardine oil had ~11-fold higher total n-3 PUFA in 
cardiolipin relative to those fed corn oil [193]. In this study, it was also shown that mitochondrial 
respiratory function was significantly impaired in rats fed sardine oil versus corn-oil. The 
researchers postulated that since cardiolipin is required for cytochrome c oxidase activity, the diet-
mediated change in cardiolipin composition in sardine-oil fed rats had decreased cardiolipin 
content and, thus, mitochondrial respiratory function [193]. A summary of dietary intervention 
studies that examined alterations in CL content and fatty acyl profile is shown in Table 3.  
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Table 3: Influence of dietary intervention on cardiolipin content and fatty acyl profile. 
 Animal Model Tissue 
Diet 
length 
Diet (%w/w, except 
where noted) 
Diet Type Effect on CL Ref. 
SFA vs. PUFA        










5% Fish Oil 
30% Lard 





High-fat (30%) diets increased 18:2n-6 
cardiolipin by ~20% 
DHA in cardiolipin unchanged at low-fat 
(5%) levels, but decreased at high-fat (30%) 
levels except in the 30% fish oil rats. 
AA in cardiolipin decreased by 1% 
respectively between basal, lard, and fish 
diets at 5%. No change in cardiolipin AA at 
30% diet between basal and lard diets, but 
decreased in the fish oil diet. 
No changes in SFA between diets. 
[189] 










20% Lard (%kcal) 





Heart 18:2n-6 cardiolipin unchanged by lard 
diet 
HL-Safflower diet increased heart 18:2n-6 
cardiolipin by 40% 
[138] 
MUFA vs. PUFA        







20% Corn Oil 
20% Olive Oil 




Heart 18:2n-6 cardiolipin increased in rats on 
corn and soybean oil diets relative to those on 
the olive oil diet 
 
[137] 
n-3 vs. n-6 PUFA        





20% Corn Oil 
20% Sardine Oil 
n-6 PUFA 
n-3 PUFA 
Corn oil-fed rats had 2-fold higher 18:2n-6 in 
heart cardiolipin vs. sardine oil-fed rats 
Sardine oil-fed rats had 11-fold higher n-3 
PUFA in heart cardiolipin vs. corn oil-fed rats 
[193] 







5% Menhaden Oil 
10% Menhaden Oil 




(5%) Increased menhaden oil increased 22:6n-
3 in heart cardiolipin vs. controls 
(10%) Increased menhaden oil increased 
20:5n-3 in heart cardiolipin vs. controls 
(20%) Increased menhaden oil decreased 
18:2n-6 and 20:4n-6 vs. controls 
[191] 





15% Animal Fat 
15% Fish Oil 
n-6 PUFA 
n-3 PUFA 
Increased n-6:n-3 diet had no effect in 
changing 18:2n-6 levels in heart cardiolipin 
[192] 
*DHA = docosahexanoic acid, AA = arachidonic acid, HL = high linoleate 
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Diseases associated with aberrant cardiolipin remodeling 
Changes in cardiolipin content or molecular species can have functional and pathological 
consequences.  
 
Barth Syndrome (BTHS) 
 BTHS is a rare, X-linked autosomal recessive disorder first described by Peter Barth in 
1983 [176]. Because BTHS is an X-linked disorder, it is much more prevalent in males [180], 
although cases in females have been reported as well [194]. BTHS typically manifests as skeletal- 
and cardiomyopathies [151, 176, 180], first presenting as heart failure [176, 195-197], and it is 
also characterized by cyclic neutropenia [176, 195], 3-methylglutaconic aciduria [198], stunted 
growth [199], and cognitive impairment [179, 196]. The estimated incidence in 2013 was 1.5 
cases/1 million births [200], however, there is speculation that the disease as a whole may be under-
diagnosed [178]. Recently, a clinical test for cardiolipin species [201] has been developed, which 
may facilitate detection of this disease.  
Traditional testing for Barth Syndrome involves measurement of the MLCL:tetralinoleoyl 
cardiolipin ratio, as well as sequencing of the TAZ gene [202], since BTHS results from loss-of-
function mutations in humans of TAZ (also known as G4.5) on chromosomal region Xq28 [203], 
which translates to a loss of function of the phosphatidylcholine transacylase Tafazzin [175]. 
Mutations in Tafazzin do not decrease the rate of de novo cardiolipin synthesis, but rather cause a 
failure to remodel cardiolipin with linoleoyl residues [152, 174]. Despite this, both a decline in 
total cardiolipin levels and reduced remodeling of cardiolipin is evident in cells with TAZ 
mutations, because cardiolipin is inadequately reformed from MLCL. Effects of this mutation are 
most evident in cardiolipin of the heart and skeletal muscle [152]. The loss of tetra-linoleoyl 
cardiolipin formation through mutations in Tafazzin causes an increase in trilinoleoyl MLCL, an 
intermediate species found in cardiolipin remodeling [174, 204, 205]. This ultimately changes the 
mitochondrial ultrastructure in BTHS patients [206]. Thus far, there have been more than 70 
disease-causing mutations reported in the TAZ gene [205]. These span all exons, although 





 Defective cardiolipin remodeling has also been linked to the pathogenesis of 
neurodegenerative diseases. Alzheimer’s and Parkinson’s Diseases are associated with increased 
oxidative stress and lipid peroxidation [144, 145, 208-215]. As a highly unsaturated lipid, 
cardiolipin is a target for ROS-mediated damage [216, 217]. During aging, the brain content of 
cardiolipin decreases [148, 158], and this has been attributed to peroxidative destruction of 
cardiolipin by ROS [218]. Indeed, post-mortem analysis of cardiolipin in brains from Alzheimer’s 
Disease patients demonstrates a reduction in DHA and total PUFA species [115] that is thought to 
contribute to the early synaptic mitochondrial dysfunction seen in this disease [154].  
Cardiolipin is a potent regulator of both mitophagy and mitochondrial-mediated apoptosis, 
since it functions to anchor cytochrome c to the inner mitochondrial membrane. However, when 
cardiolipin becomes peroxidized, it translocates to the outer mitochondrial membrane in a process 
that is mediated by the mitochondrial proteins NPDK-D [124], and PLS3 [125]. Upon 
externalization to the outer mitochondrial membrane, cardiolipin releases cytochrome c into the 
cytoplasmic space, which acts as a signal to initiate mitophagy, resulting in the elimination of 
damaged mitochondria [128]. Failure to achieve the correct acyl species of cardiolipin is 
detrimental to mitochondrial function [155-157], and may cause the mitochondrial membrane to 
undergo depolarization, which can induce mitophagy [127, 128]. Decreased mitochondrial content 
is often seen in neurodegenerative diseases, as well as aging [158, 219]. In Parkinson’s Disease, 
α-synuclein binds to phospholipids associated with mitochondrial membranes [220-223], forming 
a complex with cardiolipin and cytochrome C that promotes cardiolipin oxidation. This may be a 
factor in the etiology of the disease [224].  
 
Cardiomyopathies 
 Abnormalities in cardiolipin, the third most abundant phospholipid in heart [105], are 
associated with the progression of cardiomyopathies. During the development of heart failure in 
both rats and humans there is a decrease in total cardiolipin, as well as a loss of the hallmark 
molecular species tetralinoleoyl-cardiolipin [225]. These losses are also observed in pediatric 
idiopathic dilated cardiomyopathy, although unique cardiolipin fatty acyl profiles are seen in 
children with heart failure as compared to adults [226]. Many of these changes are explained by 
differences in expression of enzymes involved in cardiolipin biosynthesis and remodeling during 
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heart failure [157]. MLCL-AT1 has 3-5-fold higher expression during heart failure, whereas 
Tafazzin expression significantly decreases, and ALCAT1 expression does not change [157].  
Although the functional significance of changes in cardiolipin fatty acyl profile are 
currently uncharacterized in most tissues, it is clear that tetra-linoleoyl-cardiolipin is critical for 
normal heart function [174, 225], and that alterations in the fatty acyl profile of heart cardiolipin 
can have significant consequences for the development of disease. ALCAT1-mediated remodeling 
increases the peroxidation index of cardiac cardiolipin, rendering mitochondria more susceptible 
to oxidative damaged-induced dysfunction [143], which is highlighted by studies in mice. Cardiac 
overexpression of ALCAT1 in mice causes increases in both oxidative stress and depletion of 
mitochondrial DNA [227, 228], while genetic ablation of ALCAT1 prevents the onset of 
cardiomyopathy, and cardiac dysfunction [227]. Future work will be required to determine whether 
changes in unsaturation of mitochondrial cardiolipin are linked to function of this organelle and 
susceptibility to damage in tissues other than heart. 
 
Tumor progression 
There is increasing evidence that aberrant cardiolipin remodeling, as well as decreased 
cardiolipin content, are factors in the development of tumors. Studies report significantly increased 
contents of ‘immature’ or unremodeled cardiolipin in tumor cells and experimental tumors from 
murine models [229-233]. Atypical molecular species of cardiolipin are thought to contribute to 
tumor progression by dysregulating mitochondrial function, since cardiolipin remodelling is 
required for normal oxidative phosphorylation activity [155-157]. Mature cardiolipin is involved 
in the formation and stabilization of electron transport chain complexes [123, 234, 235] and  has a 
role as a proton trap during oxidative phosphorylation [13]. Promotion of tumor growth through 
defects in mitochondrial function was first hypothesized by Otto Warburg in 1956 [236], and is 
known as the Warburg theory of cancer. This theory remains the subject of controversy and 
ongoing research. In support, however,  Kiebish et al. (2008), have observed significant decreases 
in cardiolipin content and ETC activity in mitochondria from mouse brain tumors as compared to 
mitochondria from control brain tissue [229]. Additionally, a significant reduction in the diversity 
of molecular species of cardiolipin has also been reported in mouse brains affected by the presence 
of microgliomas [229, 233, 237, 238]. In prostate tumors, cardiolipin enriched in palmitoleic acid 
(16:1n-7) has been found to accelerate prostate tumor growth, and to be significantly higher in 
 42 
malignant tissue as compared to non-malignant tissue [231]. The functional relationship between 




While cardiolipin in eukaryotic cells is almost exclusively localized to the inner 
mitochondrial membrane, in prokaryotes it is resident in the outer plasma membrane [129]. Thus, 
prokaryotic cardiolipin on the plasma membrane of bacteria can act as a potent immunogenic 
target, which would not typically be detected by immunosurveillance of eukaryotic cells due to 
the deep internalization of this lipid within intracellular organelles. Glyco- and phospholipids act 
as natural ligands for major histocompatibility complexes (MHC) and MHC-like proteins, which 
are involved in presenting antigenic structures to T-cells [239-241]. Specifically, CD1d, an MHC-
like protein, has been observed to bind and present cardiolipin to  T-cells [242], a subset of T 
cells that exist in the spleen and livers of healthy mice. Thus, cardiolipin may help to regulate host-
pathogen interactions. As well, it has recently been demonstrated that both bacterial and 
mitochondrial cardiolipin externalization on the plasma membrane serves as an ‘eat-me’ signal, 
which is mediated by the CD36 receptor [243]. Thus, externalized cardiolipin generated during the 
cellular processes of mitophagy and mitochondrial-mediated apoptosis [127, 128, 244] may serve 
as factors regulating host-host interactions in which mitochondria or the entire cell is phagocytosed 
[243]. X-ray crystallography has characterized the physical interaction between CD1d and 
cardiolipin [242]. However, it has not yet been determined whether modification of specific 





Methods and Materials 
 
Materials 
 Lysophospholipids, phospholipid standards, and non-radiolabeled acyl-CoAs were from 
Avanti Polar Lipids (Alabaster, AL). Reverse Transcriptase was purchased from Thermo Scientific 
(Waltham, MA). TRIzol, cell culture medium and additives were from Life Technologies 
(Carlsbad, CA). Thin layer chromatography (TLC) plates were from Analtech (Newark, DE). 
Radiochemicals were purchased from Moravek Biochemicals (Brea, CA) and American 
Radiolabeled Chemicals (St. Louis, MO). The TnT Coupled Reticulocyte Lysate System was 
purchased from Promega (Madison, WI).  
 
Animals 
 All animal procedures were approved by the University of Waterloo Animal Care 
Committee under AUPP-13-13 and AUPP-17-18. Animals were housed in a temperature and 
humidity controlled environment, on a 12:12 hour reversed light/dark cycle. Where possible, 
littermates were used. Male C57BL/6J mice aged 12 weeks were used for studies on endogenous 
HRASLS1 content and subcellular localization in brain cellular fractions. All animals had ad 
libitum access to food and water. 
 
Cell Culture and Cell Counting 
 All cells were maintained at 37C, with the addition of 5% CO2. Human embryonic kidney 
(HEK-293) cells were cultured in 10 cm tissue culture-treated dishes in Dulbecco’s Modified 
Eagle’s Medium (DMEM) containing 10% fetal bovine serum (FBS) and 1% penicillin-
streptomycin. Epstein-Barr virus-transformed Barth Syndrome (BTHS) B-lymphocytes from a 10-
year-old Caucasian male, and male age- and ethnicity-matched control B-lymphocytes were 
obtained from Coriell Biorepository. The specific mutation of BTHS B-lymphocytes utilized was 
a hemizygous change of C>T in exon 3 of the TAZ (G4.5) gene [C.280>T), resuting in the 
substitution of cysteine for arginine at codon 94. B-lymphocytes were cultured in suspension in 25 
mL flasks in Roswell Park Memorial Institute (RPMI) 1640 medium containing 2 mM L-
glutamine, 10% FBS, and 1% penicillin-streptomycin. For experiments requiring the addition of 
NAE treatments, charcoal-stripped FBS (HyClone, ThermoFisher, Waltham MA, USA) was 
 44 
utilized in replacement of standard FBS (Gibco, ThermoFisher). Cells were routinely sub-cultured 
upon reaching 90% confluence by trypsinization with 0.25% trypsin-EDTA.  
 Cell counting was performed using a Z2 Coulter Counter (Beckman-Coulter) as previously 
described [245], with minor modifications. Briefly, cells were centrifuged at 1,000 x rpm for 5 
minutes at room temperature in order to pellet cells. Cells were then re-suspended in 2 mL of 
appropriate media, following which 100 μL of cells was aliquoted to a counting vial containing 10 
mL of sheath fluid. Cells were counted by the Z2 Coulter Counter, and plated at appropriate 
seeding densities based on the cell type. 
 
RNA Extraction, Reverse Transcription (RT) and Real-Time (q) PCR 
Total RNA was isolated from mouse organs or cell homogenates using TRIzol Reagent 
(1 mL/100 mg tissue) using a Polytron homogenizer (VWR, Radnor PA) set at the highest 
speed. Samples were then incubated at room temperature for 5 minutes, followed by the addition 
of chloroform (20% of TRIzol volume) with vigorous shaking for 15-20 seconds, incubation at 
room temperature for 2 minutes, and centrifugation at 12,000 x g for 15 minutes at 4C. The upper 
aqueous phase of each sample was removed and mixed with isopropanol (50% of initial volume 
of TRIzol), and incubated at room temperature for 10 minutes to precipitate the RNA. Samples 
were then centrifuged at 12,000 x g for 10 minutes at 4C, pelleting the RNA. The supernatant was 
discarded and the pellet was washed in 1 mL of 75% ethanol-25% DEPC-ddH2O, centrifuged at 
7,500 x g for 5 minutes at 4C, then air-dried for 5-10 minutes prior to suspension in 50 L DEPC-
ddH2O. The samples were then incubated at 58C for 10 minutes to facilitate solubilisation, and 
stored long-term at -80C. RNA samples were quantified using a Nanodrop 2000 
Spectrophotometer and samples were adjusted to 1 g/L. cDNA was synthesized from 1 g of 
RNA by oligo(dT) priming using a High-Capacity cDNA Reverse Transcription Kit according to 
the manufacturer’s protocol (Thermo Scientific). Briefly, 1 g of RNA was mixed with 10 L of 
a reverse-transcription master mix with pre-added RNAse inhibitors (2 L of 10X RT Buffer, 0.8 
L of dNTP mix (100 mM), 2 L of RT Random Primers (oliogoDT), 1 L of Reverse 
Transcriptase, 4.2 L of ddH2O). Samples were then incubated in a thermocycler at 25C for 10 
minutes, followed by 37C for 120 minutes, then finally 85C for 5 minutes. cDNA was stored 
long term at -20C. To examine semi-quantitative changes in gene expression, cDNA was diluted 
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1:4 and 1 L was mixed with a master mix containing 2 L of 10X PCR Buffer with added MgCl2, 
0.4 L of 25 mM dNTPs, 1 L each of Forward and Reverse primers (5 M each), 0.1 L of Taq 
Polymerase, and 14.5 L of ddH2O. Samples were then incubated in a thermocycler under the 
following conditions: 95C for 4 minutes, followed by 30 cycles at 95C for 30 seconds, 60C for 
30 seconds, 72C for 1 minute. Samples underwent a final extension at 72C for 7 minutes. 
Amplicons were resolved on a 2% TAE-agarose gel with ethidium bromide for visualization under 
UV light by a Chemidoc Touch Imaging System (BioRad). A list of primer sequences used for 
semi-quantitative PCR analysis is found in Table 4 below. 
For real-time PCR assays (qPCR), 2 L of cDNA was added to a 96-well plate pre-loaded 
in each well containing 7.5 L of SYBR Green (BioRad) Master Mix, 6.67 M of each forward- 
and reverse-primer (pre-diluted to 100 M stock, 1 L of each added), and 4.5 L of ddH2O. In 
the case of 18S, expression studies were performed using a TaqMan gene expression assay 
(Hs99999901_s1) and PerfeCTA qPCR FastMix (Quanta Biosciences, Gaithersburg, MD). 
Thermal cycling conditions were 95C for 2 minutes, followed by 40 cycles at 95C for 10 
seconds, then 60C for 20 seconds. At the end of the cycling protocol, a melt curve analysis was 
run to ensure primer specificity for the intended product of interest. Gene expression levels were 
calculated using the 2-Ct method, expressing results normalized to 18S, and relative to expression 
in control samples. A list of primer sequences used for qPCR analysis is found in Table 5 below.
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Gene Organism Primer name Direction  Primer Sequence (5’ → 3’) 
Product 
size 
Hrasls1 Mouse Hrasls1-1L 
Forward TGC CTG AGG CGT GCT TGG AGG ATT TG 
124 bp 
Reverse CGC CGC GCC ACC TCT GAT CCC TCC GC 
Hrasls1 Mouse Hrasls1-1SA 
Forward CTG AGC TGT GAG CAG GCG ATT TGT GTG 
166 bp 
Reverse AGC CAT CAC CCA AGT ACA GTG CCC AG 
Hrasls1 Mouse Hrasls1-1SB 
Forward TAA GAC AAC CCA GCT TGA GCA GGG AG 
115 bp 





Forward GAT CCA TTG GAG GGC AAG TCA 
79 bp 






Forward TGC TGT CTC CAT GTT TGA TGT ATC T 
86 bp 




Forward CAC CCA AGA ACA GGG TTT GT 
107 bp 
Reverse TGG CCA TGG GTA TGT TGT TA 
MT-ND1 Human MT-ND1 
Forward TCC TCT TCT TAA CAA CAT ACC 
227 bp 
Reverse AGA GGG TGA TGG TAG ATG T 
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Gene Forward Sequence, 5’ → 3’ Reverse Sequence, 5’ → 3’ Product size 
GPAT1 TCG GGC AGG ACT TTT GTC AG GGT TTG CCC AGT TGT TCA CC 135 bp 
GPAT2 CAT CAG AAG CTC CTG GGG GA GCC CAG AGA AGC CTA CAT CA 79 bp 
GPAT3 GCC TCT GAG GGT TAC CTT GG GAT CCG GCA GCA AGT CAG AT 133 bp 
GPAT4 TGC CGG AAA GGA ATG GAG AC CCA GTG CTA TCC TGA GCG G 193 bp 
AGPAT1 AAC GTG GCG CCT TCC A GAA GTC TTG GTA GGA GGA CAT GAC T 77 bp 
AGPAT2 GGT ACT CGC AAC GAC AAT GG TTG GTG TTG TAG AAG GAG GAG AAG 125 bp 
AGPAT3 CTC TGG AGC CAA CTG GTC AT GAG GAT GAT GAC TGC GTG CT 114 bp 
AGPAT4 GCA CGG AAT GCA CCA TCT TC CTT GGA GCC CCC TAA CAG C 149 bp 
AGPAT5 GGA CGC AGG AAC TCC AAT GT GCA GCA AAT GCC TGA ACT AGC 99 bp 
CDS1 GTG TTT GGA TTC AAT GCT GCC T AGG GCT CAC ATT CTG TCA CG 106 bp 
CDS2 CAG TCA GTC ATT GGC TGG AAA A ATC CTC CAA AGG GGC CAA TG 100 bp 
PGS GTC AAG CTC CAG AGG CTG TT CAG CCA TGG TGA CCT AAG GA 95 bp 
CLS CTT GGT GGC AGC TTC TTT GG GGC CCT GTT CCC ATT GAT GT 210 bp 
TAZ TGG ACC AAG TAC ATG AAC CAC C TTC AGG TTC CAG ATG TGG CG 169 bp 
ALCAT1 CAT GGT GTC ATG GAA AGG GA TCC AAT AAT GCC ACA GGT AGG G 136 bp 
TFP TCG GCA TCT GGG TTT TAG TC GGT CAG CAA AGC AGA AGA CC 234 bp 
PPAR GCG AAC GAT TCG ACT CAA GC AAA ACG AAT CGC GTT GTG TG 139 bp 
RXRa TTT CCT GCC GCT CGA TTT CT AGC TGA TGA CCG AGA AAG GC 194 bp 
TRPV1 TGC GGT CAA GCA GAG TTT CA CGT GAC GTC CTC ACT TCT CC  198 bp  
GPR55 CAG TCC ACC TGG GGT TCT TC  TGC TTG GCT CTG CAC TCT AC 70 bp 
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Cloning of Full-length HRASLS1 cDNA, HRASLS1-GFP, and generation of HRASLS1 
adenovirus  
Full length murine Hrasls1 (NM_013751.5) was amplified by PCR from mouse whole 
brain cDNA with the addition of NotI and SalI restriction sites to the N-terminal and C-terminal 
ends, respectively, using the following primers: Forward: 5’- ACA GGA TTC CTC GGC GTG 
CTA CC -3’, Reverse: 5’- GGT TCT CCT CAT CAG GGA CTC TA -3’ The resulting amplicon 
was subcloned into pGEM-T-Easy resulting in production of pGEM-Hrasls1 that was verified by 
direct sequencing, and was then cut with NotI/SalI restriction enzymes for directional subcloning 
into pET 43.1 resulting in production of pET-Hrasls1-6His. Adenovirus was generated using the 
Ad-Easy® Adenoviral Vector System. A full-length HRASLS1 amplicon with a C-terminal 6 x 
His tag and Not1 and SalI restriction sites at the N-terminal and C-terminal ends was produced by 
PCR using 50 ng of pGEM-HRASLS1 as template and the following primers: Forward: 5’ATT 
TCT AGG GCC CTC CAG GAC CA-3’, Reverse: 5’-TGG GTC CTA AAA GCG CTA TTC GTC 
CAA-3’. The resulting amplicon was subcloned in frame into pShuttle-IRES-hrGFP2. pShuttle-
IRES-hrGFP2-HRASLS1 was linearized by digested with PmeI, and transformed into chemically 
competent BJ-5183 cells that are pre-transformed with Ad-1. Recombinant adenovirus was 
verified by PacI digest and direct sequencing, amplified in E. coli, linearized by PacI digest, then 
transfected into HEK-293 cells for formation and amplification of active adenoviral HRASLS1. 
Control adenovirus was produced by the same method, but using pShuttle-IRES-hrGFP2 without 
DNA insertion into the multiple cloning site for the formation of Ad-1 recombinants in BJ-5183 
cells. Amplified virus was titred by serial dilution in cultures of HEK-293 cells grown in 12-well 
plates, and quantified by fluorescence microscopy-based counting of infected cells in multiple 
frames per well. 
 
Generation of HRASLS1 Protein in HEK-293 Cells 
For production of lysates overexpressing HRASLS1 or control virus, HEK-293 cells grown 
in 150 mm plates were infected at a multiplicity of infection (MOI) of 20 infectious units (IFU) 
per cell, then harvested 48 hours later, washed with PBS, and lysed in Lysis Buffer 2 (100 mM 
Tris-HCl, pH 7.0, 10mM NaCl) by sonication on ice (65% output, 3 x 6 s), which efficiently 
disrupts mitochondria and other organelles. Unbroken cells and organelles, and cellular debris 
were cleared by centrifugation (10,000 x g for 10 minutes). This process will pellet any remaining 
unbroken mitochondria, but not sub-mitochondrial particles generated by sonication. Protein 
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content in supernatant fractions were quantified using Bradford assay solution and kept at -80°C 
for long-term storage. 
 
Generation of HRASLS1 Recombinant Protein from Reticulocyte Lysates 
 Recombinant HRASLS1 was generated in reticulocyte lysates by utilizing a transcription-
translation TnT Coupled Reticulocyte Lysate System under a T3 promoter (Promega) as per the 
manufacturer’s directions. Briefly, 1 g of either pCMV-3Tag-3A (control) or pCMV-HRASLS1-
3FLAG DNA was added to a tube pre-loaded with a master mix containing the following 
components: 25 L TnT Reticulocyte Lysate, 2 L TnT Reaction Buffer, 1 L TnT T3 RNA 
Polymerase, 0.5 L Amino Acid Mixture, Minus Leucine (1 mM stock), 0.5 L Amino Acid 
Mixture, Minus Methionine (1 mM stock), and 17 L ddH2O. Samples were incubated in a heating 
block at 30C for 90 minutes, following which they were immediately placed on ice. Relative 
protein concentrations were determined by loading 1 L of sample into a SDS-PAGE stain free 
acrylamide gel, which was then electrophoresed at 200 V for 40 minutes. Following 
electrophoresis, a stain-free image was taken on a ChemiDoc Touch Imaging System (BioRad), 
and analysed for total protein per lane by ImageLab Software (BioRad). Arbitrary units 
representing total protein per lane of sample were made relative to units representing total protein 
per lane for 5 g of BSA loaded as a control, in order to estimate protein concentrations. To 
minimize differences in loading between samples, sample concentrations were then adjusted 
relative to one another (See Appendix A for illustration of this method). Samples were separated 
into 10 L aliquots and stored long term at -80C. For use in enzyme assays, samples were thawed 
a maximum of two times to minimize loss of enzyme activity due to freeze-thawing.  
 
Protein Extraction and Immunoblot Analysis 
 Protein lysates were extracted from cultured cells or whole murine tissue. For protein used 
in enzymatic assays, cells were mechanically scraped in 5 mL of PBS and transferred into a 15 mL 
tube, upon which samples were centrifuged at 3,000 x rpm for 5 minutes to pellet the cells. The 
supernatant was removed and the cell pellet was reconstituted in 100 L Buffer A (100 mM Tris-
HCl, pH 7.4, 5 mM NaCl, 3 mM MgCl2, with 1% protease inhibitor cocktail) and lysed by 
sonication in an ice-slurry bath (65% output, 3 x 6 seconds), which efficiently disrupts 
mitochondria and other organellar membranes. Unbroken cells and organelles were cleared by 
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centrifugation at 10,000 x g for 10 minutes at 4C. This process will pellet any remaining 
mitochondria, but not sub-mitochondrial particles generated by sonication. Protein in supernatants 
were quantified using Bradford assay [246] solution for use in radiochemical enzymatic activity 
assays. 
 Protein lysates prepared only for use in immunoblotting were prepared in Buffer B (50 mM 
Tris-HCl, pH 6.8, 1 mM EDTA, and 0.5% Triton X-100). Samples were then mixed with 6X 
Laemmeli Buffer (125 mM Tris-HCl, pH 6.8, 20% glycerol, 4% SDS, 10% 2-mercaptoethanol, 
and 0.05% bromophenol blue) and denatured by heating to 95C for 5 minutes. Samples were 
electrophoresed on 12% SDS-PAGE stain-free gels at 200 V for 40 minutes, and transferred to 
nitrocellulose membranes at 350 mA for 90 minutes. Membranes were blocked for 1 hour with 5% 
skim-milk blocker (w/v) in TBST (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% Tween-20), 
then probed overnight in TBST with 3% skim-milk blocker (w/v) using primary antibodies (1:1000 
dilution) directed against HRASLS1, HA, FLAG, CPT1A, SCD1, ACSL4, Histone H3, 
Cytochrome C (Cell Signaling). Membranes were washed 3x with TBST then probed with HRP-
conjugated antibodies in TBST with 3% skim-milk blocker. Blots were washed 3x with TBST and 
bands were detected by enhanced chemiluminescence on a ChemiDoc Touch Imaging System 
(Bio-Rad).   
 
Subcellular Fractionation 
 Subcellular fractions were separated as previously described [247], with minor 
modifications. Briefly, whole mouse brains from C57BL/6J mice were harvested and homogenized 
at 1,000 x rpm in Buffer C (250 mM Sucrose, 50 mM Tris-HCl, pH 7.4, 5 mM MgCl2) then 
centrifuged at 800 x g for 15 minutes to isolate the nuclear fraction. All centrifugation steps were 
performed at 4C. Post-nuclear supernatants were removed to a fresh tube on ice for further 
processing. The nuclear pellet was washed twice by re-suspending in 300 L of Buffer A, with 
added protease and phosphatase inhibitor cocktails, followed by 15 minutes of centrifugation at 
500 x g, then another 15 minutes at 1000 x g. The final pellet was re-suspended in 300 L of Buffer 
B (20 mM HEPES, pH 7.9, 1.5 mM MgCl2, 0.5 M NaCl, 0.2 mM EDTA, 20% (w/v) glycerol, and 
1% Triton X-100), incubated on ice for 30 minutes, then sonicated into homogenous suspension 
while held in an ice bath using three pulses at 65% output for 6 seconds with a 30 second cooling 
period in between pulses. Sonicated nuclei were spun at 9,000 x g for 30 minutes to pellet debris, 
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and the supernatant containing the nuclear fraction was recovered. Post-nuclear supernatants from 
the initial lysis and centrifugation of cells were spun at 11,000 x g for 10 minutes to pellet 
mitochondria. The post-mitochondrial supernatant was removed to a fresh tube and centrifuged 
for 60 minutes at 100,000 x g to pellet the microsomal fraction, following which the cytosolic 
supernatant was removed and placed in a fresh tube. The microsomal pellet was re-suspended in 
50 L of Buffer B by brief suspension of tubes in an ice-cold sonicating water bath. The 
mitochondrial pellet was re-suspended in 100 L of Buffer B and sonicated with three 6 second 
bursts at 65% output in an ice water bath slurry, with a 30 second cooling period in between pulses. 
 Subfractionation of the MAM was performed according to the protocol that is described in 
detail by Wieckowski et al. [248], with minor modifications. Briefly, whole mouse brains or 
vHRASLS1-infected HEK-293 cells were harvested and washed 3x in Buffer F (225 mM 
mannitol, 75 mM sucrose, 30 mM Tris-HCl, pH 7.4), then homogenized with a Polytron® at 1,500 
x rpm in Buffer G (225 mM mannitol, 75 mM sucrose, 0.5% BSA (w/v), 0.5% EGTA, 30 mM 
Tris-HCl, pH 7.4). To isolate crude mitochondria, homogenates were centrifuged at 740 x g for 5 
minutes, and the supernatant was removed and placed in a fresh tube, and then centrifuged for 740 
x g for an additional 5 minutes, upon which the supernatant from the second spin was removed 
once more and placed in a fresh tube. That supernatant was then centrifuged at 9,000 x g for 10 
minutes to pellet crude mitochondria, and the supernatant containing microsomes, lysosomes, and 
the cytosol was discarded. The crude mitochondrial pellet was twice re-suspended in 200 µL of 
Buffer H (225 mM mannitol, 75 mM sucrose, 0.5% BSA, 30 mM Tris-HCl, pH 7.4) and 
centrifuged for 10 minutes at 10,000 x g. The supernatants were discarded and the final crude 
mitochondrial pellet was re-suspended in 200 µL of Buffer I (250 mM mannitol, 5 mM HEPES, 
pH 7.4, 0.5 mM EGTA). To isolate MAM from crude mitochondria, 8 mL of Buffer J (225 mM 
mannitol, 25 mM HEPES, pH 7.4, 1mM EGTA, 30% Percoll (v/v)) was pipetted into an 
ultracentrifugation conical tube. The entire crude mitochondrial homogenate was then carefully 
layered on top of buffer I and approximately 350 µL of Buffer I was layered on top of the crude 
mitochondria suspension to fill up the ultracentrifugation tube. Samples were then centrifuged at 
95,000 x g for 30 minutes, which separated MAM from purified mitochondria. Both the purified 
mitochondrial fraction as well as the MAM fraction were collected, and each was diluted 10X with 
Buffer I. Samples were then centrifuged at 6,300 x g for 10 minutes. To purify the MAM fraction, 
the supernatant of the MAM samples following the previous centrifugation was removed and 
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centrifuged at 100,000 x g for 1 h to pellet the MAM, upon which the supernatant was removed, 
and the pellet was re-suspended in 100 µL of Buffer B. The pellet of the purified mitochondrial 
fraction was re-suspended in 200 µL of Buffer I and centrifuged at 6,300 x g for 10 minutes. The 
supernatant was discarded, and the pellet was re-suspended in 100 µL of Buffer B.  
 
Lipid Extraction, Thin Layer Chromatography (TLC), and Gas Chromatography (GC) 
Total lipids were extracted from HEK-293 cells, or B-Lymphocytes by the method of Folch 
[249]. Briefly, brains were homogenized by a Polytron® homogenizer set at the highest speed in 
3 mL of 2:1 (v/v) chloroform:methanol with added butylated hydroxytoluene as an antioxidant 
(Sigma-Aldrich, Bellfonte PA). Samples were then vortexed at maximum speed for 15 s, followed 
by the addition of 500 µL of Na2PO4, upon which samples were inverted thrice and centrifuged at 
3,000 x rpm for 5 minutes to separate the organic and aqueous layers. The bottom organic layer 
was removed and placed in a freshly labeled tube. Samples were dried under a gentle stream of 
N2, then were reconstituted in 50 µL of chloroform and individual lipid classes resolved by TLC 
as described below.  
Total lipids were extracted from HEK-293 cells  following in vitro radiochemical enzyme 
activity assays via Bligh and Dyer extraction [250]. Briefly, quenched reactions were mixed with 
0.25 mL of chloroform, vortexed thoroughly, mixed with 0.25 mL of ddH2O, vortexed again, then 
centrifuged at 1,000 x g for 5 minutes to separate the aqueous (upper) and organic (lower) phases. 
The organic phase was recovered and dried under a stream of N2. Samples were reconstituted in 
50 μL of chloroform, applied to a silica gel G plate, and resolved by TLC using a hexane:diethyl 
ether:glacial acetic acid solvent system (80:20:2, v/v/v) to resolve neutral lipid classes. Bands 
corresponding to known standards were identified and total phospholipid as well as triacylglycerol 
bands were scraped for determination of fatty acid composition and content by gas 
chromatography. To isolate individual phospholipid species, the scraped phospholipid band 
underwent a double Folch extraction, was dried under N2 gas, then reconstituted in 50 μL of 
chloroform. Phospholipids were then resolved by TLC on a silica gel H-plate using a 
chloroform:methanol:2-propanol:0.25% KCl:trimethylamine solvent front (30:9:25:6:18, 
v/v/v/v/v). Bands corresponding to individual phospholipid species were identified using known 
standards. For radiochemical assays, bands were scraped and counted in 10 ml of liquid scintillant 
(Ecolite, MP Biomedicals, Santa Ana CA, USA). For non-radioactive samples, identified 
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phospholipids were overlaid with 10 μg of 22:3n-3 ethyl ester internal standard (Nu-Check Prep, 
Elysian MN), and scraped for determination of fatty acid composition and content by gas 
chromatography (GC) with flame ionization detection as previously described [251]. Briefly, fatty 
acid methyl esters were derivatized by transesterification using 14% boron trifluoride in methanol 
(Thermo Scientific, Bellfonte PA) with hexane on a 95°C heat block for 1 h. Fatty acid methyl 
esters were analyzed on a Varian 3900 gas chromatograph equipped with a DB-FFAP 15 m x 0.10 
mm injected dose x 0.10 μm film thickness, nitroterephthalic acid modified, polyethylene glycol, 
capillary column (J&W Scientific from Agilent Technologies, Mississauga, Ontario, Canada) with 
hydrogen as the carrier gas. Samples (2 μL) were introduced by a Varian CP-8400 autosampler 
into the injector heated to 250°C with a split ratio of 200:1. Initial temperature was 150°C with a 
0.25-minute hold followed by a 35°C/minute ramp to 200°C, an 8°C/minute ramp to 225°C with 
a 3.2-minute hold, and then an 80°C/minute ramp up to 245°C with a 15-minute hold at the end. 
The flame ionization detector temperature was 300°C with air and nitrogen make-up gas flow rates 
of 300 and 25 mL/min, respectively, and a sampling frequency of 50 Hz [251].  
 
In-vitro Acyl-CoA:Lysophospholipid Acyltransferase Enzyme Assays 
To test direct acyl-CoA-dependent acyltransferase activity by HRASLS1, a substrate 
mixture containing 80 μM of test lysophospholipid, 200 μM oleoyl-CoA, and 0.025 μCi per 
reaction [14C]oleoyl-CoA was prepared, dried under a gentle stream of N2 and reconstituted in 100 
μL of acyltransferase reaction buffer (100 mM Tris, pH 7.0, 4 mg/mL BSA) by vortexing at high 
speed for 30 seconds. To test direct acyl-CoA-independent acyltransferase activity by HRASLS1, 
a substrate mixture containing 80 μM of monolysocardiolipin, 200 μM of oleate and 0.025 μCi per 
reaction [14C]oleate was prepared, dried under a gentle stream of N2, and reconstituted in 100 μL 
of acyltransferase reaction buffer (100 mM Tris, pH 7.0, 4 mg/mL BSA) by vortexing at high 
speed for 30 seconds. Unless otherwise indicated, lysophospholipids utilized were all 1-18:1n-9-
2-hydroxy-lysophospholipid. Reactions were initiated by addition of 100 μL of pre-warmed 
substrate mixture to either 100 μg of sonicated, cleared lysates (i.e. crude lysates) from HEK-293 
cells infected with either adenoviral GFP (control) or adenoviral HRASLS1, prepared as described 
above, or 10 μg of control or HRASLS1-reticulocyte lysates. Reactions were mixed gently, and 
incubated in a 37°C water bath for 30 minutes, then quenched by addition of 0.75 mL of 
methanol:chloroform (2:1, v/v). Lipids were extracted by the method of Bligh & Dyer [250], and 
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resolved by TLC. Individual phospholipid bands were identified using known standards, and 
corresponding bands were scraped and radioactivity quantified by liquid scintillation counting. 
 
In vitro PC:MLCL Transacylase Activity Assay 
To test the transacylase activity of HRASLS1, a protocol similar to that published by Uyama et al. 
was performed, with minor modifications [35]. Briefly, a substrate mixture containing 100 nmol 
of MLCL, 10 nmol of one of 18:0/18:0 PC, 18:1n-9/18:1n-9 PC, or 16:0/18:2n-6 PC, containing 
0.1 μCi (2 nmol) of either [3H-1,2]-18:0/18:0 phosphatidylcholine, [3H-1,2]-18:1n-9/18:1n-9 
phosphatidylcholine, or 1-palmitoyl-2-[14C]-linoleoyl phosphatidylcholine, respectively, was 
mixed and dried under a gentle stream of N2 and reconstituted in 100 μL of pre-warmed (37°C) 
Transacylase Reaction Buffer (50 mM Tris-HCl, pH 8, 2 mM DTT, 0.1% Nonidet P-40). Reactions 
were initiated by addition of 100 μL of pre-warmed substrate mixture to either 100 μg of sonicated, 
cleared lysates (i.e. crude lysates) from HEK-293 cells infected with either adenoviral GFP 
(control) or adenoviral HRASLS1, prepared as described above, or 10 μg of control or HRASLS1-
reticulocyte lysates. Reactions were mixed gently, and incubated in a 37°C water bath for 30 
minutes, then quenched by addition of 0.75 mL of methanol:chloroform (2:1, v/v). Lipids were 
extracted by the method of Bligh & Dyer [250], and resolved by TLC. Individual phospholipid 
bands were identified using known standards, and corresponding bands were scraped and 
quantified by liquid scintillation counting. 
 
High-Resolution Mitochondrial Respirometry 
Mitochondrial fractions were obtained as previously described [252, 253], with minor 
modifications. Briefly, 90-100% confluent 10 cm culture dishes of HEK-293 cells overexpressing 
control or HRASLS1 protein were harvested into 2 mL of MiR05 buffer (0.5 mM EGTA, 3 mM 
MgCl2, 60 mM lactobionic acid, 20 mM taurine, 10 mM potassium dihydrogenphosphate, 20 mM 
HEPES, 110 mM sucrose, and 1g/L essential fatty acid free bovine serum albumin). MiR05 buffer 
is hypertonic to cells, allowing for gentle lysis, and is a mitochondrial respiration buffer developed 
by Oroboros Instruments (Innsbruck, Austria). For mitochondrial isolation, 10 μL of protease 
inhibitor cocktail was added per mL of MiR05 buffer. All centrifugation steps were performed at 
4°C. Homogenates were centrifuged at 1,400 × g for 7 min, which pellets nuclei and cellular 
debris, but not mitochondria. The supernatant was removed and spun at 1,400 × g for 3 min to 
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remove remaining debris. The supernatant was removed to a fresh tube, which was spun at 10,000 
× g for 5 minutes to pellet mitochondria. The mitochondrial pellet was washed in 1 mL of MiR05 
with protease inhibitor, and spun at 1,400 × g for 3 min to further purify the mitochondrial fraction 
from any contaminating nuclei or cell debris. The supernatant was then removed into a fresh tube, 
and spun at 10,000 × g for 5 minutes to pellet the mitochondria again. The supernatant was 
removed, and the mitochondrial pellet was then re-suspended in 250 μL of MiR05 with protease 
inhibitor, and 40 μL was immediately injected into a chamber of Oxygraph-2k respirometer. The 
rest was frozen at -80oC for subsequent protein and immunoblot analysis. 
The rate of mitochondrial oxygen consumption was measured using the Oxygraph-2k 
respirometer (Oroboros, Austria) equipped with the O2k-Fluorescence LED2-Module for 
simultaneous measurement of H2O2 production using Amplex Red [254]. All measurements were 
performed at 37oC. Prior to the addition of mitochondria, 2 mL of MiR05 was equilibrated to the 
chamber and oxygenated to approximately 300 nmol/mL of O2. Components of the Amplex Red 
detection system were added to each chamber (final concentrations; 10 μM Amplex Red, 1 U/mL 
of horse radish peroxidase, and 5 U/mL of superoxide dismutase), as described previously [254]. 
After a baseline was recoded, H2O2 was injected into each chamber (final concentration of 0.1 μM) 
to allow for an initial calibration of the fluorescent signal. To examine the components of the 
electron transport chain in detail, a substrate-uncoupler-inhibitor titration (SUIT) procedure 
adapted from Afshordel et al. 2015 was performed [252]. Forty μL of the isolated mitochondria 
solutions were added to each chamber and respiration was allowed to equilibrate (endog). A 
solution of complex I substrates, including glutamate (5 mM), pyruvate (5 mM) and malate (2 
mM), was added to each chamber in the absence of ADP to determine mitochondrial leak (leak 
(P/G/M). ADP (2 mM) was added to determine the capacity of complex I (CI), followed by the 
addition of the complex II substrate succinate (10 mM) to determine the capacity of complex I+II 
(CI + CII). Cytochrome C (10 μM) was subsequently added to test for mitochondrial integrity. The 
inhibition of ATP synthase with oligomycin (2.5 μM) was then added to determine substrate 
limited leak state (leak (only)). As a maximal measure of ETS capacity, the uncoupler carbonyl 
cyanide m-chlorophenyl hydrazone CCCP (2.5 μM) was added (ETS). Complex II supported non-
coupled respiration (CII) was determined with the addition of rotenone (0.5 μM). The addition of 
antimycin A (2.5 μM), a complex III inhibitor, allowed for the quantification of residual oxygen 
consumption (ROX). Finally, tetramethylphenylenediamine (TMPD) (0.5 mM) and ascorbate (2 
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mM) were added to each chamber to stimulate cytochrome-c oxidase activity (CIV). Autoxidation 
was determined with the subsequent addition of sodium azide (100 mM). All values were corrected 
for ROX, and CIV activity was also corrected for autoxidation. All respirometry and Amplex Red 
fluorescent values were normalized to total protein concentrations, which were determined via 
Bradford assay.  
 
 Metabolic Radiolabelling Experiments in NAE-treated cells 
 Metabolic labelling experiments were performed similarly as described by Uyama et al. 
(2013) [53], with minor modifications. For radiolabeled metabolic experiments, HEK-293 cells 
were grown in 10 cm culture dishes in DMEM with the addition of 10% charcoal-stripped FBS, 
and 1% penicillin. Upon reaching 80% confluence, cells with labelled with the addition of 1 μCi 
of [14C] palmitate and either 0.1, 1, or 10 μM of PEA, OEA, or SEA. Cells were then incubated 
for 48 hours, upon which lipids were extracted by the method of Folch [249]. Phospholipids were 
then resolved on a silica gel H plate in a chloroform:methanol:2-propanol:0.25% 
KCl:triethylamine (30:9:25:6:18, v/v/v/v/v) solvent front. Bands corresponding to cardiolipin as 
identified by known standards were scraped and counted by scintillation counting. 
 
NAE treatment of HEK-293 cells or B-lymphocytes 
 For NAE treatment experiments, HEK-293 cells or B-lymphocytes were seeded into 10 cm 
culture dishes, or 25 mL culture flasks, respectively. Cells were seeded in DMEM (HEK-293) or 
RPMI1640 (B-lymphocytes) with the addition of 10% charcoal-stripped FBS, 1% pencillin-
streptomycin, and NAE added to a final concentration of either 0.1, 1, or 10 μM. Cells were 
incubated for 48 hours, upon which they were harvested for total lipid and RNA extractions. 
 
N-acylethanolamine and 1-AG and 2-AG sample extractions and liquid chromatography-tandem 
mass spectrometry (LC-MS/MS) analysis 
To quantify changes in NAE species and content, HEK-293 cells were infected with control 
or HRASLS1 adenovirus for 48 hours, following which cells were collected by trypsinization and 
pelleted by centrifugation at 1,000 x g for 5 minutes. The supernatant was removed, and the 
pelleted cells were flash frozen in liquid nitrogen and stored at -80C for analysis. Quantification 
of varying NAE species, 1- and 2-arachidonylglycerols (1- and 2-AG), was performed by our 
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collaborators Lin Lin, MSc and Dr. Richard Bazinet at the University of Toronto, as they have 
previously described [255, 256].  
   
Statistical Analysis 
 The results are expressed as means  S.E.M. Statistically significant differences between 
two groups were assessed by Student’s t test. Differences between multiple groups were assessed 






Thesis Study I – Cellular and biochemical characterization of HRASLS1 
 
Introduction and Study Rationale 
The Harvey-Ras-like tumor suppressor (HRASLS) enzymes are a homologous group of 
proteins that are a part of a larger papain-like NIpC/P60 superfamily of vertebrate thiol proteases 
[18, 19]. Growing evidence has indicated a role for HRASLS enzymes in glycerophospholipid 
metabolism due to their abilities to function as O- and N-transacylases, and as phospholipases 
A1/2 [35, 45]. While these enzymes have the ability to perform all three enzymatic roles, each 
isoform has its unique preference of predominant enzymatic activity. HRASLS1 has been 
demonstrated to have phospholipase A1/2 hydrolytic activity, PC:PE N-transacylase activity, and 
PC:LPC O-transacylase activities [45]. These in vitro observations have been supported as well by 
metabolic labeling experiments in cells [35, 36, 45, 53]. However, studies have indicated that the 
O-transacylase activity of HRASLS1 is approximately 8-fold higher than the N-transacylase 
activity, and approximately 5-fold higher than the PLA1/2 activity, indicating that in vitro, 
HRASLS1 predominately acts as an O-transacylase [45].  
While the majority of O-transacylase activity assays of HRASLS enzymes have been 
performed by utilizing PC or PE as the acyl donor, it is reasonable to speculate that HRASLS1 
may be able to hydrolyze and transfer acyl groups from other phospholipids or precursor lipids as 
well. In fact, investigators have also observed O-transacylase activity for other HRASLS family 
enzymes when utilizing lysophospholipids as acyl donors [45, 46]. Additionally, the Duncan study 
(2009) indicated that another HRASLS family member, HRASLS3, shows PLA1 activity with 
other phospholipids including PS and PI, but not PA, indicating diversity in substrate recognition 
[48]. Thus, evidence suggests that it would be reasonable to investigate whether HRASLS1 has 
direct O-transacylase activity in the synthesis of phospholipids other than PC. The O-transacylase 
activity of HRASLS1 has been previously characterized using PC as an acyl donor, and LPC as an 
acyl acceptor [45]. This coupled activity suggests that HRASLS1 may function similar to the 
transacylase Tafazzin, which is a PC:MLCL transacylase that helps to produce tetra-linoleoyl 
cardiolipin [118]. HRASLS1 is most abundant in tissues that have a relatively high mitochondrial 
content including heart, brain, and skeletal muscle [33], signifying a potential role for this enzyme 
in the synthesis and/or remodeling of cardiolipin. However, no specific study has yet 
investigated or proposed a role of HRASLS1 in regulating cardiolipin metabolism. Thus, the 
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overarching objective of this study was to perform the cellular and biochemical characterization 
of HRASLS1. Both O-acyltransferase and O-transacylase activities were investigated, as well as 





Objectives and Hypotheses 
The objectives and hypotheses for this study were as follows: 
1. Objective: To characterize the tissue expression profiles of HRASLS1. 
Hypothesis: HRASLS1 will be ubiquitously expressed, albeit with highest expression in 
heart and brain tissue.  
 
2. Objective: To characterize the subcellular localization of HRASLS1. 
Hypothesis: Consistent with its putative role in cardiolipin biosynthesis, HRASLS1 will 
localize to the outer mitochondrial membrane, but not the mitochondria-associated ER 
membranes (MAM). 
 
3. Objective: To characterize the in vitro acyl-CoA-dependent O-acyltransferase and acyl-
CoA-independent PC:MLCL O-transacylase activities of HRASLS1 in phospholipid 
biosynthesis using crude lysates. 
Hypotheses: As compared to controls, crude lysates overexpressing HRASLS1 will:  
i. Not have significant in vitro oleoyl-CoA-dependent O-acyltransferase activity.  
ii. Have significant in vitro PC:MLCL transacylase activity using MLCL as an acyl acceptor 
and [3H-1,2]18:0/18:0-PC, [3H-1,2]18:1n-9/18:1n-9-PC , and 16:0/[14C]18:2n6-PC as acyl 
donors. 
 
4. Objective: To characterize the direct in vitro O-acyltransferase and O-transacylase 
activities of HRASLS1 in cardiolipin synthesis using reticulocyte lysates. 
Hypotheses: As compared to controls, reticulocyte lysates overexpressing HRASLS1 will:  
i. Not have significant in vitro oleoyl-CoA-dependent O acyltransferase activity utilizing 
oleoyl-CoA as an acyl donor and MLCL as an acyl acceptor. 
ii. Have significant in vitro PC:MLCL transacylase activity using MLCL as an acyl acceptor 







Figure 10: Schematic of the study design of Thesis Study I 
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Results 
HRASLS1 is ubiquitously expressed, but with highest expression in brain and heart 
 Mouse tissue distribution of Hrasls1 was analyzed by RT-PCR. Three Hrasls1 transcript 
variants of variable lengths were analyzed including a longer isoform (referred to as Hrasls1-1L, 
XM_006522203) that has an additional 110 amino acids at the N-terminus, and two transcripts 
encoding the shorter forms (referred to as Hrasls1-1SA [NM_013751] and Hrasls1-1SB 
[NM_001357092.1], respectively). The tissue distribution of Hrasls1 mRNA was analyzed and, 
as expected [33], all three murine transcript variants were found to be highly expressed in mouse 
brain and heart (Fig. 11). All transcript variants of Hrasls1 were also present, albeit at variable 
levels, in the other tissues examined, including liver, lung, kidney, gonadal white adipose tissue 
(WAT), skeletal muscle, spleen, pancreas, and testes (Fig. 11).  
 
HRASLS1 localizes to the endoplasmic reticulum 
 Due to the relative abundance of Hrasls1 in mouse brain, this tissue was used as a source 
for studies examining subcellular localization of endogenous HRASLS1. Following differential 
centrifugation and immunoblot analysis, it was evident that endogenous HRASLS1 is 
predominately found in the microsomal fraction, with a faint band appearing in the mitochondrial 
fraction, but essentially no expression in the nuclear fraction (Fig. 12A). Fractional purity was 
assessed by immunoblotting for the mitochondrial protein cytochrome C, the nuclear protein 
histone H3, and the endoplasmic reticular protein stearoyl-CoA desaturase 1 (SCD1). Although 
fraction purity was very good, the presence of an HRASLS1 band in the mitochondrial fraction 
suggested that either slight microsomal contamination had occurred, or that some HRASLS1 was 
present in a fraction that would potentially co-fractionate with the mitochondria, such as the MAM. 
As a result, further analysis was performed to test whether HRASLS1 is present in the 
mitochondria, or in the MAM. First described by Jean Vance in 1990, the MAM is a sub-fraction 
of the endoplasmic reticulum, which shares contact points with mitochondria, and has been 
implicated in lipid transfer between the two organelles [17]. Mitochondrial isolates were further 
processed, in order to separate the purified mitochondrial fraction from a purified microsomal 
fraction, and a MAM fraction. Immunoblot analysis of isolated fractions indicated that, 
endogenous HRASLS1 was observed almost exclusively in the microsomal fraction, with a slight 
band appearing in the MAM fraction, but with no observable detection in the mitochondrial 
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fraction (Fig. 12B). Fractional purity was assessed by immunoblot analysis for the MAM-specific 
protein acyl-CoA synthase long chain family member 4 (ACSL4), as well as cytochrome C and 
SCD1 for the mitochondrial and microsomal fractions, respectively.   
 
Crude lysates prepared from HEK-293 cells overexpressing HRASLS1 have significant acyl-CoA-
dependent LPI, MLCL, and DLCL O-acyltransferase activity and di-18:1n-9-PC:MLCL 
transacylase activity 
Prior analysis of HRASLS1 by others indicated that the predominant in vitro function of 
this enzyme is PC:LPC O-transacylase activity (rather than N-transacylase activity, or PLA1/2 
activity) [45]. However, the ability of HRASLS1 to catalyze the synthesis of additional classes of 
glycerophospholipids had not been reported. Additionally, whether HRASLS1 catalyzes acyl-
CoA-dependent or acyl-CoA independent reactions had not been directly tested. Therefore, to first 
test whether HRASLS1 has acyl-CoA-dependent O-acyltransferase activity in vitro, crude (post 
nuclear) cell lysates from HEK-293 cells overexpressing control or HRASLS1 (by adenoviral 
infection for 48 hours) were produced (Fig. 13A), and acyl-CoA dependent O-acyltransferase 
activity was assayed. For this work, [14C]oleoyl-CoA was utilized as an acyl donor, and major 
classes of lysophospholipid acyl acceptors were tested, including lysophosphatidic acid (LPA), 
LPC, lysophosphatidylethanolamine (LPE), lysophosphatidylserine (LPS), 
lysophosphatidylglycerol (LPG), lysophosphatidylinositol (LPI), MLCL, and DLCL. Compared 
to reactions performed with control lysates, reactions with lysates overexpressing HRASLS1 
produced significantly more radiolabeled PI from LPI, and CL from both MLCL and DLCL, as 
quantified by liquid scintillation counting (Fig. 13B). Crude lysates overexpressing HRASLS1 
increased esterification of [14C]oleoyl-CoA into LPI by ~2.6-fold compared to control, and 
increased esterification of [14C]oleoyl-CoA into MLCL and DLCL by ~2.6-fold and ~2.9-fold, 
respectively. Under these assay conditions, overexpression of HRASLS1 had no significant effect 
on incorporation of [14C]oleoyl-CoA into LPA, LPC, LPE, LPS, or LPG.  
 Cellular pH varies significantly across different sub regions of cells, and across organellar 
membranes. Optimal pH for the oleoyl-CoA-dependent O-acyltransferase activity that was found 
in crude lysates overexpressing HRASLS1 was assessed by in vitro assay of [14C]oleoyl-
CoA:MLCL O-acyltransferase activity in reaction buffers at varying pH levels, ranging from pH 
6-8. The highest HRASLS1 oleoyl-CoA-dependent O-acyltransferase activity was observed at pH 
7 (Fig. 13C). This is in contrast to the finding by Shinohara et al. who found that pH 8 is optimal 
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for the PLA1/2 activity of HRASLS1 [45]. However, as these enzymatic processes differ, the 
finding of different optimal pH is not entirely surprising.  
 This finding of significant O-acyltransferase activity with oleoyl-CoA in HEK-293 crude 
lysates was unexpected, given prior work by others [45, 46], and the homology that HRASLS1 
shares with other HRASLS family members that have a well-characterized catalytic mechanism 
that is CoA-independent [18]. I considered two possible explanations for this phenomenon. The 
first was that all prior work is incorrect, and HRASLS1 is actually an acyl-CoA-dependent O-
acyltransferase, and this was rapidly discarded. The second was that the finding of acyl-CoA-
dependent activity is an artefact, related to the use of transduced crude lysates. Crude lysates 
contain abundant, disrupted organelles, rather than HRASLS1 alone, and therefore also contain 
abundant phospholipids, as well as other enzymes. I postulated that in this system, other CoA-
dependent transacylases naturally present could incorporate oleoyl-CoA into LPC (at the same rate 
in both control and Hrasls1 infected cells), resulting in the generation of PC substrate that was 
then used at a higher rate for LPI, MLCL, and DLCL transacylation reactions in lysates 
overexpressing HRASLS1 versus control. Alternatively, I postulated that during the 48-hour 
overexpression of HRASLS1, the N-transacylase activity of this enzyme could have generated 
NAE signaling molecules that may have led to the induction of acyl-CoA-dependent enzymes 
involved in the synthesis of PI and CL. Additional studies were thus conducted on the CoA-
independent O-transacylase activity of crude lysates, and on both the CoA-dependent O-
acyltransferase activity, and CoA-independent O-transacylase activity of HRASLS1 using a purer 
system (i.e. reticulocyte lysates).  
I therefore next investigated potential acyl-CoA-independent PC:MLCL O-transacylase 
activity. Based on activity observed in the CoA-dependent reaction, I decided to focus on a 
potential new role for this enzyme in CL synthesis, specifically. To do this, I assayed these same 
crude lysates produced from HEK-293 cells that had been infected with adenoviral Hrasls1, or 
control adenovirus, for 48 hours prior to harvest. The PC:MLCL transacylase activity of 
HRASLS1 was assessed utilizing three different radiolabelled PC acyl donors, and MLCL as an 
acyl acceptor. As compared to control lysates, lysates produced from HEK-293 cells 
overexpressing HRASLS1 produced significantly more [3H]-oleate-containing CL when utilizing 
[3H-1,2]18:1n-9/18:1n-9-PC as an acyl donor (Fig 13E). Specifically, crude lysates overexpressing 
HRASLS1 increased esterification of [3H] oleate into MLCL by ~1.6-fold compared to control, 
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P<0.05. In contrast, crude lysates overexpressing HRASLS1 did not produce significantly more 
radiolabelled cardiolipin than control lysates when utilizing either [3H-1,2]18:0/18:0-PC or 
16:0/[14C]18:2n-6-PC as acyl donors (Figs. 13D, and F, respectively).  
 
Preliminary investigation of acyl-CoA-dependent MLCL O-acyltransferase activity and 
PC:MLCL transacylase activity of HRASLS1 generated using an in vitro reticulocyte lysate 
transcription/translation system  
 After observing that crude lysates overexpressing HRASLS1 produced significantly more 
radiolabeled CL using MLCL as an acyl acceptor, and either oleoyl-CoA or di-oleoyl-PC as acyl 
donors, we examined if HRASLS1 produced via in vitro transcription/translation could also 
synthesize CL as an acyl-CoA-dependent O-acyltransferase or as a PC:MLCL O-transacylase. To 
do this, I utilized the TNT® reticulocyte lysate system. There are several benefits to using this 
system over crude lysates, including that synthesis of HRASLS1 proceeds rapidly (within a few 
hours) from a plasmid, rather than from viral infection, which can affect background metabolism 
in cells over the course of days (although this is controlled by use of an adenoviral control), and 
that NAE-mediated nuclear signaling in the regulation of other enzymes would be abrogated by 
the use of this anucleate system. Using this coupled transcription/translation system, I first 
confirmed the production of HRASLS1 protein in reticulocyte lysates by immunoblot analysis of 
the 3X FLAG tag that is cloned in frame with HRASLS1 (Fig 14A). Next, I performed the same 
oleoyl-CoA-dependent O-acyltransferase activity assay as I had performed in crude lysates. I 
utilized [14C]oleoyl-CoA as an acyl donor, and MLCL as an acyl acceptor. However, this time, I 
did not observe a significantly greater incorporation of [14C]oleoyl-CoA into CL in reticulocyte 
lysates overexpressing HRASLS1, as compared to control lysates (Fig 14B). Specifically, 
reticulocyte lysates overexpressing HRASLS1 had 1.08-fold the activity of control reticulocyte 
lysates (P=0.82, n=3). Examination of the PC:MLCL transacylase activity of reticulocyte lysates 
overexpressing HRASLS1 was performed next. When [3H-1,2] 18:0/18:0-PC (Fig 14C) was used 
as an acyl donor, initial investigation demonstrated that the incorporation of [3H]18:0 into CL by 
reticulocyte lysates overexpressing HRASLS1 was 33% higher than the incorporation by control 
reticulocyte lysates, and approached significance with n=3 samples (P=0.075), although clearly 
additional samples should be tested with this PC acyl-donor. Next, [3H-1,2] 18:1n-9/18:1n-9-PC 
(Fig 14D) was used as an acyl donor. Of note, this lipid was the one species that was incorporated 
into CL at a significantly greater rate by crude lysates (n=5) overexpressing HRASLS1. The 
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incorporation of [3H]18:1n-9 into CL by reticulocyte lysates overexpressing HRASLS1 was ~65% 
higher than the incorporation of [3H]18:1 by control reticulocyte lysates, and also approached 
significance with n=3 samples (P = 0.18, Fig. 14E), although testing with additional samples is 
also clearly required. Incorporation of [14C]18:2n-6 from 16:0/[14C]18:2n-6-PC into MLCL to 






Figure 11: Hrasls1 is highly expressed in the brain and heart.  
Representative blot showing mRNA expression of longer (Hrasls1-1L) and shorter (Hrasls1-1SA, 
Hrasls1-1SB) transcripts of Hrasls1, measured by RT-PCR in multiple tissues (A). Quantification 
of Hrasls1-1L mRNA expression (B), Hrasls1-1SA mRNA expression (C), and Hrasls1-1SB 




Figure 12: HRASLS1 localizes predominately to the endoplasmic reticulum.  
(A) Representative immunoblot of endogenous HRASLS1 in subcellular fractions isolated from 
mouse brains (n=3). (B) Representative immunoblot of endogenous HRASLS1 in purified brain 




Figure 13: Post-nuclear crude cell lysates derived from HEK293 cells infected with adenoviral Hrasls1 or control adenovirus for 
48 hours have both acyl-CoA-dependent LPI, MLCL, and DLCL acyltransferase, and also as a di-oleoyl PC:MLCL 
transacylase. 
(A) Representative immunoblot of HEK-293 cells infected with control adenovirus (expressing GFP alone) or with adenovirus 
expressing HA-tagged HRASLS1 (as well as a separate GFP reporter protein). (B) Crude post-nuclear lysates from HEK-293 cells 
infected with either control or HRASLS1 adenoviruses were assayed in vitro for acyl-CoA-dependent lysophospholipid O-
acyltransferase activity using [14C] oleoyl-CoA and a variety of lysophospholipid acceptors, as indicated. Radiolabeled phospholipids 
were quantified by liquid scintillation counting (n=3). (C) pH-dependency of HRASLS1 [14C] oleoyl-CoA:MLCL O-acyltransferase 
activity (n=3). (D) In vitro [3H, 1-2]18:0-18:0-PC:MLCL transacylase activity of HEK-293 cell lysates overexpressing control or 
HRASLS1 protein (n=5). (E) In vitro [3H, 1-2]18:1n-9-18:1n-9-PC:MLCL transacylase activity of HEK-293 cell lysates overexpressing 
control or HRASLS1 protein (n=5). (F) In vitro 16:0/[14C]18:2n-6-PC:MLCL transacylase activity of HEK-293 cell lysates 







Figure 14: Preliminary testing of acyl-CoA-dependent MLCL O-acyltransferase activity and PC:MLCL O-transacylase activity 
of reticulocyte lysates overexpressing HRASLS1 or empty vector (control). 
(A) Representative immunoblot of reticulocyte lysates overexpressing control (pCMV-3Tag-3A) or HRASLS1 (pCMV-HRASLS1-
3Tag-3A) protein. Reticulocyte lysates produced in this immunoblot differ in their protein concentrations. (B) Reticulocyte lysates 
overexpressing control or HRASLS1 protein were assayed in vitro for acyl-CoA-dependent O-acyltransferase activity using [14C] oleoyl-
CoA as an acyl donor and MLCL as an acyl acceptor. (C) Reticulocyte lysates overexpressing control or HRASLS1 protein were assayed 
in vitro for [3H, 1-2]18:0/18:0-PC:MLCL O-transacylase activity. (D) Reticulocyte lysates overexpressing control or HRASLS1 protein 
were assayed in vitro for [3H, 1-2]18:1n-9/18:1n-9-PC:MLCL O-transacylase activity. (E) Reticulocyte lysates overexpressing control 




 The major objectives of this study were to characterize the tissue expression profile, 
subcellular localization, and biochemical activity of HRASLS1. Specifically, I examined the 
oleoyl-CoA-dependent O-acyltransferase activity of HRASLS1 with a variety of lysophospholipid 
substrates using crude and reticulocyte lysates, and the PC:MLCL O-transacylase activity of 
HRASLS1 using reticulocyte lysates. Furthermore, I examined the PC:MLCL transacylase activity 
of HRASLS1 using both crude lysates and reticulocyte lysates, with di-stearoyl-PC, di-oleoyl-PC, 
and 16:0/18:2n-6-PC as acyl donors. This investigation has identified a novel function for 
HRASLS1 in the synthesis of PI and CL. To the best of my knowledge, this is the first time an 
HRASLS enzyme has been reported to function in CL or PI metabolism. 
 In agreement with prior observations from the investigation of HRASLS1 tissue 
distribution [45, 47, 167], this study indicated that longer (Hrasls-1L) and shorter (Hrasls1-1SA, 
Hrasls1-1SB) variants of HRASLS1 are ubiquitously expressed, albeit with high expression in 
brain and heart tissue. The second of the two shorter transcript variants, Hrasls1-1SB contains 
longer 5’ and 3’ untranslated regions than Hrasls1-1SA [47]. A sequence alignment of all three 
isoforms are shown in Appendix B. The shortest isoform (i.e. Hrasls1-1SA) was the isoform 
studied in subsequent biochemical characterizations in this thesis due to its preferential translation 
in mice over both Hrasls1-1L and Hrasls1-1SB [47]. Interestingly, while most studies found 
significant expression of Hrasls1 in skeletal muscle as well [47], this study found only modest 
expression in this tissue. While many factors may contribute to this observed discrepancy, at least 
two key differences exist between this study and the Hussain study [47], which reports high 
expression in skeletal muscle. First, the Hussain study utilized 8-week-old mice [47], while this 
study utilized 12-week-old mice. Gene expression is highly variable throughout aging, and 
differences in gene transcription with aging are vary in a tissue-to-tissue basis [257]. Therefore, 
although in both studies the mice utilized have reached adulthood, the discrepancies in expression 
level may result, at least in part, due to the difference in age between the mice. A second possible 
explanation may be due to the metabolic state of the animals at the time of sacrifice. Indeed, our 
prior study has demonstrated that the expression of enzymes involved in phospholipid metabolism 
is dependent on the metabolic state of the animal [258]. In this study, mice were allowed access to 
food ad libitum prior to sacrifice in the morning. Although the Hussain study does not explicitly 
state the metabolic conditions of the animals prior to sacrifice [47], it is probable that they also 
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allowed their mice to have ad libitum access to food prior to sacrifice. The time of last feeding, 
however, may be variable between the two studies, and could vary from mouse-to-mouse. Thus, 
future studies examining mRNA tissue expression of Hrasls1 should consider strictly regulating 
the metabolic state of the animals used prior to sacrifice. 
  Next, this study investigated the subcellular localization of endogenous HRASLS1. 
Immunoblot analysis of sub-fractional homogenates from mouse brain indicated that HRASLS1 
localizes to the endoplasmic reticulum, and not to the nucleus, mitochondria, or MAM. This 
finding is in contrast to a previous report by Akiyama et al. (1999), which found HRASLS1 present 
in the cytoplasm, and in the peri-nuclear region of COS-7 cells overexpressing HRASLS1 [33]. 
The reason for differences in findings between that work and the present study is unknown, but 
may be a result of the use of overexpressed rather than endogenous protein. Further immunoblot 
analysis of endogenous HRASLS1 in the cytoplasmic fraction that is obtained after harvesting the 
microsomal fraction may indicate a minor level of expression, but this would need to be tested 
directly. This finding identifies HRASLS1 as the second known HRASLS family member to 
localize to the endoplasmic reticulum. Prior to this work, only HRASLS4 has shown minor 
localization to the endoplasmic reticulum, as its C-terminal hydrophobic domain is anchored 
between the ER and the Golgi apparatus [19, 49]. Most other HRASLS family members localize 
preferentially to the peri-nuclear region, or to the cytoplasm [19].   
 Based on previous work by others indicating that LRAT and the HRASLS family of 
enzymes are well-characterized as acyl-CoA-independent O-transacylases [45]. I therefore 
hypothesized that HRASLS1 would not show acyl-CoA-dependent O-acyltransferase activity. 
Surprisingly, however, investigation in HRASLS1-overexpressing crude lysates demonstrated 
significant activity with oleoyl-CoA as an acyl donor, and LPI, MLCL, and DLCL as acyl 
acceptors. Despite this finding, I hypothesized that the CoA-dependent activity that was evident in 
crude lysates was likely not a direct function of HRASLS1, but rather may be an artefact related 
to the use of the specific model, where HRASLS1 is overexpressed for up to 48 hours in HEK-293 
cells prior to harvest. Notably, this could lead to additional cellular effects, including changes in 
other phospholipid metabolizing enzymes, possibly as a result of altered synthesis by HRASLS1 
of NAEs, which can modulate nuclear signaling pathways [259, 260]. Thus, I also tested the 
oleoyl-CoA-dependent MLCL O-acyltransferase activity of HRASLS1 using a reticulocyte lysate 
in vitro transcription/translation system, which would remove confounding caused by any potential 
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related nuclear activation signaling. As predicted, in that system there was no significant oleoyl-
CoA-dependent transacylase activity with MLCL as an acyl donor, suggesting strongly that 
HRASLS1 does not directly catalyze CL synthesis as an acyl-CoA-dependent O-acyltransferase.  
I next tested the acyl-CoA-independent PC O-transacylase activity of HRASLS1 in crude and 
reticulocyte lysates. Analysis of the PC:MLCL transacylase activity of crude lysates 
overexpressing HRASLS1 demonstrated greater incorporation of oleate from [3H-1,2] 18:1n-
9/18:1n-9-PC into CL using MLCL as an acyl acceptor, but no difference in incorporation of 
stearate (using [3H-1,2] 18:0/18:0-PC) or linoleate (using 16:0/ [14C]18:2n-6-PC) as compared to 
crude lysates overexpressing the control adenovirus. In a pilot study using a reticulocyte lysate 
expression system, there was a preliminary suggestion that PC:MLCL transacylase activity using 
[3H-1,2] 18:1n-9/18:1n-9-PC and [3H-1,2] 18:0/18:0-PC may be increased by HRASLS1 
overexpression, while activity with 1-palmitoyl-2-[14C]-linoleoyl-PC was not affected. 
Interestingly, this provides some suggestion of a preference for 18-carbon fatty acids found 
specifically in the sn-1 position, since there was no evidence that HRASLS1 could utilize 18:2n-6 
in the sn-2 position of 16:0/18:2n-6-PC. To test this, it will be important to investigate activity 
with other positional isomers of PC, such as [14C]18:2n-6/16:0-PC, as well as other substrates, 
such as [14C-1,2]18:2n-6/18:2n-6-PC, as acyl donors. There was also some suggestion from the 
combined data that sn-1 oleate may be preferred over sn-1 stearate. It is unclear whether this acyl-
preference is due to the specific stereochemical requirement for CL to be enriched in 18-carbon 
unsaturated fatty acids [261], or if the double bond in oleic acid allows for preferential binding in 
the catalytic cleft of HRASLS1. Additional investigations are warranted in order to elucidate the 
exact mechanism, but it is likely a combination of both factors. Overall, however, it is likely that 
this study was statistically underpowered (n=3), and should first be repeated with more samples. 
Crude cell lysates overexpressing HRASLS1 synthesized more PI from LPI, and more CL from 
either MLCL or DLCL, when oleoyl-CoA was used as an acyl donor. Since LPI and DLCL were 
not tested as substrates in reactions using reticulocyte lysates, it is unknown whether this occurs 
directly, or whether it is due to induction of other enzymes that have this activity. In particular, 
ALCAT1 can utilize LPI as an acyl acceptor in vitro, in addition to MLCL and DLCL [185]. 
Interestingly, like HRASLS1, ALCAT1 also predominantly localizes to the endoplasmic reticulum 
[121], which is an unexpected site of cardiolipin synthesis, a process that is known to occur 
primarily in the mitochondria [262]. Effects of HRASLS1 overexpression in HEK-293 cells on the 
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expression of other phospholipid metabolism genes, including ALCAT1, is reported in Thesis 




HRASLS1 is ubiquitously expressed, although it is highly abundant in the brain and the 
heart, and localizes to the endoplasmic reticulum. Importantly, the current work has demonstrated 
a new function for HRASLS1 in cardiolipin synthesis.  Crude lysates overexpressing HRASLS1 
had a greater capacity than control crude lysates to synthesize PI and CL using oleoyl-CoA as an 
acyl donor. This apparent oleoyl-CoA-dependent MLCL O-acyltransferase activity was not, 
however, conserved in reticulocyte lysates overexpressing HRASLS1, indicating that HRASLS1 
likely does not have direct acyl-CoA-dependent acyltransferase activity. This is in agreement with 
prior studies on the catalytic mechanism of HRASLS1 [18, 35, 45, 53]. Alternatively, I suggest 
that HRASLS1 expressed for 48 hours in growing cells may be producing NAPE as a source of 
NAE, which may in turn signal to increase CL synthesis. Thesis Study II and III will examine the 
effects of HRASLS1 overexpression on phospholipid levels and phospholipid metabolism in vivo, 






Thesis Study II – Investigation of the in vivo role of HRASLS1 in cardiolipin 
metabolism 
 
Introduction and Study Rationale 
 The HRASLS enzyme family is a group of proteins that share sequence homology with 
lecithin:retinol acyltransferases (LRATs). Five HRASLS enzymes have been identified in humans, 
with three enzymes (Hrasls1,3,5) conserved in rodents as well. Due to the fact that all members of 
this enzyme family exhibit varying levels of O-transacylase, N-transacylase, and phospholipase 
A1/2 activity [26, 45, 46, 53], they are also known as PLA/ATs [19]. A prior study has 
demonstrated a role for HRASLS1 in the O-transacylation of phospholipids, specifically PC and 
PE [35]. However, the ability of HRASLS1 to function in synthesizing other phospholipids had 
not yet been investigated.  
Results from this thesis have uncovered a novel role for HRASLS1 in the in vitro synthesis 
of the mitochondrial phospholipid cardiolipin. HRASLS1 may act in vitro as a PC:MLCL 
transacylase, and may prefer PC that has 18-carbon fatty acyl chains in the sn-1 position. While 
this novel enzymatic function may have broad implications for understanding cardiolipin 
metabolism, it is important to determine if these activities are conserved in vivo. Crude lysates 
prepared from HEK293 cells overexpressing HRASLS1 for 48 hours demonstrated an increased 
capacity to incorporate oleoyl-CoA into MLCL, which was not observed in reticulocyte lysates. 
This suggests that HRASLS1 may be indirectly involved in CL synthesis through the modulation 
of cellular CL metabolic pathways as well. The exact mechanism(s) underlying this phenomenon 
are currently unknown, but the N-acyltransferase activity exhibited by HRASLS1 in vivo may play 
an important role [35]. I speculated that HRASLS1 may be producing NAPE in vivo, which can 
be hydrolyzed into bioactive NAEs that may signal in cellular pathways, including pathways 
regulating nuclear transcription that is absent in reticulocyte lysates, to increase cellular CL 
production. In this scenario, identification of the specific NAEs that are produced by HRASLS1 
may shed insight into any observed in vivo modulation of cellular CL metabolism. Thus, the 
overarching objective of this chapter was to assess the in vivo role of HRASLS1 and NAEs in 




Objectives and Hypotheses 
The objectives and hypotheses for this study were as follows: 
1. Objective: To characterize alterations in phospholipid and fatty acyl profiles of HEK-293 
cells overexpressing HRASLS1 protein relative to control cells. 
Hypothesis: As compared to controls, HEK-293 cells overexpressing HRASLS1 will have 
a significantly higher content of PI and CL. Furthermore, fatty acyl analysis of CL will 
show enrichment with 18-carbon fatty acids (i.e. 18:0, 18:1n-9 and 18:2n-6). 
 
2. Objective: To characterize alterations in mitochondrial function and content of 
mitochondrial DNA in mitochondria isolated from HEK-293 cells overexpressing control 
or HRASLS1 protein. 
Hypothesis: Consistent with HRASLS1 overexpression resulting in increased CL content, 
mitochondrial function will be impaired in HEK-293 cells overexpressing HRASLS1. 
There will be no differences in mitochondrial DNA content between HEK-293 cells 
overexpressing control or HRASLS1 protein. 
 
3. Objective: To characterize changes in the expression of genes involved in cardiolipin and 
glycerolipid synthesis following overexpression of HRASLS1 protein in HEK-293 cells. 
Hypothesis: As compared to controls, HEK-293 cells overexpressing HRASLS1 will have 
a significantly higher expression of genes involved in cardiolipin synthesis. Specifically, 
CDS1/2, PGS, CLS, and TAZ will all be significantly induced as compared to controls. 
 
4. Objective To investigate alterations in the mRNA expression of NAE receptors following 
HRASLS1 overexpression in HEK-293 cells. 
Hypothesis: As compared to controls, HEK-293 cells overexpressing HRASLS1 will have 
a significantly higher expression of PPAR, RXRa, TRPV1, and GPR55. 
 
5. Objective: To investigate if treatment with OEA, PEA, or SEA can significantly increase 
endogenous CL content in HEK-293 cells. 
Hypothesis: As compared to controls, HEK-293 cells treated with OEA will have a 
significantly higher endogenous content of CL. 
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6. Objective: To characterize any changes in abundant NAEs or 1- or 2-arachidonylglycerol 
in HEK-293 cells overexpressing control or HRASLS1 protein.  
Hypothesis: As compared to controls, HEK-293 cells overexpressing HRASLS1 will have 
a significantly higher content of OEA, SEA, and LEA. No differences will be observed in 






Figure 15: Schematic of the study design of Thesis Study II 
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Results 
HRASLS1 overexpression increases the cellular content of CL in HEK-293 cells 
 HEK-293 cells were infected with adenoviral HRASLS1 or control virus for 48 hours, then 
harvested and extracted for total endogenous lipids. Individual phospholipids were resolved by 
TLC, identified by comparison with known standards, scraped, and analyzed for fatty acyl 
composition and content, which was also used to calculate the corresponding cellular phospholipid 
levels. Cells overexpressing HRASLS1 had a 62% greater total cellular CL content compared to 
control cells (16.43 ± 3.53 nmol CL/109 cells versus 26.74  1.87 nmol CL/109 cells, respectively, 
P = 0.0176) (Fig. 16A). There were no other significant differences in total levels of any of the 
other phospholipids analyzed, including PC, PE, PG, or PI. Data showing cardiolipin content as a 
percentage of total cellular phospholipid content is shown in Appendix Figure E. 
 While total cellular CL content is important for mitochondrial metabolism and cellular 
health, the specific fatty acyl composition of CL is also of critical importance [227, 263]. The fatty 
acyl composition of CL was determined and quantified from HEK-293 cells overexpressing 
HRASLS1. There was a significant increase in the total content of saturated fatty acyl species (Fig. 
16B). Among individual saturated fatty acyl species, there was a significantly higher content of 
myristic acid (control, 0.40 ± 0.08 nmol C14:0/mg protein versus HRASLS1, 0.73 ± 0.08 nmol 
C14:0/mg protein, P = 0.017), palmitic acid (control, 3.99 ± 0.73 nmol C16:0/mg protein versus 
HRASLS1, 7.54 ± 0.96 nmol C16:0/mg protein, P = 0.011), and stearic acid (control, 6.24 ± 1.07 
nmol C18:0/mg protein versus HRASLS1, 11.51 ± 1.57 nmol C18:0/mg protein, P = 0.016) in 
cells overexpressing HRASLS1 as compared to controls (Fig. 16C). Several other fatty acyl 
species including lauric acid (C12:0), arachidic acid (C20:0), and tricosylic acid (C23:0) showed 
an increase that approached significance (P0.06). Of the monounsaturated fatty acids analyzed, 
only erucic acid (C22:1n-9) in CL was higher in HRASLS1 overexpressing cells (Fig. 16D). There 
were no significant differences in CL content of any of the n-6 PUFA species analyzed, including 
linoleic acid (C18:2n-6) (Fig. 16E). Although linoleate appeared to be higher (control, 1.21 ± 0.20 
nmol C18:2n-6/mg protein versus HRASLS1, 2.65 ± 0.91 nmol C18:2n-6/mg protein, P = 0.1633) 
in the HRASLS1 overexpressing group, it did not reach significance (P=0.16). However, a few of 
the n-3 PUFA species were significantly increased in HRASLS1-overexpressing cells compared 
to controls, including -linolenic acid (C18:3n-3), eicosatrienoic acid (C20:3n-3), and 
eicosapentanoic acid (C20:5n-3) (Fig. 16F). Overall, the increased CL in HRASLS1 
overexpressing HEK-293 cells was associated primarily with a greater content of saturated, and, 
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to some extent, also n-3 polyunsaturated fatty acyl species. It is important to note that this data is 
reflective of the fatty acid concentrations in cardiolipin, and not necessarily the relative abundance 
of these fatty acids in cardiolipin. No statistically significant differences were observed in the 
relative content of fatty acids in cardiolipin in HEK-293 cells overexpressing HRASLS1 as 
compared to controls (data shown in Appendix F). 
 
Adenoviral overexpression of HRASLS1 alters mitochondrial function, but not mitochondrial DNA 
content 
 Cardiolipin is found predominantly in the inner mitochondrial membrane, and in most 
tissues, requires enrichment with C18:2n-6 for optimal function [262]. Since HRASLS1 
overexpression in HEK-293 cells increased the cellular content of CL enriched with saturated fatty 
acids, I investigated whether the function of isolated mitochondria from HEK-293 cells infected 
with adenoviral control or HRASLS1 had impaired function. As compared to control 
mitochondria, mitochondria isolated from HRASLS1-overexpressing HEK-293 cells showed a 
significantly lower endogenous respiration rate (control, 0.067  0.0019 pmol/s/total protein 
versus HRASLS1, 0.056  0.0020 pmol/s/total protein, P = 0.0040) (Fig. 17A). After the addition 
of pyruvate, glutamate, and malate (P/G/M), there was no longer a statistically significant 
difference in the respiratory capacity between the groups. However, assessment of the individual 
electron transport chain complexes showed distinct differences between mitochondria isolated 
from control versus HRASLS1-overexpressing cells. Although mitochondria isolated from 
HRASLS1-overexpressing HEK-293 cells initially showed a significantly decreased level of 
endogenous respiration, Complex I-supported respiration (assessed by the addition of P/G/M and 
ADP) was significantly higher in mitochondria isolated from HRASLS1-overexpressing HEK-293 
cells versus controls (0.13  0.0046 pmol/s/total protein versus 0.11  0.0003 pmol/s/total protein, 
respectively, P = 0.0064). However, this phenomenon was reversed upon the addition of succinate, 
which allows for the assessment of Complex I+II-supported respiration, and which decreased to 
less than half the control level (0.12  0.004 pmol/s/total protein (HRASLS1-overexpressing) 
versus 0.26  0.007 pmol/s/total protein (control), respectively, P < 0.001). Upon the final addition 
of TMPD, which allows for Complex I+II+IV-supported respiration, mitochondria isolated from 
HEK-293 cells overexpressing HRASLS1 were observed once again to respire at a significantly 
lower level than controls (0.59  0.017 pmol/s/total protein versus 0.50  0.017 pmol/s/total 
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protein, respectively, P = 0.0034) (Fig 17A). H2O2 production by isolated mitochondria was not 
significantly different between groups during endogenous respiration, nor during the activation of 
electron transport chain complexes (Fig 17B). 
 To estimate if the observed differences in mitochondrial respiration could be attributed to 
changes in mitochondrial DNA content, and by extension, mitochondrial number, semi-
quantitative RT-PCR analysis of two markers of mitochondrial DNA and one marker of nuclear 
DNA was performed (Fig. 17C), and quantified (Figs. 17D, E, F). No statistically significant 
differences were observed in the content of either the MT-TL1 gene, which encodes for 
mitochondrial tRNA, nor the mitochondrial MT-ND1 gene, which encodes for a protein that is a 
subunit of NADH dehydrogenase (ubiquinone), also known as Complex I. As well, no statistically 
significant difference was observed in the content of nuclear 2 microglobulin that was analyzed 
for comparison.    
 
HRASLS1 overexpression significantly increases the expression of genes involved in phospholipid, 
and specifically, cardiolipin biosynthesis 
 Real-time PCR was performed to investigate if the observed increased cellular cardiolipin 
content was possibly related to an induction of phospholipid biosynthetic genes. HEK-293 cells 
were infected with either control- or HRASLS1-expressing adenovirus for 48h, upon which total 
RNA was harvested and analyzed by RT-qPCR for relative expression of genes involved in 
phospholipid synthesis. Gene expression was normalized to 18S. A general induction of 
glycerophospholipid biosynthesis genes was observed. The expression of a microsomal GPAT 
(GPAT1, Fig. 18A) and mitochondrial GPAT (GPAT3, Fig. 18C) were significantly induced 
following HRASLS1 overexpression, as were AGPAT2 (Fig. 18F), AGPAT4 (Fig. 18H), and 
AGPAT5 (Fig. 18I). The product of AGPAT-mediated catalysis, PA, represents a unique branching 
point in the Kennedy Pathway, where it can either be shuttled into serving as a precursor for DAG 
and TAG synthesis (along with the synthesis of PC, PE, and PS), or instead be phosphorylated into 
CDP-DAG, which feeds into CL synthesis. Since HRASLS1 increased the cellular content of CL, 
alterations in the latter branch were investigated. A highly significant induction was observed in 
the expression of both CDS1 (Fig. 18J), and CDS2 (Fig. 18K), which convert PA into CDP-DAG. 
Conversion of CDP-DAG into PG is catalyzed by PGS, which was also observed to be 
significantly up-regulated in HRASLS1-overexpressing HEK-293 cells (Fig. 18L). The largest 
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induction was observed in CLS, which was significantly up-regulated approximately ~5.5-fold as 
compared to controls (Fig. 18M). Following de novo synthesis, CL is subject to acyl chain 
remodeling by one of four known enzymes. Analysis of the expression of these enzymes indicated 
a significant upregulation in TAZ (Fig. 18N), which remodels CL with linoleic acid residues. The 
expression of the other tested CL remodeling enzymes, ALCAT1 (Fig. 18O) and TFP (Fig. 18P) 
were not significantly different from controls.  
 
Adenoviral overexpression of HRASLS1 increases the mRNA expression of PPAR and TRPV1  
 Changes in gene expression that are evident in cells overexpressing HRASLS1 for 48 hours 
suggests the activation of a cell signaling pathway or pathways that can affect nuclear transcription. 
I hypothesized that HRASLS1 may be indirectly involved in CL synthesis through the production 
of NAPE that are cleaved into NAE, which are bioactive in multiple pathways including 
transcription regulation. To assess possible alterations in the downstream target receptors of NAEs, 
real-time PCR was performed. cDNA prepared from HEK-293 cells infected with either control 
or HRASLS1 adenovirus was analyzed by RT-qPCR for relative expression of PPAR, RXRa, 
TRPV1, and GPR55. As compared to controls, a highly significant upregulation was observed in 
the expression of PPAR (P<0.05) (Fig. 19A) and TRPV1 (P<0.001) (Fig. 19C) in HRASLS1-
overexpressing HEK-293 cells. The expression of RXRa, a known interactor of PPAR, verged on 
statistical significance (P=0.0589) (Fig. 19B), whereas the expression of GPR55 was not 
significantly different from controls (Fig. 19D).  
 
Content of endogenous CL is not increased following 48 hour OEA, PEA, or SEA treatment of 
HEK-293 cells 
 To assess whether candidate NAEs have an effect on cellular CL content, HEK-293 cells 
were treated with 0.1, 1, or 10 M PEA, OEA, or SEA (Fig. 20). Cells were incubated for 48 hours, 
and total lipids were then extracted and resolved by TLC. Phospholipid bands corresponding to 
known standards were identified, scraped, and fatty acids were quantified by GC-FID. As 
compared to control cells, endogenous CL content was not significantly higher following treatment 
with PEA, OEA, or SEA, at any of the concentrations tested. In addition, metabolic labeling 
experiments utilizing [14C] palmitate along NAE treatment demonstrated a similar effect, as CL 
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content was not significantly higher following treatment with PEA, OEA, or SEA (data shown in 
Appendix C).  
 
HRASLS1 overexpression alters the NAE profile of HEK-293 cells 
 To assess if overexpression of HRASLS1 alters the content of various NAE species, HEK-
293 cells were infected with control or HRASLS1 adenovirus for 48 hours, following which they 
were harvested by trypsinization. Samples were stored at -80ºC until they could be analyzed by 
our collaborators at the University of Toronto. Surprisingly, as compared to controls, HEK-293 
cells overexpressing HRASLS1 had a significantly lower content of PEA (control, 21.58  2.15 
pmol PEA/g versus HRASLS1 14.83  1.40 pmol PEA/g, P = 0.0250) (Fig. 21A) and OEA 
(control, 28.57  4.29 pmol OEA/g versus HRASLS1 16.15  1.02 pmol OEA/g, P = 0.0182) (Fig. 
21B). Although linoleoylethanolamide (LEA) appeared to be somewhat (~48%) elevated in 
HRASLS1-overexpressing HEK-293 cells (6.44 ± 1.99 pmol/g versus control, 4.34 ± 0.68 
pmol/g), this difference was also not statistically significant (P = 0.38) in the current samples (Fig 
21C). The content of 1-arachidonylglycerol (1-AG) appeared to be lower ~31% lower in cells 
infected with HRASLS1, but this did not reach significance (P = 0.0956) (Fig. 21D). Likewise, the 
content of 2-arachidonoylglycerol (2-AG) was not significantly different between control- and 
HRASLS1-infected cells in the sample tested (n=6) (Fig. 21E). Other NAEs analyzed included 
SEA and docosahexaenoylethanolamide (DHEA), but these were undetected in most samples. 







Figure 16: Adenoviral overexpression of HRASLS1 in HEK-293 cells increases cellular 
content of cardiolipin. 
(A) Endogenous phospholipid content of HEK-293 cells overexpressing control or HRASLS1. (B) 
Relative proportion of major fatty acid classes (i.e. saturates (SFA), monounsaturates (MUFA), 
and n-3 and n-6 polyunsaturated fatty acids (PUFA)) within CL isolated from HEK-293 cells 
infected with adenoviral HRASLS1 or control virus. Concentrations of individual fatty acids 
within CL from control or HRASLS1-overexpressing HEK-293 cells including SFA (C), MUFA 






Figure 17: Adenoviral overexpression of HRASLS1 in HEK-293 cells significantly reduces mitochondrial respiration, but does 
not alter H2O2 production or mtDNA content. 
(A) Respiratory activities of individual mitochondria electron transport chain complexes (CI, CI plus CII, CI plus CII and CIV) were 
determined in isolated mitochondria from HEK-293 cells overexpressing control or HRASLS1 protein, along with baseline activity 
(endogenous), proton leak (PGM), and following the addition of cytochrome c. (B) Hydrogen peroxide production by mitochondria 
isolated from HEK-293 cells overexpressing control or HRASLS1 protein. (C) Representative RT-PCR of mRNA expression of markers 
of mitochondrial DNA (MT-ND1, MT-TL1, quantified in (D), and (E), respectively) and nuclear DNA (nDNA 2 microglobulin, 
quantified in (F)) taken from HEK-293 cells overexpressing control or HRASLS1 protein. Data are means  S.E.M. **P<0.01, 








Figure 18: HRASLS1 overexpression in HEK-293 cells 
significantly increases the expression of genes involved 
in phospholipid synthesis and remodeling.  
Analysis of gene expression from HEK-293 cells 
overexpressing control or HRASLS1 protein for genes 
involved in phospholipid, and specifically, cardiolipin 
synthesis and acyl-chain remodeling. (A-D), Glycerol-3-
phosphate acyltransferases 1-4 (GPAT1-4). (E-I) 
Acylglycerophosphate acyltransferases 1-5 (AGPAT1-5). 
(J) Phosphatidate cytidylyltransferase 1 (CDS1). (K) 
Phosphatidate cytidylyltransferase 2 (CDS2). (L) 
Phosphatidylglycerol synthase (PGS). (M) Cardiolipin 
synthase (CLS). (N) Tafazzin (TAZ). (O) Acyl-
CoA:lysocardiolipin acyltransferase 1 (ALCAT1). (P) -
trifunctional protein (TFP). Data are means  S.E.M. 





Figure 19: HRASLS1 overexpression in HEK-293 cells significantly increases the mRNA 
expression of PPAR and TRPV1. 
Analysis of gene expression in HEK-293 cells overexpressing control or HRASLS1 protein for 
known receptors of NAEs including (A) PPAR, (B) RXRa, (C) TRPV1, and (D) GPR55. Data 





Figure 20: NAE treatment does not increase endogenous CL content in HEK-293 cells. 
HEK-293 cells were treated for 48 hours with 0.1, 1, or 10 µM of either PEA, OEA, and SEA. 
Total lipids were harvested and separated by TLC, and total endogenous CL content was 
analyzed by GC-FID. No significant differences in CL content were observed in any treatment 




Figure 21: Adenoviral overexpression of HRASLS1 in HEK-293 cells significantly reduces 
PEA and OEA content. 
LC-MS/MS analysis of alterations in the content of major NAE species including (A) PEA, (B) 
OEA, and (C) LEA, as well as (D) 1-AG and (E) 2-AG in HEK-293 cells overexpressing control 




In Thesis Study 1, I found that HRASLS1 can play novel roles in cardiolipin synthesis, 
based on assays conducted in vitro. HRASLS1 overexpression in HEK-293 cells indirectly induces 
oleoyl-CoA-dependent MLCL O-acyltransferase activity, although it does not directly catalyze 
reactions with these substrates. HRASLS1 overexpression may also indirectly induce PC:MLCL 
O-transacylase activity in these cells, although evidence from reticulocyte lysates suggests that 
HRASLS1 may additionally directly catalyze specific PC:MLCL O-transacylase reactions. In the 
current study, I investigated the effects of 48-hour HRASLS1 overexpression on phospholipid 
metabolism in HEK-293 cells, including measurement of phospholipid content and composition, 
and expression of phospholipid synthesis genes. I also analyzed effects of HRASLS1 
overexpression on mitochondrial content and function. Finally, I tested potential roles for common 
NAEs in CL metabolism, and determined effects of HRASLS1 overexpression on the abundance 
of common NAEs in HEK-293 cells.  
In Thesis Study II, I demonstrate for the first time that HRASLS1 overexpression 
significantly, and specifically, increases cellular cardiolipin content. To the best of my knowledge, 
this is the first study to-date to provide evidence for an in vivo role of HRASLS1 in cardiolipin 
metabolism. Phospholipid content and acyl composition are highly regulated within the cell [5], 
and must be maintained in correct relative proportion to one another to preserve homeostasis. 
Although cardiolipin is a relatively minor constituent of cellular membranes and only accounts for 
~2-5% of total phospholipids [5], its content and acyl composition are subject to a high degree of 
regulation. Cardiolipin is the only known dimeric phospholipid, containing four fatty acyl side 
chains instead of two. Importantly, the specific composition of cardiolipin is essential for its proper 
functioning in mitochondria [118, 151, 175, 177], and since this specificity is not achieved initially 
during de novo synthesis, it must be acquired through enzymatic remodeling. 
I now show, for the first time, that adenoviral overexpression of HRASLS1 in HEK-293 
cells primarily results in a significant increase of endogenous CL that is enriched with saturated 
and n-3 polyunsaturated fatty acids. One of the largest effects observed was an increase in the 18-
carbon saturated fatty acid, stearate. This is different from CL in many tissues including heart [114, 
116, 117], liver [142, 159], kidney [142], skeletal muscle [142], and spleen [142], which is 
enriched in linoleic acid. However, it is notable that HEK-293 cells have a relatively low content 
of 18:2n-6 in cellular CL, and instead are primarily enriched in CL containing 18:0, 18:1n-9, and 
 92 
16:0. Interestingly, the linoleate content of endogenous CL in HEK-293 cells nearly doubled 
following HRASLS1 overexpression compared to control virus overexpression, although this did 
not reach significance with the current sample size. Increasing the sample size in this experiment 
would reduce variation and may lead to a statistically significant finding with regards to linoleate 
content. Overexpression of HRASLS1 did not significantly alter the total MUFA content of CL, 
nor did it alter the content of most individual MUFA species  including oleic acid, which is the 
second most abundant fatty acyl species found in CL in most tissues [262], and also in CL from 
control HEK-293 cells.  
Previous studies have demonstrated that alterations in CL metabolism can significantly 
contribute to cellular dysregulation. Decreases in CL content are associated with pathological 
consequences, the best-characterized of which is the development of Barth Syndrome (BTHS) 
[176], but CL deficiency is also evident in ischemia-reperfusion injury [149], hypothyroidism 
[264, 265], and heart failure [266, 267]. On the other hand, increased CL has also been associated 
with cellular dysfunction, since increases in CL content are evident in studies on hyperthyroidism 
in both mouse skeletal muscle and rat hearts [268-271]. These studies demonstrate the absolute 
requirement for the cell to maintain CL, along with other phospholipids, in correct relative 
abundance and proportion to one another, for the maintenance of health.  
Perhaps equally as important as the total cellular content of CL is its acyl chain 
composition, which is directly regulated by at least four major known enzymes, and can vary by 
tissue, and diet [262]. Improper acyl-chain remodeling of CL leads to a disease state even if total 
levels of CL are not reduced, as is evidenced by studies on ALCAT1 [121, 143, 228]. CL that is 
remodeled by ALCAT1 is significantly enriched in highly unsaturated fatty acids (HUFA: 20 
carbons, 3 double bonds) that are more susceptible to peroxidative damage than fatty acids with 
a lesser degree of unsaturation [121, 143, 227]. Cardiac overexpression of ALCAT1 in mice causes 
increases in both oxidative stress and depletion of mitochondrial DNA, while ALCAT1 knockout 
prevents the onset of cardiomyopathy and cardiac dysfunction [227]. Therefore, I hypothesized 
that the significant increase in CL content following adenoviral overexpression of HRASLS1 
would contribute to mitochondrial dysfunction. Moreover, with the observation that HRASLS1 
enriches CL with SFA, I hypothesized that the lack of proper acyl chain remodeling (i.e. to 18:2n-
6 or 18:1n-9-containing CL) would also result in significant detrimental consequences for 
mitochondrial function.  
 93 
Analysis of results from high-resolution mitochondrial respirometry indicated that 
mitochondria isolated from HEK-293 cells overexpressing HRASLS1 had significantly lower 
maximal respiration than controls. Evidence from this work suggests that CL enriched with SFA 
may not allow for proper functioning of ETC complexes. CL is critical for mitochondrial energy 
metabolism, since it is required for the proper membrane orientation, assembly, and activity of 
mitochondrial enzymes including cytochrome c oxidase [272-274], glycerol-3-phosphate 
dehydrogenase [275], and ATP synthase [234, 276], and for the stabilization of large mitochondrial 
protein complexes [123, 277]. Moreover, although CL acyl-chain specificity can vary from tissue-
to-tissue, a recurrent theme observed in the acyl chain remodeling patterns of this phospholipid is 
its preference for 18-carbon unsaturated fatty acids (typically either linoleic or oleic acid) [278]. 
While the precise function of these specific fatty acids in mitochondrial function is not yet fully 
understood, it has been suggested that repeating chains of oleate or linoleate may create structural 
uniformity, molecular symmetry, and a relatively high degree of fluidity in the membrane that 
provides a conducive environment for optimal functioning of ETC complexes [261]. Since 
overexpression of HRASLS1 both increases CL content, and causes an enrichment of CL with 
saturated fatty acids, it is not surprising that we observed a significant decrease in mitochondrial 
respiration.  
It is of note that although changes in CL composition were associated with impaired 
mitochondrial function in this study, the production of SFA-enriched CL may also confer a 
protective benefit against lipid peroxidation and mitochondrial DNA damage, and therefore be 
beneficial in some instances. Lipid peroxidation typically affects unsaturated fatty acids as 
compared to saturates [279], and can further induce damage to mitochondrial DNA [280, 281]. 
Consistent with this evidence, we observed no difference in H2O2 production, nor alterations in 
markers of mitochondrial DNA content in HRASLS1-overexpressing HEK-293 cells, where CL 
is enriched in SFA. By comparison, the production of CL by ALCAT1, which is remodeled with 
HUFA, is targeted by reactive oxygen species that leads to mitochondrial DNA dysfunction [143, 
227]. Clearly, a cost-benefit analysis is needed to examine the trade-off between mitochondrial 
function and maintenance of membrane and mitochondrial DNA integrity in cells. The generation 
of HRASLS1-overexpressing mice and/or HRASLS1 knockout mice would serve as valuable 
models to study the downstream effects of altered CL acyl chain composition and mitochondrial 
function on a cellular, organellar, and organismal basis.  
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In Thesis Study I, I observed an indirect induction of oleoyl-CoA-dependent MLCL O-
acyltransferase activity in lysates from cells that overexpressed HRASLS1 for 48 hours. To explain 
this, I hypothesized that HRASLS1 may induce the synthesis of NAPE that acts as substrate to 
increase the synthesis of NAE, which could activate expression of genes involved in phospholipid 
biosynthesis. To determine if there is any evidence to support this notion, I investigated the mRNA 
expression of genes involved in phospholipid, and specifically, cardiolipin biosynthesis in HEK-
293 cells overexpressing control or HRASLS1 protein. Following overexpression of HRASLS1, I 
observed a significant increase in the expression of the majority of the Kennedy Pathway genes 
analyzed. Interestingly, five acyl-CoA-dependent O-acyltransferases – GPAT1, GPAT3, 
AGPAT2, AGPAT4, and AGPAT5 - were significantly increased. This could lead to increased 
incorporation of [14C]oleoyl-CoA into PC, which could then act as a substrate for PC:MLCL O-
transacylase activity by HRASLS1. Notably, the largest difference in gene expression observed 
was an ~5.5-fold higher expression of CLS in HRASLS1-overexpressing HEK-293 cells, which 
could also increase CL content from precursor substrates generated by GPAT and AGPAT 
enzymes. The magnitude and scope of increases observed in the mRNA expression of nearly every 
Kennedy Pathway gene supports the idea that HRASLS1 can indirectly regulate cardiolipin 
biosynthesis through effects on gene expression. The data therefore suggests that in vivo N-
acyltransferase activity of HRASLS1 may be at least partially responsible for mediating these 
effects by increasing the synthesis of NAPEs/NAEs. Future studies with NAE receptor antagonists 
will be important for establishing causality. 
NAEs are well-known endogenous activators of transcriptional regulators including 
TRPV1 [64], GPR55 [65], and GPR119 [65, 66], although perhaps they have been best 
characterized through their agonism of PPAR [67, 68]. Studies have demonstrated that PPAR 
can be activated by several highly abundant NAE species including PEA [67], OEA [282], and 
LEA [260]. I hypothesized that overexpression of HRASLS1 in HEK-293 cells would result in a 
significant induction in the expression of the transcriptional regulators PPAR, and TRPV1, and 
consistent with my hypotheses, I observed a significant up-regulation of the mRNA expression of 
these genes. While this finding does not necessarily confirm a greater content of these receptors as 
the experiment only measures relative changes in mRNA expression, it does suggest that there 
may be increased flux through this pathway. NAEs are well-known to play key roles in several 
physiological processes including nocioception [283], inflammation [284], and food intake [260]. 
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However, their abilities to modulate cardiolipin metabolism have not yet been reported. Although 
specific research in this area is lacking, it is likely that NAEs signal through the same receptor 
proteins (i.e. PPAR and TRPV1) to mediate phospholipid metabolism. PPAR is a well-known 
regulator of lipid metabolism and plays a significant role in regulating the phospholipid and TAG 
content in several murine tissues including the liver [285]. In a study performed by Lee et al. 
(2004) [285], PPAR-/- mice exhibited a 45% decrease in the hepatic content of total 
phospholipids. In addition, PPAR is known to regulate the expression of several Kennedy 
Pathway genes including the LPAATs/AGPATs [286] and, importantly, PPAR is also able to 
regulate de novo CL biosynthesis via the specific activation of PGPS, CDS1, and CDS2 [287]. 
Highly abundant NAEs such as PEA and OEA are known to signal through TRPV1 [288], and 
although TRPV1 does not yet have a defined role in phospholipid biosynthesis, its activation has 
been shown to stimulate the synthesis of phosphatidylinositol phosphates (PIPs), which are 
downstream effector lipids that originate from PI [289]. Interestingly, while many different species 
of NAE are endogenous agonists of TRPV1, evidence has suggested that NAEs comprised of 18-
carbon, unsaturated fatty acids including oleic acid and linoleic acid can activate TRPV1 more 
efficiently than NAEs comprised of 18-carbon saturated fatty acids [290].  
Thus, a rationale has been formed for a potential role for NAEs in CL biosynthesis. In 
particular, PEA, OEA, and SEA are abundant species of NAE in most tissues [291]. Therefore, I 
examined the ability of these NAEs to modulate CL content in HEK-293 cells, and expected to see 
a significant increase. However, a 48-hour treatment with any tested NAE species did not result in 
an increase in endogenous CL content. Results from this experiment suggest that these three 
species of NAE do not modulate CL in HEK-293 cells. Determination of the effect of HRASLS1 
overexpression on NAE levels in HEK-293 cells therefore constitutes a critical next step.  
Consequently, I initiated a collaboration to identify alterations in the content of NAEs in 
HEK-293 cells overexpressing HRASLS1. Surprisingly, a significant decrease in the content of 
both PEA and of OEA was detected. These data suggest that in HEK-293 cells, PEA and OEA do 
not play a major role in mediating effects of HRASLS1 on CL synthesis, which helps to explain 
my finding that treatment of HEK-293 cells with PEA and OEA does not increase endogenous CL 
content in HEK-293 cells. SEA was not present at a detectable concentration in HRASLS1-
overexpressing HEK-293 cells, suggesting a negligible role in regulation of this cell line. 
Interestingly, a moderate, although not statistically significant, increase was observed in the 
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content of LEA. While there exists a deficit in the literature in regards to the role of LEA in CL 
metabolism, LEA is known to exhibit anti-inflammatory effects [292], in addition to its role in 
mediating satiety [260]. Like other NAEs, LEA can exert its effects through activation of both 
PPAR and TRPV1 [260]. While a larger sample size will likely reduce the variation present in 
the measurement of this NAE species, future studies should aim to investigate the ability of LEA 




In conclusion, the current study has demonstrated the existence of a role for HRASLS1 in 
cardiolipin metabolism in vivo, extending observations in Thesis Study I on the function of this 
enzyme in CL metabolism in vitro. Overexpression of HRASLS1 in HEK-293 cells significantly 
increased cellular CL content, and specifically enriched CL with SFA. While the full physiological 
significance of SFA-enriched CL is unknown, it is likely detrimental to cellular health. 
Mitochondrial respiration in HEK-293 cells overexpressing HRASLS1 was significantly lower 
than in controls, while mitochondrial DNA content was not different, suggesting less functional, 
but not fewer mitochondria. The global increase in the mRNA content of multiple genes involved 
in phospholipid metabolism, along with PPAR and TRPV1, suggested that HRASLS1 may exert 
effects on cellular CL levels indirectly, potentially through the signaling of NAEs synthesized 
downstream of NAPE. While treatment of HEK-293 cells with OEA, PEA, or SEA did not increase 
CL content, it is likely that other NAE species, such as LEA, may mediate the downstream 
signaling effects of HRALSL1 on CL in HEK-293 cells. 
Future investigations should be performed to test a role for LEA in the synthesis of CL in 
HEK-293 cells. Data from those studies would provide valuable insight into the potential 
mechanism(s) of LEA action, and may shed further light into the importance of 18-carbon, 
unsaturated NAE species in mediating phospholipid metabolism. In addition, the capacity for 
NAEs to increase CL content in cellular models that exhibit CL deficits should be examined. While 
decreases in CL are associated with several disease states, individuals suffering from Barth 
Syndrome can provide a direct model of CL deficiency to study NAE function. Hence, the next 




Thesis Study III – Effects of OEA on CL metabolism and proliferation of 
cultured B-Lymphocytes from an Individual with Barth Syndrome 
 
Introduction and Study Rationale 
 Thesis Study I and Thesis Study II demonstrated new roles for HRASLS1 in the in vitro 
and in vivo synthesis and acyl chain remodeling of the mitochondrial phospholipid CL. In that 
work, I observed widespread increases in the mRNA expression of nearly all genes involved in 
phospholipid metabolism, and thus hypothesized that HRASLS1 may in fact exert at least some of 
its CL metabolizing effects through signaling mediated downstream of its N-transacylase activity, 
and resultant production of NAPEs/NAEs. Direct treatment experiments suggested that OEA, 
PEA, or SEA are likely not significant regulators of the increase in CL that was evident in HEK-
293 cells infected with HRASLS1. Data on changes in major detectable NAE species following 
HRASLS1 overexpression in HEK-293 cells further supported this notion. Interestingly, these data 
also suggested a potential role for LEA in HEK-293 cells that suggests it would be a first choice 
as a therapeutic target in treating CL deficiency in Barth Syndrome, and certainly also merits 
further investigation in HEK-293 cells. Unfortunately, Thesis Study III was almost completed by 
the time these data were available. Thus, OEA was selected as a test agent for preliminary 
therapeutic investigation in BTHS, based on the erroneous prediction that it would turn out to be 
a major NAE species produced downstream of HRASLS1, which had shown some preference for 
the use of 18-carbon unsaturated fatty acyls at the sn-1 position. Regardless, OEA testing in BTHS 
lymphocytes yielded interesting results.   
Thus, at the same time as the NAE experiments in HEK-293 cells were being performed, 
a parallel set of experiments utilizing cultured B-lymphocytes derived from healthy controls and 
BTHS patients were carried out simultaneously. B-lymphocytes derived from BTHS patients have 
been shown to have abnormal CL metabolism, CL deficiency, and impaired cellular function 
[293], and thus represent a useful experimental model to assess the capacity of NAE to modulate 
CL metabolism in a disease state. The overarching objective of this chapter was to assess the 
capacity of OEA to act as a potential therapeutic mediator of CL metabolism and cellular function 





Figure 22: Schematic of the study design of Thesis Study III 
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Objectives and Hypotheses 
The objectives and hypotheses for this study were as follows: 
1. Objective: To investigate if treatment for 48 hours with 1 M OEA can increase the total 
CL content in cultured B-lymphocytes derived from a 10-year-old male with BTHS relative 
to the same cells treated with vehicle alone (control), and to a level comparable to that of 
an age-, sex, and ethnicity-matched control patient. 
Hypothesis: A 48-hour treatment with 1 M OEA will significantly increase cardiolipin 
content in BTHS-derived B-lymphocytes as compared to vehicle treated BTHS cells, and 
will partially restore CL levels to those observed in control patient lymphocytes. Treatment 
of control B-lymphocytes with OEA will not alter total CL levels. 
 
2. Objective: To characterize the fatty acyl composition of CL in cultured B-lymphocytes 
derived from age-, sex-, and ethnicity-matched control and Barth Syndrome individuals 
that have been treated for 48-hour with vehicle or with 1 M OEA. 
Hypothesis: A 48-hour treatment with 1 M OEA will significantly enrich cardiolipin with 
saturated fatty acids and n-3 polyunsaturated fatty acids in BTHS B-lymphocytes as 
compared to mock treated and treated control B-lymphocytes. 
 
3. Objective:  To investigate if treatment for 48 hours with 1 M OEA can increase the 
proliferation of cultured B-lymphocytes derived from a 10-year-old male with BTHS 
relative to the same cells treated with vehicle alone (control), and can rescue cellular 
proliferation to a level comparable to that of an age-, sex, and ethnicity-matched control 
patient.  
Hypothesis: A 48-hour treatment with 1 M OEA will significantly increase the 
proliferative rate of BTHS-derived B-lymphocytes as compared to vehicle treated BTHS 
cells, and will partially restore proliferation to levels observed in control patient 
lymphocytes.  
4. Objective: To assess changes in mRNA expression in cultured B-lymphocytes derived 
from an age-, sex-, and ethnicity-matched control and Barth Syndrome patient of genes 
involved in phospholipid biosynthesis following a 48-hour treatment with 1 M OEA. 
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Hypothesis: A 48-hour treatment with 1 M OEA will significantly increase the expression 
of CDS1/2, PGS, and CLS in BTHS-derived B-lymphocytes as compared to vehicle-
treated BTHS-derived B-lymphocytes. This treatment will have no effect significant effect 





OEA treatment of BTHS B-lymphocytes increases total cellular CL content 
 B-lymphocytes derived from a healthy control or BTHS patient were treated either with 
vehicle control, or 1 M OEA for 48 hours, then harvested and extracted for total endogenous 
lipids. Individual phospholipids were resolved by TLC, and endogenous CL was identified by 
comparison with known standards, scraped, and analyzed for fatty acyl composition and content. 
As expected, vehicle-treated BTHS cells displayed an ~40% lower content of CL than control 
vehicle-treated cells (control vehicle, 2.07  0.16 g FA of CL/106 cells versus BTHS vehicle, 
1.25  0.13 g FA of CL/106cells, P<0.05) (Fig. 23A). However, this difference was no longer 
significant following treatment of cells with 1 M OEA (control OEA, 1.85  0.27 g FA of 
CL/106 cells versus BTHS OEA, 1.63  0.19 g FA of CL/106 cells, P = 0.528). It is important to 
note that although treatment with 1 M OEA partially rescued CL content in BTHS B-
lymphocytes, it did not do so at a statistically significant level (BTHS vehicle, 1.25   0.13 g FA 
of CL/106 cells versus BTHS OEA, 1.63  0.19 g FA of CL/106cells, P=0.13). 
 
OEA treatment of BTHS B-lymphocytes significantly alters the relative content of individual 
fatty acids in CL 
 The fatty acid composition of CL in B-lymphocytes derived from a healthy control subject 
or a BTHS patient treated with either vehicle or 1 M OEA was determined and quantified by GC-
FID. Analysis of the relative changes in the major fatty acyl classes within CL displayed an overall 
higher relative content of SFA, and a lower relative content of MUFA, in both vehicle- and OEA-
treated BTHS cells as compared to both vehicle- and OEA-treated control cells (Fig. 23B).  
 Several differences were observed between the groups upon examination of individual fatty 
acyl species within CL. In particular, there was a significantly higher relative content of both 
palmitic acid (C 16:0) and stearic acid (C 18:0) in both vehicle- and OEA-treated BTHS cells as 
compared to both vehicle- and OEA-treated controls (Fig. 24A). Of the monounsaturated fatty acyl 
species analyzed, a significantly lower relative content of palmitoleic acid (C 16:1) was observed 
in CL from the vehicle-treated BTHS cells as compared to vehicle-treated controls. However, this 
difference was not conserved in the OEA-treated BTHS cells as compared to the OEA-treated 
control cells. A significantly lower relative content of oleic acid (C18:1n-9) was observed in both 
BTHS treatment conditions as compared to both control treatment conditions, although it is notable 
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that treatment with OEA helped to restore C18:1n-9 in CL from the BTHS cells to levels seen in 
vehicle-treated control cells (Fig. 24B).  
 The relative percent of linoleic acid (C18:2n-6) was highly significantly lower in content 
in both BTHS vehicle and OEA-treated cells as compared to both control vehicle- and OEA-treated 
cells (Fig. 24C). Notably, treatment of BTHS lymphocytes with OEA did not reduce the relative 
abundance of linoleic acid in CL relative to control lymphocytes, and may even have slightly, but 
non-significantly, enriched this acyl species. Of the n-3 PUFA species, only a difference in -
linolenic acid, (ALA, C 18:3n-3) was observed, where vehicle- and OEA-treated BTHS cells had 
a significantly higher relative content of ALA as compared to both vehicle-treated control cells 
(Fig. 24D). Interestingly, the ALA content of control lymphocytes did not differ significantly from 
BTHS lymphocytes after treatment with OEA due to a slight increase in the content of this fatty 
acyl in control cell CL, and a slight decrease in the content in BTHS cell CL. 
 
OEA treatment of BTHS B-lymphocytes reverses growth impairments 
 Control or BTHS-derived B-lymphocytes were seeded in 15 mL culture flasks at a density 
of approximately ~1 million cells/flask. Growth media was RPMI-1640 with 10% charcoal-
stripped FBS, 1% penicillin-streptomycin, and cells were treated with either OEA at a final 
concentration of 1 M (treated), or with only the vehicle control (ethanol). Baseline measurements 
of cell numbers were taken at Day 0 to ensure accurate seeding densities, and counts were 
performed subsequently at 24 hour and 48 hours. On Day 0, all groups of control and BTHS B-
lymphocytes were seeded at approximately 1 million cells/flask. After 24 hours (Day 1), cell 
counts in the control (vehicle) groups began to demonstrate the expected growth impairments of 
BTHS B-lymphocytes as compared to control B-lymphocytes. At the 48-hour time-point (i.e. Day 
2), differences in cell growth were statistically significant. As compared to the vehicle-treated 
control B-lymphocytes, there were significantly fewer vehicle-treated BTHS-derived B-
lymphocytes (i.e. control vehicle-treated, 5.04 x 106  5.30 x 105 total cells versus BTHS vehicle-
treated 2.94 x 106  3.86 x 105 total cells, P = 0.0094) (Fig. 25). Treatment of BTHS-derived B-
lymphocytes with 1 M OEA reduced this difference, so that after two days, the number of BTHS 
lymphocytes treated with OEA (4.23 x 106  5.45 x 105 total cells) was not significantly different 
from the number of control lymphocytes either treated (4.64 x 106  3.77 x 105 total cells), or 
untreated (5.04 x 106  5.30 x 105 total cells) with OEA. However, the rescue of cell proliferation 
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was only partial, since at 48 hours, the number of BTHS lymphocytes treated with OEA was not 
statistically different from the number of vehicle-treated BTHS lymphocytes (1 M OEA BTHS 
4.23 x 106  5.45 x 105 total cells total cells, versus BTHS vehicle-treated 2.94 x 106  3.86 x 105 
total cells, P=0.0832).  
 
BTHS B-lymphocytes have significantly higher mRNA expression of GPAT3 and CDS1 as 
compared to control B-lymphocytes 
 Real-time PCR was performed to investigate any underlying differences in the mRNA 
expression of genes involved in phospholipid biosynthesis between control and BTHS B-
lymphocytes. Cells were treated with vehicle or OEA, grown for 48 hours, following which total 
RNA was harvested and analyzed by RT-qPCR for relative mRNA expression of genes involved 
in phospholipid biosynthesis. All data was normalized to the mRNA expression of 18S. Vehicle-
treated lymphocytes from control subjects were compared with vehicle-treated lymphocytes from 
BTHS subjects (Fig. 26), and it was determined that the majority of phospholipid and CL synthesis 
genes were not differently expressed. Only two significant differences were evident. GPAT3 
mRNA was ~7-fold more abundant in BTHS lymphocytes versus control subject lymphocytes 
(control, 1.00  0.672 versus BTHS, 7.46  0.836, P = 0.0038) (Fig. 26C). And, similarly, CDS1, 
was 18-fold more abundant in BTHS cells as compared to controls (control, 1.00  1.048 versus 
BTHS, 18.25  1.141, P = 0.0004) (Fig. 26J).  
 
OEA treatment of BTHS B-lymphocytes increases the expression of Agpat4 as compared to OEA-
treated controls 
OEA-treated lymphocytes from control subjects were compared with OEA-treated 
lymphocytes from BTHS subjects (Fig. 27), and it was determined that, similar to effects observed 
in vehicle-treated cells, the majority of phospholipid and CL synthesis genes were not differently 
expressed. The only significant difference observed was an ~2.5-fold increase in the mRNA 
expression of AGPAT4 in OEA-treated BTHS cells compared to OEA-treated controls (control, 





Figure 23: OEA treatment partially rescues CL content in BTHS-derived B-lymphocytes 
(A) Endogenous CL content of B-lymphocytes derived from healthy controls or BTHS patients treated with vehicle (control) or 1 M 
OEA for 48 hours. (B) Relative proportion of major fatty acid classes (i.e., SFA, MUFA, n-6 PUFA, n-3 PUFA) within CL isolated 
from healthy controls and BTHS patients treated either with vehicle alone (control) or 1 M OEA. Data are means  S.E.M. *P<0.05, 




Figure 24: Fatty acyl profiles of CL isolated from healthy control B-lymphocytes and BTHS B-lymphocytes with or without 
OEA treatment. 
Relative proportion of fatty acyls within CL from cultured B-lymphocytes of healthy controls or BTHS patients treated with vehicle 
alone, or 1 M OEA for 48 hours, including SFA (A), MUFA (B), n-6 PUFA (C), and n-3 PUFA (D). Data are means  S.E.M. 




Figure 25: OEA treatment partially rescues the growth deficit observed in BTHS B-lymphocytes 
Growth curves of B-lymphocytes derived from a healthy control or BTHS patient, treated either with vehicle alone, or 1 M OEA for 
48 hours. Cellular proliferation rate, as calculated by area under the curve (AUC) is shown in the inset figure. Data are means  S.E.M. 








Figure 26: Expression of phospholipid biosynthetic 
genes in vehicle-treated healthy control and BTHS B-
lymphocytes. 
Analysis of B-lymphocytes derived from vehicle-treated 
healthy controls or BTHS patients for expression of genes 
involved in phospholipid, and specifically, CL synthesis 
and acyl-chain remodeling. (A-D), Glycerol-3-phosphate 
acyltransferases 1-4 (GPAT1-4). (E-I) 
Acylglycerophosphate acyltransferases 1-5 (AGPAT1-5). 
(J) Phosphatidate cytidylyltransferase 1 (CDS1). (K) 
Phosphatidate cytidylyltransferase 2 (CDS2). (L) 
Phosphatidylglycerol synthase (PGS). (M) Cardiolipin 
synthase (CLS). (N) Tafazzin (TAZ). (O) Acyl-
CoA:lysocardiolipin acyltransferase 1 (ALCAT1). (P) -
trifunctional protein (TFP). Data are means  S.E.M. 


















Figure 27: Expression of phospholipid biosynthetic 
genes in healthy control and BTHS B-lymphocytes 
treated with 1 M OEA. 
Analysis of B-lymphocytes derived from a healthy control 
subject or BTHS patient and treated with 1 M OEA, for 
genes involved in phospholipid, and specifically, CL 
synthesis and acyl-chain remodeling. (A-D), Glycerol-3-
phosphate acyltransferases 1-4 (GPAT1-4). (E-I) 
Acylglycerophosphate acyltransferases 1-5 (AGPAT1-5). 
(J) Phosphatidate cytidylyltransferase 1 (CDS1). (K) 
Phosphatidate cytidylyltransferase 2 (CDS2). (L) 
Phosphatidylglycerol synthase (PGS). (M) Cardiolipin 
synthase (CLS). (N) Tafazzin (TAZ). (O) Acyl-
CoA:lysocardiolipin acyltransferase 1 (ALCAT1). (P) -
trifunctional protein (TFP). Data are means  S.E.M. 





 The current study examined the ability of OEA to modulate CL metabolism in B-
lymphocytes taken from a healthy control subject and an individual with BTHS. This work 
demonstrates, for the first time, that treatment with an NAE (specifically OEA) can partially rescue 
CL content and cellular growth of BTHS B-lymphocytes relative to controls.  
Since this study was performed in parallel with the previous study (Thesis Study II) 
examining an in vivo role for HRASLS1 in CL metabolism, the protocol was not informed by 
results from our collaborator on relative changes in species of NAEs occurring as a result of 
HRASLS1 infection. Quantifiably, OEA is amongst the most abundant NAE species produced in 
many cell types [294], and is produced in greater amounts than the well-studied anandamide [295]. 
In addition, NAE receptors such as PPAR and TRPV1, which may regulate phospholipid 
metabolism, have shown preference for activation by species which contain an 18-carbon, 
unsaturated fatty acid, such as oleic acid [290]. Thus, OEA was selected for use as a potential 
candidate modulator of CL in both HEK-293 cells, and B-lymphocytes.  
Although HRASLS1 increased CL in HEK-293 cells, it decreased OEA levels 
significantly, strongly suggesting that this NAE is not involved in the modulation of CL by 
HRASLS1, and that other NAEs should be investigated. This was substantiated by the finding that 
treatment of HEK-293 cells with OEA did not alter the endogenous cardiolipin content. 
Regardless, since this was not known when studies with BTHS lymphocytes were initiated, OEA 
was tested as a potential therapeutic. Although results from this work do not assist in explaining 
the effects of HRASLS1 on CL metabolism, as was originally intended, they are highly novel, and 
of strongly related interest to this thesis in the context of exploring the broader regulation of CL 
synthesis.  
The study was performed with the overarching hypothesis that candidate NAEs, such as 
OEA, could be useful as potential therapeutics in disorders of impaired CL metabolism. This is 
not the first time that an NAE species has been tested for a therapeutic purpose in the treatment of 
a disease. Indeed, several studies have examined the use of OEA and PEA in modulating disease 
conditions including intestinal hyperpermeability and inflammation [296], obesity [297, 298], 
inflammatory bowel disease [299], and neurodegeneration [300]. In fact, the focus of a growing 
number of pharmacological studies is the development of inhibitors against N-acylethanolamine 
acid amidase (NAAA), an enzyme which hydrolyzes, and therefore degrades, endogenous NAEs 
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[301]. This is, however, the first time that an NAE has been tested for the purpose of modulating 
CL synthesis to ameliorate a disease associated with deficiency of this mitochondrial lipid.  
Analysis of the CL content of vehicle-treated control and BTHS lymphocytes demonstrated 
an expected deficit in CL content in BTHS cells that has already been well characterized [174, 
278, 293]. Following a 48-hour treatment with 1 µM OEA, however, an ~30% increase in 
endogenous CL was observed in the OEA-treated BTHS cells as compared to vehicle-treated 
BTHS cells. While the increased level in OEA-treated BTHS cells did not fully restore CL to levels 
found in either treated or untreated control cells, the significant difference between the groups was 
lost, due to the increase in CL in the OEA-treated BTHS cells. These data therefore indicate that 
treatment with OEA can, at least in part, increase the cellular content of CL in cells that exhibit 
CL deficiencies. This outcome is in contrast to the findings that were observed in OEA-treated 
HEK-293 cells, which did not show an increase in CL content. It is not clear whether the efficacy 
of OEA in BTHS B-Lymphocytes is due to the difference in cell type (lymphocytes versus 
embryonic kidney cells), or due to the CL-deficient state of these cells, a combination, or some 
other factor.  
Increasing CL content in BTHS patients is a primary objective in the treatment of this 
disorder. At the present time, several potential therapies are under investigation including TAZ-
enzyme replacement therapy (ERT), and gene therapy via the use of recombinant adeno-associated 
viruses (rAAV). ERT has already shown effectiveness in treating other metabolic disorders 
including Fabry disease [302], and Pompe disease [303]. In addition, rAAV gene therapy is a 
viable therapeutic option for mouse models of both Fabry disease [304-306] and Pompe disease 
[307, 308]. Unfortunately, however, while they are the focus of current investigation by several 
laboratories, no viable ERT or rAAV therapies have been developed that are yet effective or used 
in BTHS. Another potential therapy to restore CL in BTHS is lipid replacement therapy (LRT), 
which was recently investigated by Ikon et al. (2017) in BTHS [309]. In that study, the use of 
exogenous CL nanodisk (CL-ND) delivery particles was examined for its ability to increase CL 
content in TAZ-KD mice [309]. While CL-ND treatment had been previously found to be effective 
in increasing CL content in cultured cells [310], it failed to alter the CL profile of TAZ-knockdown 
mice, indicating that CL-ND therapy is not suitable for in vivo treatment of BTHS [309]. Thus, the 
discovery that exogenous OEA treatment can increase CL content in cultured BTHS B-
lymphocytes represents an exciting opportunity. Further studies should aim to investigate whether 
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this effect is conserved in vivo, beginning with Taz-knockout mice. In addition, future studies 
should investigate the use of a wider range of NAE species, to attempt to achieve a more complete 
rescue of the CL content in BTHS B-lymphocytes. One such NAE species that may be of particular 
interest is LEA, due to the prior observation that LEA content is modestly elevated in HEK-293 
cells overexpressing HRASLS1. NAEs are produced at varying levels in a cell-specific manner 
[311, 312]. In this regard, the characterization of major NAE species that are present in BTHS B-
lymphocytes would likely provide valuable insight for future therapeutic applications within these 
cells.  
Perhaps equally as exciting as the finding that exogenous OEA treatment can increase CL 
content in BTHS B-lymphocytes is the observation that it can also partially rescue the growth 
deficiency that is observed in these cells. While BTHS is highly variable in both its clinical 
presentation and progression [195], a common feature of this disease is growth delay [199], 
especially during early childhood [202, 313]. This deficit was easily observed after 48 hours of 
growth by comparing the number of vehicle-treated or OEA-treated control cells to the number of 
vehicle-treated BTHS B-lymphocytes, which was almost half, despite equivalent initial (day 0) 
seeding densities. Treatment of BTHS B-lymphocytes with OEA caused a striking improvement 
in cell proliferation by ~44%, such that the number of treated BTHS cells was not significantly 
different from the number of treated or untreated controls.  
Thus, OEA represents an exciting therapeutic option for the treatment of BTHS that may 
help to ameliorate the CL deficits and growth deficiency that is present in these individuals, and 
that can contribute to serious adverse health effects including neutropenia. Interestingly, OEA 
treatment only restored both CL content and cellular growth to approximately 80-85% of the levels 
that are seen in healthy untreated controls, respectively. While these data are exciting, it is unclear 
why OEA treatment does not result in a full rescue of CL content or growth. While I had previously 
observed a significant upregulation of the mRNA content of genes involved in phospholipid 
biosynthesis in HEK-293 cells overexpressing HRASLS1, the same effects were not observed in 
B-lymphocytes treated with OEA (again supporting the idea that increased OEA does not regulate 
effects on CL observed in HRASLS1-overexpressing cells). Indeed, there were no significant 
differences between OEA-treated control and BTHS B-lymphocytes in the mRNA expression of 
almost all Kennedy Pathway or CL remodeling genes, with the exception of AGPAT4. This may 
suggest that OEA does not induce a significant increase in the de novo biosynthesis of CL. 
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However, it is interesting that only a single AGPAT is upregulated following OEA treatment, since 
previous work from our laboratory has suggested that AGPAT enzymes may produce individual 
pools of PA that are shunted into the synthesis of specific downstream phospholipids [3, 4, 314, 
315]. Thus, the upregulation of AGPAT4 in BTHS B-lymphocytes following OEA treatment may 
be the factor that leads to increased CL content in these cells. Further work, however, is clearly 
needed to properly examine what role, if any, AGPAT4 plays in BTHS B-lymphocytes.  
CL isolated from BTHS B-lymphocytes has a substantial deficiency in 18:2n-6. Treatment 
with OEA resulted in a slight, but not statistically significant increase in the relative content of 
linoleate in BTHS cells, as compared to BTHS cells treated with vehicle alone. However, linoleate 
in BTHS CL was only observed at a third of the level that is normally found in healthy control 
cells. This suggests that the incomplete rescue in cellular growth may be due to an increased total 
CL content that could not fully compensate functionally, since it was not appropriately enriched 
in sufficient linoleate. This contention is supported by a prior case study performed by Bowron et 
al. (2015), which identified seven BTHS patients from three unrelated families, whose linoleate-
enriched CL was present within the control range [316]. These individuals present with a mild 
form of BTHS. Most have excellent exercise tolerance that is atypical in BTHS [151, 317], and 
two individuals are even asymptomatic [316]. Thus, CL acyl chain remodeling with linoleate may 
not be necessarily required to improve growth in BTHS B-lymphocytes, but may be required for 





In conclusion, the current study has demonstrated that treatment with OEA may improve 
major biochemical and functional defects stemming from Taz-deficiency in BTHS B-
lymphocytes. Specifically, OEA treatment was found to partially rescue CL content and cellular 
proliferation in BTHS B-lymphocytes relative to B-lymphocytes from a healthy matched donor. 
While OEA did not cause any major differences in the mRNA expression of genes specifically 
involved in CL biosynthesis, CL content was higher in these cells. The content of linoleate in CL 
was not significantly increased by OEA treatment of BTHS cells, suggesting that at least in B-
lymphocytes, linoleate-enriched CL may not be required for cells to derive a functional benefit, 
such as enhanced growth capacity. Clearly, future studies are warranted to elucidate the exact 
mechanisms by which OEA treatment can increase CL content and cellular growth in these cells. 
In addition, the analysis of major NAE species present in BTHS B-lymphocytes may lead to the 
identification of other NAE species, that may result in a more complete restoration of CL content 
and cellular growth. Nonetheless, these findings provide exciting initial data supporting 
investigation of the use of NAEs in the treatment of BTHS and other metabolic disorders that 





Thesis Summary, Integrated Discussion, and Future Perspectives 
 
Thesis Summary 
The major objective of this thesis was to conduct an initial characterization of the role of 
HRASLS1 in cellular physiology and metabolism, and to extend understanding of the role of 
HRASLS1 in phospholipid metabolism. While HRASLS1 has previously been shown to 
participate directly in the synthesis of PC and PE [35], no study had investigated its ability to 
synthesize other phospholipids, including CL. I hypothesized that since HRASLS1 can act as a PC 
O-transacylase by transferring a fatty acyl from the sn-1 position (and, to a lesser extent, the sn-2 
position) from either PC or PE to LPC, it may also be able to function as a PC:PL O-transacylase 
in the synthesis of other phospholipids that had not yet been tested.  
I found that crude lysates harvested from HEK-293 cells adenovirally transduced with 
HRASLS1 for 48 hours developed an increased ability to acylate MLCL, DLCL, and LPI when 
radiolabeled oleoyl-CoA was added as the acyl-donor source. However, based on extensive prior 
biochemical and molecular studies [45, 46, 53], including X-ray crystallographic characterization 
of the catalytic domain of homologous enzymes[18, 51], it seemed highly unlikely that the 
catalytic action of HRASLS1 would be acyl-CoA-dependent. Rather, HRASLS1 is expected to 
use a phospholipid such as PC as an acyl donor in transacylase reactions. A study with reticulocyte 
lysates confirmed that acyl-CoA-dependent activity of HRASLS1 is absent when the enzyme is 
produced through in vitro transcription/translation in a system that lacks a nucleus. Importantly, 
the discrepancy between activity in crude lysates and reticulocyte lysates overexpressing 
HRASLS1 strongly suggested that this enzyme may function to increase CL synthesis in cells (i.e. 
in vivo) through the activation of alternate cellular pathways, including transcription.  
Investigation of a direct PC:MLCL O-transacylase activity for HRASLS1 in a pilot study 
using the reticulocyte lysate expression system yielded promising results with two PC acyl donors 
species, that will need to be confirmed with additional samples. This finding suggests that 
HRASLS1 may function similar to the CL remodeling enzyme Tafazzin [118]. However, while 
my results tentatively suggest that HRASLS1 may have some specificity for 18-carbon fatty acyl 
chains at the sn-1 position of PC, it is not yet known if this enzyme has a preference for linoleate. 
This should also be tested directly. It is of interest that, similar to Tafazzin, HRASLS1 also shows 
high levels of expression in the heart and brain. Interestingly, however, although HRASLS1 has a 
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putative role in the synthesis of CL, a mitochondrial phospholipid, it localizes endogenously to the 
endoplasmic reticulum. This is not the first enzyme involved in cardiolipin metabolism to localize 
to the ER, as the CL remodeling enzyme ALCAT1 was shown to localize there by Cao et al. in 
2004 [121].  
The next major objective of this thesis was to investigate the role of HRASLS1 in cells. 
Following overexpression of HRASLS1 in HEK-293 cells, I observed an ~50% increase in 
endogenous CL content. The CL produced from HRASLS1 overexpression was enriched in SFA, 
which I hypothesized may have a detrimental effect on mitochondrial function. This hypothesis 
was substantiated. Mitochondria isolated from HEK-293 cells respired significantly less than 
control mitochondria, although the content of mitochondrial DNA was found to be the same, 
strongly suggesting that mitochondria containing SFA-enriched CL are present in similar numbers, 
but are less functional.  
Although only the increase in CL reached significance, all groups of phospholipids 
appeared to increase somewhat in cells overexpressing HRASLS1 for 48 hours. This suggested 
that HRASLS1 may act to promote CL synthesis both directly as a PC:MLCL (or PC:DLCL) O-
transacylase, and indirectly through the regulation of cell signaling affecting phospholipid 
pathways associated with CL production. Previous work performed by Uyama et al. (2012) 
demonstrated that HRASLS1 has significant PC:PE N-transacylase activity in vivo. I therefore 
hypothesized that HRASLS1 may exert indirect effects on CL metabolism through the increased 
production of NAPE and, consequently, NAE, which would signal for the cell to increase CL 
synthesis. I expected that HRASLS1 overexpression would cause an increase in the mRNA 
expression of enzymes involved in CL synthesis and remodeling, namely CLS, TAZ, ALCAT1, and 
TFP. While this was observed, I also found that overexpression of HRASLS1 in HEK-293 cells 
caused a significant increase in the mRNA expression of the majority of Kennedy Pathway genes. 
These data supported the notion that HRASLS1 was likely exerting at least some of its effects on 
CL via an indirect signaling mechanism.  
 
Based on the known N-transacylase activity of HRASLS1, it was hypothesized that 
changes in the cellular concentrations of specific NAEs were most likely responsible for this 
signaling.  NAEs are present at exceedingly low levels, and unfortunately, we do not currently 
have the capacity to identify them at the University of Waterloo. A collaborative investigation with 
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Dr. Richard Bazinet’s lab at the University of Toronto was initiated to identify these changes. 
However, these data were only completed a few weeks ago. Thus, studies on the effects of NAEs 
were conducted with candidate species that were predicted (but not known) to increase with 
HRASLS1 activity. Three of the most abundant NAE species were selected for testing. HRASLS1 
is reported to show some preference for activity at the sn-1 position of PC, that is typically enriched 
in SFA and MUFA. I therefore tested the effect of PEA, OEA, and SEA treatment of HEK-293 
cells on CL levels. Unfortunately, later data from the Bazinet Lab indicated that PEA and OEA 
were not increased, and instead decreased significantly in HRASLS1-overexpressing HEK-293 
cells, and SEA was undetected in most samples. It was therefore not surprising that these NAE 
species had no significant effect on CL synthesis in HEK-293 cells. Of interest, one species of 
NAE, LEA was slightly increased, although the assayed concentration was variable, and levels 
were not significantly different from control. It is therefore suggested that the LEA content of 
HRASLS1-overexpressing cells be analyzed in a larger sample size to decrease variability in 
means, and also that LEA is tested for effects on CL production in HEK-293 cells. 
At the same time as I was investigating the ability of NAE treatment to increase CL in 
HEK-293 cells, I performed a parallel set of experiments with OEA treatment only, using B-
lymphocytes taken from a healthy control, and an individual suffering from BTHS. These studies 
formed the third major study in this thesis. Although OEA treatment did not increase CL synthesis 
in HEK-293 cells, it increased the CL content in BTHS B-lymphocytes, partially rescuing the CL 
deficit that is present in cells of individuals afflicted with BTHS [174]. This finding is in contrast 
to our previous finding that NAE treatment does not increase CL in HEK-293 cells, suggesting 
either a different function for OEA in different cell types, or that OEA effects on CL synthesis 
may be more effective when a CL deficiency is present. Regardless, the functional consequences 
of increasing CL synthesis were significant. Perhaps the most exciting finding from this study is 
that treatment with OEA improved cellular growth of BTHS B-lymphocytes, matching nearly 85% 
of the growth observed in healthy controls. These data therefore show that NAE treatment is 
effective in partially restoring both CL content and cellular growth, to a similar extent, in B-
lymphocytes from an individual with BTHS. A summary of the key findings and novel 
contributions of each thesis study is shown in Table 6.   
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Table 6: Summary of key findings and novel contributions  
Thesis Study I: Cellular and biochemical characterization of HRASLS1 
Key Findings • HRASLS1 is ubiquitously expressed, but has high expression in the heart and brain 
• HRASLS1 localizes to the ER, and not the mitochondria, nor the MAM 
• HRASLS1 overexpression in cells for 48 hours results in increased oleoyl-CoA-dependent O-
acyltransferase activity with MLCL, DLCL, and LPI as acyl acceptors, and also increased 
PC:MLCL O-transacylase activity in lysates 





• A novel role for HRASLS1 in cardiolipin metabolism has been discovered 
• Since significant oleoyl-CoA-dependent O-acyltransferase activity was only observed in crude 
lysates and not reticulocyte lysates, data suggests that the N-acyltransferase activity of HRASLS1 
may play an important role in CL synthesis. 
 
Thesis Study II: Investigation of the in vivo role of HRASLS1 in cardiolipin metabolism 
Key Findings • HRASLS1 overexpression in HEK-293 cells increases total CL content 
• CL produced by HRASLS1 overexpression is enriched in SFA 
• Mitochondrial respiration is impaired in HEK-293 cells overexpressing HRASLS1, but content of 
mtDNA is not different 
• Overexpression of HRASLS1 in HEK-293 cells causes a significant upregulation in the expression 
of Kennedy Pathway genes. These data suggest that HRASLS1 may mediate CL metabolism 
through the generation of NAPE, and therefore downstream NAE. 
• The mRNA content of PPAR and TRPV1, targets of NAE signaling, are increased following 
HRASLS1 overexpression in HEK-293 cells. 
• 48-hour treatment of HEK-293 cells with 0.1, 1, or 10 µM of PEA, OEA, or SEA does not increase 
endogenous CL content 
• Overexpression of HRASLS1 in HEK-293 cells causes a significant decrease in the content of 





• Discovery that HRASLS1 overexpression regulates CL metabolism in vivo 
• Overexpression of HRASLS1 significantly upregulates mRNA expression of genes involved in 
phospholipid biosynthesis and in CL metabolism  
• Overexpression of HRASLS1 alters the NAE profile of HEK-293 cells 
 
Thesis Study III: Effects of OEA on CL metabolism and growth of Cultured B-Lymphocytes from an Individual with 
Barth Syndrome 









Integrated Discussion and Future Perspectives 
 
The results from this thesis have identified HRASLS1 as potentially the first new CL 
remodeling enzyme that has been discovered in over a decade [121]. Prior to this finding, only 
four enzymes were known to participate directly in CL remodeling including TAZ, ALCAT1, 
MLCL-AT1, and TFP [262]. As such, HRASLS1 will likely be the subject of additional studies. 
Although this thesis tested the enzymatic activity for HRASLS1 in the synthesis of CL, because 
of the small sample size in the reticulocyte lysate work, it is still unclear if it has both a direct 
PC:MLCL O-transacylase, and indirect (via NAE production) role in this process. Experiments 
from this thesis demonstrated that HRASLS1 overexpression for 48 hours induces oleoyl-CoA-
dependent MLCL, DLCL, and LPI O-acyltransferase activity in crude lysates produced from those 
cells. However, this activity was not detected in reticulocyte lysates, indicating that HRASLS1 is 
unable to catalyze this reaction directly. Rather, it is most likely that HRASLS1 mediates at least 
some of its effects on CL metabolism through the generation of NAPE, and NAE. The finding of 
a general induction of lipid biosynthetic genes in cells overexpressing HRASLS1 supports this. It 
is important, nonetheless, to either include or exclude a direct role for HRASLS1 in the catalysis 
of CL, and therefore additional study of HRASLS1 PC:MLCL O-transacylase activity in 
reticulocyte lysates is critical.  
 Future studies should seek to further investigate the physiological role of HRASLS1 in the 
context of CL metabolism. In this sense, the generation of either Hrasls1-/+ and/or Hrasls1-/- mice 
would be invaluable. While I observed that HRASLS1 overexpression increases CL content in 
HEK-293 cells in vivo, it would be interesting to see if these effects are conserved in an animal 
model as well. Previous studies, including a relatively recent investigation by Ikon et al. (2015), 
have shown that CL content modulation is possible in cultured cells [310], but may not be 
conserved in more complex models, such as mice [309]. In this regard, the generation of a liver-
specific Hrasls1 transgenic mouse would likely provide rapid insight into this question, and could 
be readily achieved through tail-vein injections of purified adenoviral HRASLS1 into C57BL/6J 
mice.   
Interestingly, this thesis demonstrated that HRASLS1 overexpression produces CL that is 
enriched in SFA. It is not known whether this indicates substrate preference by HRASLS1, either 
for SFA specifically, or for transacylase activity at the sn-1 position, which is typically enriched 
in SFA, or if it merely reflects the increased synthesis of immature (i.e. under-remodeled) CL 
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through the ‘indirect’ induction of phospholipid and CL synthesis genes, mediated by HRASLS1-
NAPE-NAE signaling. Regardless, an important insight has been generated from this finding, 
wherein it was demonstrated that mitochondrial respiration is impaired in HEK-293 cells that 
contain SFA-enriched CL. While this finding in an isolated system is of interest, the physiological 
consequences bear further investigation. I hypothesized that since SFA are generally less 
susceptible to peroxidation than MUFA or PUFA, the production of SFA-enriched CL by 
HRASLS1 may, under certain conditions, and in some tissues, be partially protective against ROS 
attack. Thus, this altered CL profile may confer a benefit in specific instances, although the 
increased content of SFA in CL likely provides an unfavourable typical environment for ATP 
production, and cellular function as a whole. Future work is warranted to understand the 
physiological consequences stemming from production of CL enriched in SFA, and the role of 
HRASLS1 in this process in specific tissues.  
Future work on the role and regulation of HRASLS1 in CL deficiency disorders is also 
merited. In certain disease states, such as BTHS, the increase of CL content that may be mediated 
by HRASLS1 overexpression could provide an overall benefit to the cell that outweighs the 
potential impairments in optimal cellular function due to enrichment with SFA. While the loss of 
linoleate-containing CL has been shown to be critical in the development of BTHS [174], an 
overall increase in total CL content may reduce the severity of the disease. In this sense, the 
generation of Taz-/-/Hrasls1-transgenic  mice will likely provide valuable insights. 
An important finding from this thesis is that exogenous OEA treatment can partially rescue 
CL content and cellular proliferation in BTHS B-lymphocytes. To the best of my knowledge, this 
is the first time NAEs have been demonstrated to play a role in CL metabolism. While future work 
should address if alternative NAE species such as LEA may cause a greater effect, the notion that 
exogenous NAEs can be used as therapeutics in BTHS is exciting nonetheless. Currently, there is 
no known cure for BTHS, and treatment is often restricted to symptom management [318]. While 
progress is being made in the development of ERT and rAAV-mediated gene therapies for use in 
BTHS, no commercial therapies are available on the market. In addition, both ERT and rAAV-
mediated gene therapy are extremely costly therapeutic options. A report by van Dussen et al. 
estimated that ERT typically averages a cost upwards of ~$250,000 USD per patient, per year for 
treatment of type 1 Gaucher disease [319], and Rombach et al. have estimated that ERT for Fabry 
disease can cost approximately $115,000 – $200,000 USD per patient, per year [320].  
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Thus, the realization that exogenous NAE treatment can partially rescue CL content and 
cellular growth in BTHS is exciting, as NAEs are currently utilized for several pharmacological 
therapies, and are widely available at a significantly lower cost than ERT. Historically, 
pharmacological agents that have targeted the endocannaboid system have been formulated to 
inhibit the CB1 receptor in an attempt to restrict food intake for the treatment of obesity, and 
obesity-related disorders [298, 321]. A well-known pharmacological anorectic agent that was 
developed was known as Rimonabant [321], and while this drug showed promising results in 
reducing obesity and improving cardio-metabolic outcomes in overweight and obese individuals 
[322], its use has been banned in several countries due to adverse psychiatric side-effects including 
anxiety and depression [298, 323]. Consequently, research has focused on the use of exogenously-
administered NAEs that do not inhibit the CB1 receptor [298]. Perhaps the most well-studied is 
PEA, which when administered exogenously has demonstrated therapeutic effects in a wide variety 
of disorders including multiple sclerosis [324], eczema [325], and resolving inflammation and 
providing chronic pain relief [326-328]. Currently, OEA is under investigation for its anorectic 
effects as a therapy for obesity [298], although it may mediate beneficial effects on atherosclerosis 
as well [329]. However, precaution should be exercised before implementing OEA treatment in 
BTHS, as its anorectic effects may pose a serious risk to BTHS patients, who already have 
difficulties in eating [318, 330, 331]. OEA may therefore be a beneficial therapy for BTHS if it is 
used in combination with a pharmacological agent that could mediate its anorectic effects. In order 
to better understand the mechanism by which OEA exerts its effects in restoring CL content and 
cell growth in BTHS, future studies should investigate oral supplementation of exogenous NAE 
in a mouse model of BTHS, namely, TAZ knockdown (KD) or knockout (KO) mice [151, 332]. 
Both the TAZ-KD and TAZ-KO mice display aberrant CL metabolism, along with cardiac and 
skeletal muscle defects, recapitulating the biochemical and physiological deficiencies that are 
observed in human BTHS [151, 332, 333]. Identification of decreased NAE species found in the 
hearts and skeletal muscle of BTHS patients or TAZ-deficient mice may be helpful in guiding the 
selection of candidate NAEs with the greatest likelihood of therapeutic benefit.  
The use of exogenous NAE may also have therapeutic applicability beyond the treatment 
of BTHS. Although this thesis only examined the use of NAE in the treatment of B-Lymphocytes 
from a subject with BTHS, several disorders are associated with impairments in CL metabolism 
including, but not limited to, diabetes [136, 334], obesity [334], cardiovascular disorders [136, 
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334], neurodegeneration [154, 212], and cancers [229, 231, 335].  In addition, major alterations 
are known to occur in CL metabolism, even in the absence of overt disease throughout the normal 
course of aging [336-338]. Thus, future studies should investigate the utility of exogenous NAE 
supplementation in treatment of these disorders, and perhaps also as a preventative measure to 
maintain optimal CL metabolism, prior to the onset of disease. 
There are several strengths to the studies that have been performed in this thesis. First, by 
testing multiple substrates the in vitro investigation of HRASLS1 activity identified a novel role 
for the enzyme in increasing the capacity of cells to catalyze the oleoyl-CoA-dependent acylation 
of MLCL, DLCL, and LPI, as well as PC:MLCL O-transacylation. Enzyme assays performed in 
reticulocyte lysates narrowed the MLCL acylation activity of HRASLS1 to, likely PC:MLCL O-
transacylase activity, and excluded oleoyl-CoA-dependent acylation as a direct function of this 
enzyme. Next, transacylase experiments utilized three different species of PC, and demonstrated 
that HRASLS1 likely prefers the sn-1 position, and likely shows acyl specificity for 18-carbon 
fatty acids. Prior to this work, only PC and PE had been investigated as possible acyl acceptors 
[35]. These data will help inform the design of future studies to investigate the substrate-specificity 
of this enzyme. In addition, the in vivo investigations characterized most genes involved in 
phospholipid, and cardiolipin biosynthesis. This is significant. The Kennedy Pathway represents a 
complex series of acylation and de-acylation events catalyzed by at least thirteen distinct enzymes, 
with an additional four enzymes involved in CL acyl chain remodeling. The extent of 
characterization of the mRNA expression of HEK-293 cells overexpressing HRASLS1, as well as 
treated and untreated control and BTHS B-lymphocytes, helps to illustrate cellular phospholipid 
synthesis in these cells. The identification of the alterations in NAE content following HRASLS1 
overexpression also provide important information for future studies. Finally, in any experiment 
assessing the effects of exogenous NAE treatment, charcoal-stripped FBS was used in order to 
remove exogenous NAEs in serum, which could confound the results.  
However, this thesis is not without its limitations as well. Studies II and III utilized cultured 
cells as an in vivo measurement of CL content and cellular growth. While cultured cells are more 
widely available and less expensive than animal models, future studies should confirm these 
findings in mice, and if successful, eventually in humans as well. Generation of a liver-specific 
transgenic model of HRASLS1 overexpression using available adenovirus would potentially 
confirm the findings in Study II, while utilization of either TAZ-KD or TAZ-KO mice would 
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confirm the findings in Study III. Next, while data demonstrating that mitochondrial respiration is 
impaired in HRASLS1-overexpressing HEK-293 cells provides novel insights, the respiration 
protocol was not performed with ETC-complex inhibitors. Performing a substrate-uncoupler-
inhibitor titration (SUIT) procedure, as previously described [2, 252] would allow for assessment 
of possible alterations in individual ETC complexes. Finally, NAE experiments in HEK-293 cells 
were performed by adding exogenous PEA, OEA, and SEA. Unfortunately, these turned out to be 
a poor choice, since these NAEs were actually decreased (or undetected, in the case of SEA) 
following HRASLS1-overexpression in these cells. Due to differences in experimental timing with 
my collaborators, I was unaware of this fact while performing these experiments. Nevertheless, if 
possible, future experiments should investigate changes in the NAE profile of the cell culture or 
animal model being utilized, prior to assessing if certain exogenously-added NAE species have 
any effects. 
Thus, this thesis expands on the current literature by demonstrating for the first time that 
HRASLS1 plays indirect and, likely, direct roles in cellular CL metabolism. Importantly, the 
concept of multiple synergistic enzymatic activities falling on a single pathway is novel and should 
be further delineated. Although the exact mechanism by which HRASLS1 exerts its effects are 
still unknown, it is likely that it produces NAPEs, and by extension NAEs that signal for increases 
in phospholipid synthesis. Future work with NAE-receptor antagonists will be important to test 
this directly, and the discovery of this novel function will likely be the focus of several fundamental 
studies to follow. Furthermore, this thesis shows that treatment with OEA can partially rescue CL 
content and cellular growth in BTHS B-lymphocytes. Consequently, this work now provides an 
avenue for future studies to examine the use of exogenous NAEs for the treatment and prevention 





[1] K. Athenstaedt, G. Daum, Phosphatidic acid, a key intermediate in lipid metabolism, Eur J 
Biochem, 266 (1999) 1-16. 
[2] R.M. Bradley, E.B. Mardian, D. Bloemberg, J.J. Aristizabal Henao, A.S. Mitchell, P.M. 
Marvyn, K.A. Moes, K.D. Stark, J. Quadrilatero, R.E. Duncan, Mice Deficient in 
lysophosphatidic acid acyltransferase delta (Lpaatdelta)/acylglycerophosphate acyltransferase 4 
(Agpat4) Have Impaired Learning and Memory, Molecular and cellular biology, 37 (2017). 
[3] R.M. Bradley, P.M. Marvyn, J.J. Aristizabal Henao, E.B. Mardian, S. George, M.G. Aucoin, 
K.D. Stark, R.E. Duncan, Acylglycerophosphate acyltransferase 4 (AGPAT4) is a mitochondrial 
lysophosphatidic acid acyltransferase that regulates brain phosphatidylcholine, 
phosphatidylethanolamine, and phosphatidylinositol levels, Biochim Biophys Acta, 1851 (2015) 
1566-1576. 
[4] E.B. Mardian, R.M. Bradley, J.J. Aristizabal Henao, P.M. Marvyn, K.A. Moes, E. 
Bombardier, A.R. Tupling, K.D. Stark, R.E. Duncan, Agpat4/Lpaatdelta deficiency highlights 
the molecular heterogeneity of epididymal and perirenal white adipose depots, J Lipid Res, 58 
(2017) 2037-2050. 
[5] J.E. Vance, Phospholipid synthesis and transport in mammalian cells, Traffic (Copenhagen, 
Denmark), 16 (2015) 1-18. 
[6] A.K. Agarwal, K. Tunison, J.S. Dalal, S.S. Nagamma, F.K. Hamra, S. Sankella, X. Shao, R.J. 
Auchus, A. Garg, Metabolic, Reproductive, and Neurologic Abnormalities in Agpat1-Null Mice, 
Endocrinology, 158 (2017) 3954-3973. 
[7] A.G. Lee, How lipids affect the activities of integral membrane proteins, Biochimica et 
Biophysica Acta (BBA) - Biomembranes, 1666 (2004) 62-87. 
[8] J. Ratajczak, M. Wysoczynski, F. Hayek, A. Janowska-Wieczorek, M.Z. Ratajczak, 
Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell 
communication, Leukemia, 20 (2006) 1487-1495. 
[9] Y. Nishizuka, Turnover of inositol phospholipids and signal transduction, Science (New 
York, N.Y.), 225 (1984) 1365-1370. 
[10] S.H. Zeisel, Choline phospholipids: signal transduction and carcinogenesis, The FASEB 
Journal, 7 (1993) 551-557. 
[11] S. Spiegel, D. Foster, R. Kolesnick, Signal transduction through lipid second messengers, 
Current Opinion in Cell Biology, 8 (1996) 159-167. 
[12] A.I. de Kroon, D. Dolis, A. Mayer, R. Lill, B. de Kruijff, Phospholipid composition of 
highly purified mitochondrial outer membranes of rat liver and Neurospora crassa. Is cardiolipin 
present in the mitochondrial outer membrane?, Biochim Biophys Acta, 1325 (1997) 108-116. 
[13] T.H. Haines, N.A. Dencher, Cardiolipin: a proton trap for oxidative phosphorylation, FEBS 
Lett, 528 (2002) 35-39. 
[14] G.M. Hatch, Cell biology of cardiac mitochondrial phospholipids, Biochem Cell Biol, 82 
(2004) 99-112. 
[15] E.P. Kennedy, S.B. Weiss, The function of cytidine coenzymes in the biosynthesis of 
phospholipides, J Biol Chem, 222 (1956) 193-214. 
[16] A. Pagliuso, C. Valente, L.L. Giordano, A. Filograna, G. Li, D. Circolo, G. Turacchio, V.M. 
Marzullo, L. Mandrich, M.A. Zhukovsky, F. Formiggini, R.S. Polishchuk, D. Corda, A. Luini, 
Golgi membrane fission requires the CtBP1-S/BARS-induced activation of lysophosphatidic 
acid acyltransferase δ, Nature Communications, 7 (2016) 12148. 
 125 
[17] J.E. Vance, Phospholipid synthesis in a membrane fraction associated with mitochondria, J 
Biol Chem, 265 (1990) 7248-7256. 
[18] M. Golczak, P.D. Kiser, A.E. Sears, D.T. Lodowski, W.S. Blaner, K. Palczewski, Structural 
basis for the acyltransferase activity of lecithin:retinol acyltransferase-like proteins, J Biol Chem, 
287 (2012) 23790-23807. 
[19] E.B. Mardian, R.M. Bradley, R.E. Duncan, The HRASLS (PLA/AT) subfamily of enzymes, 
Journal of biomedical science, 22 (2015) 99. 
[20] C. Sers, U. Emmenegger, K. Husmann, K. Bucher, A.C. Andres, R. Schafer, Growth-
inhibitory activity and downregulation of the class II tumor-suppressor gene H-rev107 in tumor 
cell lines and experimental tumors, J Cell Biol, 136 (1997) 935-944. 
[21] K. Roder, K.H. Kim, H.S. Sul, Induction of murine H-rev107 gene expression by growth 
arrest and histone acetylation: involvement of an Sp1/Sp3-binding GC-box, Biochemical and 
biophysical research communications, 294 (2002) 63-70. 
[22] K. Roder, M.J. Latasa, H.S. Sul, Silencing of the mouse H-rev107 gene encoding a class II 
tumor suppressor by CpG methylation, J Biol Chem, 277 (2002) 30543-30550. 
[23] K. Roder, M.J. Latasa, H.S. Sul, Murine H-rev107 gene encoding a class II tumor 
suppressor: gene organization and identification of an Sp1/Sp3-binding GC-box required for its 
transcription, Biochemical and biophysical research communications, 293 (2002) 793-799. 
[24] B. Casanova, M.T. de la Fuente, M. Garcia-Gila, L. Sanz, A. Silva, J.A. Garcia-Marco, A. 
Garcia-Pardo, The class II tumor-suppressor gene RARRES3 is expressed in B cell lymphocytic 
leukemias and down-regulated with disease progression, Leukemia, 15 (2001) 1521-1526. 
[25] I. Nazarenko, R. Schafer, C. Sers, Mechanisms of the HRSL3 tumor suppressor function in 
ovarian carcinoma cells, Journal of cell science, 120 (2007) 1393-1404. 
[26] T. Uyama, J. Morishita, X.H. Jin, Y. Okamoto, K. Tsuboi, N. Ueda, The tumor suppressor 
gene H-Rev107 functions as a novel Ca2+-independent cytosolic phospholipase A1/2 of the thiol 
hydrolase type, J Lipid Res, 50 (2009) 685-693. 
[27] H. Ito, H. Akiyama, C. Shigeno, T. Nakamura, Isolation, characterization, and chromosome 
mapping of a human A-C1 Ha-Ras suppressor gene (HRASLS), Cytogenetics and cell genetics, 
93 (2001) 36-39. 
[28] R.Y. Shyu, Y.C. Hsieh, F.M. Tsai, C.C. Wu, S.Y. Jiang, Cloning and functional 
characterization of the HRASLS2 gene, Amino acids, 35 (2008) 129-137. 
[29] D. DiSepio, C. Ghosn, R.L. Eckert, A. Deucher, N. Robinson, M. Duvic, R.A. 
Chandraratna, S. Nagpal, Identification and characterization of a retinoid-induced class II tumor 
suppressor/growth regulatory gene, Proc Natl Acad Sci U S A, 95 (1998) 14811-14815. 
[30] S.L. Huang, R.Y. Shyu, M.Y. Yeh, S.Y. Jiang, Cloning and characterization of a novel 
retinoid-inducible gene 1(RIG1) deriving from human gastric cancer cells, Molecular and 
cellular endocrinology, 159 (2000) 15-24. 
[31] X.H. Jin, Y. Okamoto, J. Morishita, K. Tsuboi, T. Tonai, N. Ueda, Discovery and 
characterization of a Ca2+-independent phosphatidylethanolamine N-acyltransferase generating 
the anandamide precursor and its congeners, J Biol Chem, 282 (2007) 3614-3623. 
[32] A. Hajnal, R. Klemenz, R. Schafer, Subtraction cloning of H-rev107, a gene specifically 
expressed in H-ras resistant fibroblasts, Oncogene, 9 (1994) 479-490. 
[33] H. Akiyama, Y. Hiraki, M. Noda, C. Shigeno, H. Ito, T. Nakamura, Molecular cloning and 
biological activity of a novel Ha-Ras suppressor gene predominantly expressed in skeletal 
muscle, heart, brain, and bone marrow by differential display using clonal mouse EC cells, 
ATDC5, J Biol Chem, 274 (1999) 32192-32197. 
 126 
[34] Y. Yamano, A. Asano, K. Ohyama, M. Ohta, R. Nishio, I. Morishima, Expression of the 
Ha-ras suppressor family member 5 gene in the maturing rat testis, Bioscience, biotechnology, 
and biochemistry, 72 (2008) 1360-1363. 
[35] T. Uyama, N. Ikematsu, M. Inoue, N. Shinohara, X.H. Jin, K. Tsuboi, T. Tonai, A. 
Tokumura, N. Ueda, Generation of N-acylphosphatidylethanolamine by members of the 
phospholipase A/acyltransferase (PLA/AT) family, J Biol Chem, 287 (2012) 31905-31919. 
[36] X.H. Jin, T. Uyama, J. Wang, Y. Okamoto, T. Tonai, N. Ueda, cDNA cloning and 
characterization of human and mouse Ca(2+)-independent phosphatidylethanolamine N-
acyltransferases, Biochim Biophys Acta, 1791 (2009) 32-38. 
[37] N.C.f.B.I. National Library of Medicine (US), Hrasls HRAS-like suppressor [ Mus musculus 
(house mouse) ], in, Bethesda (MD), 2017. 
[38] N.C.f.B.I. National Library of Medicine (US), Pla2g16 phospholipase A2, group XVI [ Mus 
musculus (house mouse) ], in, Bethesda (MD), 2017. 
[39] N.C.f.B.I. National Library of Medicine (US), Hrasls5 HRAS-like suppressor family, 
member 5 [ Mus musculus (house mouse) ], in, Bethesda (MD), 2017. 
[40] T. Uyama, K. Tsuboi, N. Ueda, An involvement of phospholipase A/acyltransferase family 
proteins in peroxisome regulation and plasmalogen metabolism, FEBS Lett, 591 (2017) 2745-
2760. 
[41] C.M. Vaccari, M.V. Romanini, I. Musante, E. Tassano, S. Gimelli, M.T. Divizia, M. Torre, 
C.G. Morovic, M. Lerone, R. Ravazzolo, A. Puliti, De novo deletion of chromosome 11q12.3 in 
monozygotic twins affected by Poland Syndrome, BMC medical genetics, 15 (2014) 63. 
[42] V. Anantharaman, L. Aravind, Evolutionary history, structural features and biochemical 
diversity of the NlpC/P60 superfamily of enzymes, Genome biology, 4 (2003) R11. 
[43] F. Sievers, A. Wilm, D. Dineen, T.J. Gibson, K. Karplus, W. Li, R. Lopez, H. McWilliam, 
M. Remmert, J. Söding, J.D. Thompson, D.G. Higgins, Fast, scalable generation of high‐quality 
protein multiple sequence alignments using Clustal Omega, Molecular Systems Biology, 7 
(2011). 
[44] A.E. Sears, K. Palczewski, Lecithin:Retinol Acyltransferase: A Key Enzyme Involved in the 
Retinoid (visual) Cycle, Biochemistry, 55 (2016) 3082-3091. 
[45] N. Shinohara, T. Uyama, X.H. Jin, K. Tsuboi, T. Tonai, H. Houchi, N. Ueda, 
Enzymological analysis of the tumor suppressor A-C1 reveals a novel group of phospholipid-
metabolizing enzymes, J Lipid Res, 52 (2011) 1927-1935. 
[46] T. Uyama, X.H. Jin, K. Tsuboi, T. Tonai, N. Ueda, Characterization of the human tumor 
suppressors TIG3 and HRASLS2 as phospholipid-metabolizing enzymes, Biochim Biophys 
Acta, 1791 (2009) 1114-1124. 
[47] Z. Hussain, T. Uyama, K. Kawai, I.A.S. Rahman, K. Tsuboi, N. Araki, N. Ueda, 
Comparative analyses of isoforms of the calcium-independent phosphatidylethanolamine N-
acyltransferase PLAAT-1 in humans and mice, Journal of lipid research, 57 (2016) 2051-2060. 
[48] R.E. Duncan, E. Sarkadi-Nagy, K. Jaworski, M. Ahmadian, H.S. Sul, Identification and 
functional characterization of adipose-specific phospholipase A2 (AdPLA), J Biol Chem, 283 
(2008) 25428-25436. 
[49] F.M. Tsai, R.Y. Shyu, S.Y. Jiang, RIG1 suppresses Ras activation and induces cellular 
apoptosis at the Golgi apparatus, Cell Signal, 19 (2007) 989-999. 
[50] S.L. Huang, R.Y. Shyu, M.Y. Yeh, S.Y. Jiang, The retinoid-inducible gene I: effect on 
apoptosis and mitogen-activated kinase signal pathways, Anticancer research, 22 (2002) 799-
804. 
 127 
[51] H. Wei, L. Wang, X. Ren, W. Yu, J. Lin, C. Jin, B. Xia, Structural and functional 
characterization of tumor suppressors TIG3 and H-REV107, FEBS Lett, 589 (2015) 1179-1186. 
[52] K. Jaworski, M. Ahmadian, R.E. Duncan, E. Sarkadi-Nagy, K.A. Varady, M.K. Hellerstein, 
H.Y. Lee, V.T. Samuel, G.I. Shulman, K.H. Kim, S. de Val, C. Kang, H.S. Sul, AdPLA ablation 
increases lipolysis and prevents obesity induced by high-fat feeding or leptin deficiency, Nature 
medicine, 15 (2009) 159-168. 
[53] T. Uyama, M. Inoue, Y. Okamoto, N. Shinohara, T. Tai, K. Tsuboi, T. Inoue, A. Tokumura, 
N. Ueda, Involvement of phospholipase A/acyltransferase-1 in N-acylphosphatidylethanolamine 
generation, Biochim Biophys Acta, 1831 (2013) 1690-1701. 
[54] N. Ueda, K. Tsuboi, T. Uyama, N-acylethanolamine metabolism with special reference to 
N-acylethanolamine-hydrolyzing acid amidase (NAAA), Progress in lipid research, 49 (2010) 
299-315. 
[55] N. Ueda, K. Tsuboi, T. Uyama, Enzymological studies on the biosynthesis of N-
acylethanolamines, Biochim Biophys Acta, 1801 (2010) 1274-1285. 
[56] D.E. Epps, V. Natarajan, P.C. Schmid, H.O. Schmid, Accumulation of N-acylethanolamine 
glycerophospholipids in infarcted myocardium, Biochim Biophys Acta, 618 (1980) 420-430. 
[57] D.E. Epps, P.C. Schmid, V. Natarajan, H.H. Schmid, N-Acylethanolamine accumulation in 
infarcted myocardium, Biochemical and biophysical research communications, 90 (1979) 628-
633. 
[58] B. Moesgaard, G. Petersen, J.W. Jaroszewski, H.S. Hansen, Age dependent accumulation of 
N-acyl-ethanolamine phospholipids in ischemic rat brain. A (31)P NMR and enzyme activity 
study, J Lipid Res, 41 (2000) 985-990. 
[59] P.C. Schmid, R.J. Krebsbach, S.R. Perry, T.M. Dettmer, J.L. Maasson, H.H. Schmid, 
Occurrence and postmortem generation of anandamide and other long-chain N-
acylethanolamines in mammalian brain, FEBS Lett, 375 (1995) 117-120. 
[60] W. Devane, L. Hanus, A. Breuer, R. Pertwee, L. Stevenson, G. Griffin, D. Gibson, A. 
Mandelbaum, A. Etinger, R. Mechoulam, Isolation and structure of a brain constituent that binds 
to the cannabinoid receptor, Science (New York, N.Y.), 258 (1992) 1946-1949. 
[61] I. Brown, M.G. Cascio, K.W. Wahle, R. Smoum, R. Mechoulam, R.A. Ross, R.G. Pertwee, 
S.D. Heys, Cannabinoid receptor-dependent and -independent anti-proliferative effects of 
omega-3 ethanolamides in androgen receptor-positive and -negative prostate cancer cell lines, 
Carcinogenesis, 31 (2010) 1584-1591. 
[62] F. Rodriguez de Fonseca, M. Navarro, R. Gomez, L. Escuredo, F. Nava, J. Fu, E. Murillo-
Rodriguez, A. Giuffrida, J. LoVerme, S. Gaetani, S. Kathuria, C. Gall, D. Piomelli, An anorexic 
lipid mediator regulated by feeding, Nature, 414 (2001) 209-212. 
[63] T. Sugiura, S. Kishimoto, S. Oka, M. Gokoh, Biochemistry, pharmacology and physiology 
of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, Progress in lipid 
research, 45 (2006) 405-446. 
[64] M. Van Der Stelt, V. Di Marzo, Endovanilloids. Putative endogenous ligands of transient 
receptor potential vanilloid 1 channels, Eur J Biochem, 271 (2004) 1827-1834. 
[65] R.A. Ross, The enigmatic pharmacology of GPR55, Trends in pharmacological sciences, 30 
(2009) 156-163. 
[66] H.A. Overton, A.J. Babbs, S.M. Doel, M.C. Fyfe, L.S. Gardner, G. Griffin, H.C. Jackson, 
M.J. Procter, C.M. Rasamison, M. Tang-Christensen, P.S. Widdowson, G.M. Williams, C. 
Reynet, Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in 
the discovery of small-molecule hypophagic agents, Cell Metab, 3 (2006) 167-175. 
 128 
[67] J. Lo Verme, J. Fu, G. Astarita, G. La Rana, R. Russo, A. Calignano, D. Piomelli, The 
nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory 
actions of palmitoylethanolamide, Molecular pharmacology, 67 (2005) 15-19. 
[68] J. Fu, S. Gaetani, F. Oveisi, J. Lo Verme, A. Serrano, F. Rodriguez De Fonseca, A. 
Rosengarth, H. Luecke, B. Di Giacomo, G. Tarzia, D. Piomelli, Oleylethanolamide regulates 
feeding and body weight through activation of the nuclear receptor PPAR-alpha, Nature, 425 
(2003) 90-93. 
[69] P.C. Schmid, P.V. Reddy, V. Natarajan, H.H. Schmid, Metabolism of N-acylethanolamine 
phospholipids by a mammalian phosphodiesterase of the phospholipase D type, J Biol Chem, 
258 (1983) 9302-9306. 
[70] V. Natarajan, P.C. Schmid, P.V. Reddy, H.H. Schmid, Catabolism of N-acylethanolamine 
phospholipids by dog brain preparations, J Neurochem, 42 (1984) 1613-1619. 
[71] Y. Okamoto, K. Tsuboi, N. Ueda, Enzymatic formation of anandamide, Vitamins and 
hormones, 81 (2009) 1-24. 
[72] D. Leung, A. Saghatelian, G.M. Simon, B.F. Cravatt, Inactivation of N-acyl 
phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of 
endocannabinoids, Biochemistry, 45 (2006) 4720-4726. 
[73] G.M. Simon, B.F. Cravatt, Endocannabinoid biosynthesis proceeding through 
glycerophospho-N-acyl ethanolamine and a role for alpha/beta-hydrolase 4 in this pathway, J 
Biol Chem, 281 (2006) 26465-26472. 
[74] G.M. Simon, B.F. Cravatt, Anandamide biosynthesis catalyzed by the phosphodiesterase 
GDE1 and detection of glycerophospho-N-acyl ethanolamine precursors in mouse brain, J Biol 
Chem, 283 (2008) 9341-9349. 
[75] J. Liu, L. Wang, J. Harvey-White, B.X. Huang, H.Y. Kim, S. Luquet, R.D. Palmiter, G. 
Krystal, R. Rai, A. Mahadevan, R.K. Razdan, G. Kunos, Multiple pathways involved in the 
biosynthesis of anandamide, Neuropharmacology, 54 (2008) 1-7. 
[76] J. Liu, L. Wang, J. Harvey-White, D. Osei-Hyiaman, R. Razdan, Q. Gong, A.C. Chan, Z. 
Zhou, B.X. Huang, H.Y. Kim, G. Kunos, A biosynthetic pathway for anandamide, Proc Natl 
Acad Sci U S A, 103 (2006) 13345-13350. 
[77] Y.-X. Sun, K. Tsuboi, Y. Okamoto, T. Tonai, M. Murakami, I. Kudo, N. Ueda, Biosynthesis 
of anandamide and N-palmitoylethanolamine by sequential actions of phospholipase A2 and 
lysophospholipase D, Biochemical Journal, 380 (2004) 749. 
[78] B. Zheng, C.P. Berrie, D. Corda, M.G. Farquhar, GDE1/MIR16 is a glycerophosphoinositol 
phosphodiesterase regulated by stimulation of G protein-coupled receptors, Proc Natl Acad Sci 
U S A, 100 (2003) 1745-1750. 
[79] G.M. Simon, B.F. Cravatt, Characterization of mice lacking candidate N-acyl ethanolamine 
biosynthetic enzymes provides evidence for multiple pathways that contribute to 
endocannabinoid production in vivo, Molecular bioSystems, 6 (2010) 1411-1418. 
[80] S. Cohen, H. Dadi, E. Shaoul, N. Sharfe, C.M. Roifman, Cloning and characterization of a 
lymphoid-specific, inducible human protein tyrosine phosphatase, Lyp, Blood, 93 (1999) 2013-
2024. 
[81] H. An, H. Xu, M. Zhang, J. Zhou, T. Feng, C. Qian, R. Qi, X. Cao, Src homology 2 domain-
containing inositol-5-phosphatase 1 (SHIP1) negatively regulates TLR4-mediated LPS response 
primarily through a phosphatase activity- and PI-3K-independent mechanism, Blood, 105 (2005) 
4685. 
 129 
[82] N. Ueda, Y. Kurahashi, S. Yamamoto, T. Tokunaga, Partial purification and 
characterization of the porcine brain enzyme hydrolyzing and synthesizing anandamide, J Biol 
Chem, 270 (1995) 23823-23827. 
[83] K.K. Kruszka, R.W. Gross, The ATP- and CoA-independent synthesis of 
arachidonoylethanolamide. A novel mechanism underlying the synthesis of the endogenous 
ligand of the cannabinoid receptor, J Biol Chem, 269 (1994) 14345-14348. 
[84] W.A. Devane, J. Axelrod, Enzymatic synthesis of anandamide, an endogenous ligand for 
the cannabinoid receptor, by brain membranes, Proc Natl Acad Sci U S A, 91 (1994) 6698-6701. 
[85] J.M. McCue, W.J. Driscoll, G.P. Mueller, In vitro synthesis of arachidonoyl amino acids by 
cytochrome c, Prostaglandins & Other Lipid Mediators, 90 (2009) 42-48. 
[86] G. Arreaza, W.A. Devane, R.L. Omeir, G. Sajnani, J. Kunz, B.F. Cravatt, D.G. Deutsch, 
The cloned rat hydrolytic enzyme responsible for the breakdown of anandamide also catalyzes 
its formation via the condensation of arachidonic acid and ethanolamine, Neuroscience letters, 
234 (1997) 59-62. 
[87] Y. Kurahashi, N. Ueda, H. Suzuki, M. Suzuki, S. Yamamoto, Reversible hydrolysis and 
synthesis of anandamide demonstrated by recombinant rat fatty-acid amide hydrolase, 
Biochemical and biophysical research communications, 237 (1997) 512-515. 
[88] K. Katayama, N. Ueda, I. Katoh, S. Yamamoto, Equilibrium in the hydrolysis and synthesis 
of cannabimimetic anandamide demonstrated by a purified enzyme, Biochim Biophys Acta, 
1440 (1999) 205-214. 
[89] D.G. Deutsch, S.A. Chin, Enzymatic synthesis and degradation of anandamide, a 
cannabinoid receptor agonist, Biochemical Pharmacology, 46 (1993) 791-796. 
[90] B.Q. Wei, T.S. Mikkelsen, M.K. McKinney, E.S. Lander, B.F. Cravatt, A second fatty acid 
amide hydrolase with variable distribution among placental mammals, J Biol Chem, 281 (2006) 
36569-36578. 
[91] M. Kaczocha, S.T. Glaser, J. Chae, D.A. Brown, D.G. Deutsch, Lipid droplets are novel 
sites of N-acylethanolamine inactivation by fatty acid amide hydrolase-2, J Biol Chem, 285 
(2010) 2796-2806. 
[92] N. Ueda, K. Yamanaka, Y. Terasawa, S. Yamamoto, An acid amidase hydrolyzing 
anandamide as an endogenous ligand for cannabinoid receptors, FEBS Lett, 454 (1999) 267-270. 
[93] N. Ueda, K. Yamanaka, S. Yamamoto, Purification and characterization of an acid amidase 
selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance, J 
Biol Chem, 276 (2001) 35552-35557. 
[94] K. Tsuboi, Y.X. Sun, Y. Okamoto, N. Araki, T. Tonai, N. Ueda, Molecular characterization 
of N-acylethanolamine-hydrolyzing acid amidase, a novel member of the choloylglycine 
hydrolase family with structural and functional similarity to acid ceramidase, J Biol Chem, 280 
(2005) 11082-11092. 
[95] S.F. Yet, S. Lee, Y.T. Hahm, H.S. Sul, Expression and identification of p90 as the murine 
mitochondrial glycerol-3-phosphate acyltransferase, Biochemistry, 32 (1993) 9486-9491. 
[96] T.M. Lewin, N.M. Schwerbrock, D.P. Lee, R.A. Coleman, Identification of a new glycerol-
3-phosphate acyltransferase isoenzyme, mtGPAT2, in mitochondria, J Biol Chem, 279 (2004) 
13488-13495. 
[97] J. Cao, J.L. Li, D. Li, J.F. Tobin, R.E. Gimeno, Molecular identification of microsomal acyl-
CoA:glycerol-3-phosphate acyltransferase, a key enzyme in de novo triacylglycerol synthesis, 
Proc Natl Acad Sci U S A, 103 (2006) 19695-19700. 
 130 
[98] C.A. Nagle, L. Vergnes, H. Dejong, S. Wang, T.M. Lewin, K. Reue, R.A. Coleman, 
Identification of a novel sn-glycerol-3-phosphate acyltransferase isoform, GPAT4, as the enzyme 
deficient in Agpat6-/- mice, J Lipid Res, 49 (2008) 823-831. 
[99] S. Cases, S.J. Smith, Y.W. Zheng, H.M. Myers, S.R. Lear, E. Sande, S. Novak, C. Collins, 
C.B. Welch, A.J. Lusis, S.K. Erickson, R.V. Farese, Jr., Identification of a gene encoding an acyl 
CoA:diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis, Proc Natl Acad 
Sci U S A, 95 (1998) 13018-13023. 
[100] K.D. Lardizabal, J.T. Mai, N.W. Wagner, A. Wyrick, T. Voelker, D.J. Hawkins, DGAT2 is 
a new diacylglycerol acyltransferase gene family: purification, cloning, and expression in insect 
cells of two polypeptides from Mortierella ramanniana with diacylglycerol acyltransferase 
activity, J Biol Chem, 276 (2001) 38862-38869. 
[101] S.J. Stone, Z. Cui, J.E. Vance, Cloning and expression of mouse liver phosphatidylserine 
synthase-1 cDNA. Overexpression in rat hepatoma cells inhibits the CDP-ethanolamine pathway 
for phosphatidylethanolamine biosynthesis, J Biol Chem, 273 (1998) 7293-7302. 
[102] S.J. Stone, J.E. Vance, Cloning and expression of murine liver phosphatidylserine synthase 
(PSS)-2: differential regulation of phospholipid metabolism by PSS1 and PSS2, The 
Biochemical journal, 342 ( Pt 1) (1999) 57-64. 
[103] A. Lykidis, P.D. Jackson, C.O. Rock, S. Jackowski, The role of CDP-diacylglycerol 
synthetase and phosphatidylinositol synthase activity levels in the regulation of cellular 
phosphatidylinositol content, J Biol Chem, 272 (1997) 33402-33409. 
[104] G. Daum, Lipids of mitochondria, Biochim Biophys Acta, 822 (1985) 1-42. 
[105] A. Diagne, J. Fauvel, M. Record, H. Chap, L. Douste-Blazy, Studies on ether 
phospholipids. II. Comparative composition of various tissues from human, rat and guinea pig, 
Biochim Biophys Acta, 793 (1984) 221-231. 
[106] H.R. Modi, S.S. Katyare, M.A. Patel, Ageing-induced alterations in lipid/phospholipid 
profiles of rat brain and liver mitochondria: implications for mitochondrial energy-linked 
functions, The Journal of membrane biology, 221 (2008) 51-60. 
[107] Y. Zhang, A.J. McCartney, S.N. Zolov, C.J. Ferguson, M.H. Meisler, M.A. Sutton, L.S. 
Weisman, Modulation of synaptic function by VAC14, a protein that regulates the 
phosphoinositides PI(3,5)P(2) and PI(5)P, The EMBO journal, 31 (2012) 3442-3456. 
[108] M. Vicinanza, G. D'Angelo, A. Di Campli, M.A. De Matteis, Function and dysfunction of 
the PI system in membrane trafficking, 2008. 
[109] T. Ueno, B.H. Falkenburger, C. Pohlmeyer, T. Inoue, Triggering actin comets versus 
membrane ruffles: distinctive effects of phosphoinositides on actin reorganization, Science 
signaling, 4 (2011) ra87. 
[110] P.P. Sanna, M. Cammalleri, F. Berton, C. Simpson, R. Lutjens, F.E. Bloom, W. 
Francesconi, Phosphatidylinositol 3-kinase is required for the expression but not for the 
induction or the maintenance of long-term potentiation in the hippocampal CA1 region, The 
Journal of neuroscience : the official journal of the Society for Neuroscience, 22 (2002) 3359-
3365. 
[111] K.L. Arendt, M. Royo, M. Fernandez-Monreal, S. Knafo, C.N. Petrok, J.R. Martens, J.A. 
Esteban, PIP3 controls synaptic function by maintaining AMPA receptor clustering at the 
postsynaptic membrane, Nature neuroscience, 13 (2010) 36-44. 
[112] M. Schlame, K.Y. Hostetler, Cardiolipin synthase from mammalian mitochondria, 
Biochim Biophys Acta, 1348 (1997) 207-213. 
 131 
[113] K.Y. Hostetler, H. van den Bosch, L.L. van Deenen, The mechanism of cardiolipin 
biosynthesis in liver mitochondria, Biochim Biophys Acta, 260 (1972) 507-513. 
[114] G. Rocquelin, L. Guenot, P.O. Astorg, M. David, Phospholipid content and fatty acid 
composition of human heart, Lipids, 24 (1989) 775-780. 
[115] Z.Z. Guan, M. Soderberg, P. Sindelar, C. Edlund, Content and fatty acid composition of 
cardiolipin in the brain of patients with Alzheimer's disease, Neurochemistry international, 25 
(1994) 295-300. 
[116] H.J. Lee, J. Mayette, S.I. Rapoport, R.P. Bazinet, Selective remodeling of cardiolipin fatty 
acids in the aged rat heart, Lipids in health and disease, 5 (2006) 2. 
[117] M. Schlame, D. Otten, Analysis of cardiolipin molecular species by high-performance 
liquid chromatography of its derivative 1,3-bisphosphatidyl-2-benzoyl-sn-glycerol dimethyl 
ester, Anal Biochem, 195 (1991) 290-295. 
[118] Y. Xu, A. Malhotra, M. Ren, M. Schlame, The enzymatic function of tafazzin, J Biol 
Chem, 281 (2006) 39217-39224. 
[119] W.A. Taylor, G.M. Hatch, Identification of the human mitochondrial linoleoyl-coenzyme 
A monolysocardiolipin acyltransferase (MLCL AT-1), J Biol Chem, 284 (2009) 30360-30371. 
[120] W.A. Taylor, E.M. Mejia, R.W. Mitchell, P.C. Choy, G.C. Sparagna, G.M. Hatch, Human 
trifunctional protein alpha links cardiolipin remodeling to beta-oxidation, PLoS One, 7 (2012) 
e48628. 
[121] J. Cao, Y. Liu, J. Lockwood, P. Burn, Y. Shi, A novel cardiolipin-remodeling pathway 
revealed by a gene encoding an endoplasmic reticulum-associated acyl-CoA:lysocardiolipin 
acyltransferase (ALCAT1) in mouse, J Biol Chem, 279 (2004) 31727-31734. 
[122] Y. Tamura, Y. Harada, S. Nishikawa, K. Yamano, M. Kamiya, T. Shiota, T. Kuroda, O. 
Kuge, H. Sesaki, K. Imai, K. Tomii, T. Endo, Tam41 is a CDP-diacylglycerol synthase required 
for cardiolipin biosynthesis in mitochondria, Cell Metab, 17 (2013) 709-718. 
[123] K. Pfeiffer, V. Gohil, R.A. Stuart, C. Hunte, U. Brandt, M.L. Greenberg, H. Schagger, 
Cardiolipin stabilizes respiratory chain supercomplexes, J Biol Chem, 278 (2003) 52873-52880. 
[124] V.E. Kagan, J. Jiang, Z. Huang, Y.Y. Tyurina, C. Desbourdes, C. Cottet-Rousselle, H.H. 
Dar, M. Verma, V.A. Tyurin, A.A. Kapralov, A. Cheikhi, G. Mao, D. Stolz, C.M. St Croix, S. 
Watkins, Z. Shen, Y. Li, M.L. Greenberg, M. Tokarska-Schlattner, M. Boissan, M.L. Lacombe, 
R.M. Epand, C.T. Chu, R.K. Mallampalli, H. Bayir, U. Schlattner, NDPK-D (NM23-H4)-
mediated externalization of cardiolipin enables elimination of depolarized mitochondria by 
mitophagy, Cell death and differentiation, (2016). 
[125] Q. Van, J. Liu, B. Lu, K.R. Feingold, Y. Shi, R.M. Lee, G.M. Hatch, Phospholipid 
scramblase-3 regulates cardiolipin de novo biosynthesis and its resynthesis in growing HeLa 
cells, The Biochemical journal, 401 (2007) 103-109. 
[126] H. Bayir, B. Fadeel, M.J. Palladino, E. Witasp, I.V. Kurnikov, Y.Y. Tyurina, V.A. Tyurin, 
A.A. Amoscato, J. Jiang, P.M. Kochanek, S.T. DeKosky, J.S. Greenberger, A.A. Shvedova, V.E. 
Kagan, Apoptotic interactions of cytochrome c: redox flirting with anionic phospholipids within 
and outside of mitochondria, Biochim Biophys Acta, 1757 (2006) 648-659. 
[127] C.T. Chu, H. Bayir, V.E. Kagan, LC3 binds externalized cardiolipin on injured 
mitochondria to signal mitophagy in neurons: implications for Parkinson disease, Autophagy, 10 
(2014) 376-378. 
[128] C.T. Chu, J. Ji, R.K. Dagda, J.F. Jiang, Y.Y. Tyurina, A.A. Kapralov, V.A. Tyurin, N. 
Yanamala, I.H. Shrivastava, D. Mohammadyani, K.Z. Qiang Wang, J. Zhu, J. Klein-
Seetharaman, K. Balasubramanian, A.A. Amoscato, G. Borisenko, Z. Huang, A.M. Gusdon, A. 
 132 
Cheikhi, E.K. Steer, R. Wang, C. Baty, S. Watkins, I. Bahar, H. Bayir, V.E. Kagan, Cardiolipin 
externalization to the outer mitochondrial membrane acts as an elimination signal for mitophagy 
in neuronal cells, Nature cell biology, 15 (2013) 1197-1205. 
[129] W. Dowhan, Molecular basis for membrane phospholipid diversity: why are there so many 
lipids?, Annual review of biochemistry, 66 (1997) 199-232. 
[130] L. Sagan, On the origin of mitosing cells, Journal of theoretical biology, 14 (1967) 255-
274. 
[131] Z. Wang, Z. Ying, A. Bosy-Westphal, J. Zhang, B. Schautz, W. Later, S.B. Heymsfield, 
M.J. Muller, Specific metabolic rates of major organs and tissues across adulthood: evaluation by 
mechanistic model of resting energy expenditure, The American journal of clinical nutrition, 92 
(2010) 1369-1377. 
[132] V. Ristic, V. Tepsic, S.R. De Luka, S.R. Vrbaski, Phospholipid content and fatty acid 
composition in the rat heart after chronic diazepam treatment, Physiol Res, 47 (1998) 115-118. 
[133] V. Tepsic, V. Ristic, D. Ristic, N. Vasiljevic, M. Pecelj-Gec, Heart phospholipid content 
and fatty acid composition in the rat after feeding different lipid supplemented diets, Physiol Res, 
47 (1998) 413-418. 
[134] M.C. Pangborn, A New Serologically Active Phospholipid from Beef Heart, Experimental 
Biology and Medicine, 48 (1941) 484-486. 
[135] A. Emilsson, S. Gudbjarnason, Reversible alterations in fatty acid profile of 
glycerophospholipids in rat heart muscle induced by repeated norepinephrine administration, 
Biochim Biophys Acta, 750 (1983) 1-6. 
[136] Q. He, X. Han, Cardiolipin remodeling in diabetic heart, Chemistry and physics of lipids, 
179 (2014) 75-81. 
[137] J.K. Kramer, Comparative studies on composition of cardiac phospholipids in rats fed 
different vegetable oils, Lipids, 15 (1980) 651-660. 
[138] A.J. Chicco, G.C. Sparagna, S.A. McCune, C.A. Johnson, R.C. Murphy, D.A. Bolden, 
M.L. Rees, R.T. Gardner, R.L. Moore, Linoleate-rich high-fat diet decreases mortality in 
hypertensive heart failure rats compared with lard and low-fat diets, Hypertension, 52 (2008) 
549-555. 
[139] P.N. Wahjudi, K.Y. J, S.R. Martinez, J. Zhang, M. Teitell, L. Nikolaenko, R. Swerdloff, C. 
Wang, W.N. Lee, Turnover of nonessential fatty acids in cardiolipin from the rat heart, J Lipid 
Res, 52 (2011) 2226-2233. 
[140] N.M. Robblee, M.T. Clandinin, Effect of dietary fat level and polyunsaturated fatty acid 
content on the phospholipid composition of rat cardiac mitochondrial membranes and 
mitochondrial ATPase activity, J Nutr, 114 (1984) 263-269. 
[141] H. Yabuuchi, J.S. O'Brien, Brain cardiolipin: isolation and fatty acid positions, J 
Neurochem, 15 (1968) 1383-1390. 
[142] S. Courtade, G.V. Marinetti, E. Stotz, The structure and abundance of rat tissue 
cardiolipins, Biochim Biophys Acta, 137 (1967) 121-134. 
[143] J. Li, C. Romestaing, X. Han, Y. Li, X. Hao, Y. Wu, C. Sun, X. Liu, L.S. Jefferson, J. 
Xiong, K.F. Lanoue, Z. Chang, C.J. Lynch, H. Wang, Y. Shi, Cardiolipin remodeling by 
ALCAT1 links oxidative stress and mitochondrial dysfunction to obesity, Cell Metab, 12 (2010) 
154-165. 
[144] J. Miquel, A.C. Economos, J. Fleming, J.E. Johnson, Jr., Mitochondrial role in cell aging, 
Experimental gerontology, 15 (1980) 575-591. 
 133 
[145] X. Wang, W. Wang, L. Li, G. Perry, H.G. Lee, X. Zhu, Oxidative stress and mitochondrial 
dysfunction in Alzheimer's disease, Biochim Biophys Acta, 1842 (2014) 1240-1247. 
[146] J. Ji, A.E. Kline, A. Amoscato, A.K. Samhan-Arias, L.J. Sparvero, V.A. Tyurin, Y.Y. 
Tyurina, B. Fink, M.D. Manole, A.M. Puccio, D.O. Okonkwo, J.P. Cheng, H. Alexander, R.S. 
Clark, P.M. Kochanek, P. Wipf, V.E. Kagan, H. Bayir, Lipidomics identifies cardiolipin 
oxidation as a mitochondrial target for redox therapy of brain injury, Nature neuroscience, 15 
(2012) 1407-1413. 
[147] R.B. Chan, G. Di Paolo, Knockout punch: cardiolipin oxidation in trauma, Nature 
neuroscience, 15 (2012) 1325-1327. 
[148] G. Paradies, G. Petrosillo, M. Pistolese, F.M. Ruggiero, Reactive oxygen species affect 
mitochondrial electron transport complex I activity through oxidative cardiolipin damage, Gene, 
286 (2002) 135-141. 
[149] G. Paradies, G. Petrosillo, M. Pistolese, N. Di Venosa, A. Federici, F.M. Ruggiero, 
Decrease in mitochondrial complex I activity in ischemic/reperfused rat heart: involvement of 
reactive oxygen species and cardiolipin, Circulation research, 94 (2004) 53-59. 
[150] G. Paradies, G. Petrosillo, M. Pistolese, N. Di Venosa, D. Serena, F.M. Ruggiero, Lipid 
peroxidation and alterations to oxidative metabolism in mitochondria isolated from rat heart 
subjected to ischemia and reperfusion, Free radical biology & medicine, 27 (1999) 42-50. 
[151] D. Acehan, F. Vaz, R.H. Houtkooper, J. James, V. Moore, C. Tokunaga, W. Kulik, J. 
Wansapura, M.J. Toth, A. Strauss, Z. Khuchua, Cardiac and skeletal muscle defects in a mouse 
model of human Barth syndrome, J Biol Chem, 286 (2011) 899-908. 
[152] P. Vreken, F. Valianpour, L.G. Nijtmans, L.A. Grivell, B. Plecko, R.J. Wanders, P.G. 
Barth, Defective remodeling of cardiolipin and phosphatidylglycerol in Barth syndrome, 
Biochemical and biophysical research communications, 279 (2000) 378-382. 
[153] J. Shen, T. Du, X. Wang, C. Duan, G. Gao, J. Zhang, L. Lu, H. Yang, alpha-Synuclein 
amino terminus regulates mitochondrial membrane permeability, Brain research, 1591 (2014) 
14-26. 
[154] V.F. Monteiro-Cardoso, M.M. Oliveira, T. Melo, M.R. Domingues, P.I. Moreira, E. 
Ferreiro, F. Peixoto, R.A. Videira, Cardiolipin profile changes are associated to the early 
synaptic mitochondrial dysfunction in Alzheimer's disease, Journal of Alzheimer's disease : JAD, 
43 (2015) 1375-1392. 
[155] P. Divakaran, A. Venkataraman, Effect of dietary fats on oxidative phosphorylation and 
fatty acid profile of rat liver mitochondria, J Nutr, 107 (1977) 1621-1631. 
[156] S. Yamaoka-Koseki, R. Urade, M. Kito, Cardiolipins from rats fed different dietary lipids 
affect bovine heart cytochrome c oxidase activity, J Nutr, 121 (1991) 956-958. 
[157] H.K. Saini-Chohan, S. Dakshinamurti, W.A. Taylor, G.X. Shen, R. Murphy, G.C. 
Sparagna, G.M. Hatch, Persistent pulmonary hypertension results in reduced tetralinoleoyl-
cardiolipin and mitochondrial complex II + III during the development of right ventricular 
hypertrophy in the neonatal pig heart, American journal of physiology. Heart and circulatory 
physiology, 301 (2011) H1415-1424. 
[158] F.M. Ruggiero, F. Cafagna, V. Petruzzella, M.N. Gadaleta, E. Quagliariello, Lipid 
composition in synaptic and nonsynaptic mitochondria from rat brains and effect of aging, J 
Neurochem, 59 (1992) 487-491. 
[159] M. Portero-Otin, M.J. Bellmunt, M.C. Ruiz, G. Barja, R. Pamplona, Correlation of fatty 
acid unsaturation of the major liver mitochondrial phospholipid classes in mammals to their 
maximum life span potential, Lipids, 36 (2001) 491-498. 
 134 
[160] D. Dannenberger, G. Nuernberg, N. Scollan, K. Ender, K. Nuernberg, Diet alters the fatty 
acid composition of individual phospholipid classes in beef muscle, Journal of agricultural and 
food chemistry, 55 (2007) 452-460. 
[161] R.H. Houtkooper, H. Akbari, H. van Lenthe, W. Kulik, R.J. Wanders, M. Frentzen, F.M. 
Vaz, Identification and characterization of human cardiolipin synthase, FEBS Lett, 580 (2006) 
3059-3064. 
[162] K.Y. Hostetler, J.M. Galesloot, P. Boer, H. Van Den Bosch, Further studies on the 
formation of cardiolipin and phosphatidylglycerol in rat liver mitochondria. Effect of divalent 
cations and the fatty acid composition of CDP-diglyceride, Biochim Biophys Acta, 380 (1975) 
382-389. 
[163] W.C. McMurray, E.C. Jarvis, Partial purification of diphosphatidylglycerol synthetase 
from liver mitochondrial membranes, Canadian journal of biochemistry, 58 (1980) 771-776. 
[164] M. Nowicki, F. Muller, M. Frentzen, Cardiolipin synthase of Arabidopsis thaliana, FEBS 
Lett, 579 (2005) 2161-2165. 
[165] A.P. Kitson, K.D. Stark, R.E. Duncan, Enzymes in brain phospholipid docosahexaenoic 
acid accretion: a PL-ethora of potential PL-ayers, Prostaglandins, leukotrienes, and essential fatty 
acids, 87 (2012) 1-10. 
[166] W.E. Lands, Metabolism of glycerolipides; a comparison of lecithin and triglyceride 
synthesis, J Biol Chem, 231 (1958) 883-888. 
[167] A. Yamashita, T. Sugiura, K. Waku, Acyltransferases and Transacylases Involved in Fatty 
Acid Remodeling of Phospholipids and Metabolism of Bioactive Lipids in Mammalian Cells, 
Journal of Biochemistry, 122 (1997) 1-16. 
[168] T. Bayburt, B.Z. Yu, H.K. Lin, J. Browning, M.K. Jain, M.H. Gelb, Human nonpancreatic 
secreted phospholipase A2: interfacial parameters, substrate specificities, and competitive 
inhibitors, Biochemistry, 32 (1993) 573-582. 
[169] J.E. Burke, E.A. Dennis, Phospholipase A2 structure/function, mechanism, and signaling, J 
Lipid Res, 50 Suppl (2009) S237-242. 
[170] E. Diez, P. Louis-Flamberg, R.H. Hall, R.J. Mayer, Substrate specificities and properties of 
human phospholipases A2 in a mixed vesicle model, J Biol Chem, 267 (1992) 18342-18348. 
[171] L. Gesquiere, W. Cho, P.V. Subbaiah, Role of group IIa and group V secretory 
phospholipases A(2) in the metabolism of lipoproteins. Substrate specificities of the enzymes 
and the regulation of their activities by sphingomyelin, Biochemistry, 41 (2002) 4911-4920. 
[172] S. Bione, P. D'Adamo, E. Maestrini, A.K. Gedeon, P.A. Bolhuis, D. Toniolo, A novel X-
linked gene, G4.5. is responsible for Barth syndrome, Nature genetics, 12 (1996) 385-389. 
[173] S.M. Claypool, J.M. McCaffery, C.M. Koehler, Mitochondrial mislocalization and altered 
assembly of a cluster of Barth syndrome mutant tafazzins, J Cell Biol, 174 (2006) 379-390. 
[174] M. Schlame, J.A. Towbin, P.M. Heerdt, R. Jehle, S. DiMauro, T.J. Blanck, Deficiency of 
tetralinoleoyl-cardiolipin in Barth syndrome, Annals of neurology, 51 (2002) 634-637. 
[175] A.F. Neuwald, Barth syndrome may be due to an acyltransferase deficiency, Current 
biology : CB, 7 (1997) R465-466. 
[176] P.G. Barth, H.R. Scholte, J.A. Berden, J.M. Van der Klei-Van Moorsel, I.E. Luyt-Houwen, 
E.T. Van 't Veer-Korthof, J.J. Van der Harten, M.A. Sobotka-Plojhar, An X-linked mitochondrial 
disease affecting cardiac muscle, skeletal muscle and neutrophil leucocytes, Journal of the 
neurological sciences, 62 (1983) 327-355. 
 135 
[177] P.G. Barth, F. Valianpour, V.M. Bowen, J. Lam, M. Duran, F.M. Vaz, R.J. Wanders, X-
linked cardioskeletal myopathy and neutropenia (Barth syndrome): an update, American journal 
of medical genetics. Part A, 126a (2004) 349-354. 
[178] A.M. Cantlay, K. Shokrollahi, J.T. Allen, P.W. Lunt, R.A. Newbury-Ecob, C.G. Steward, 
Genetic analysis of the G4.5 gene in families with suspected Barth syndrome, The Journal of 
pediatrics, 135 (1999) 311-315. 
[179] M.M. Mazzocco, A.E. Henry, R.I. Kelly, Barth syndrome is associated with a cognitive 
phenotype, Journal of developmental and behavioral pediatrics : JDBP, 28 (2007) 22-30. 
[180] P.G. Barth, R.J. Wanders, P. Vreken, E.A. Janssen, J. Lam, F. Baas, X-linked 
cardioskeletal myopathy and neutropenia (Barth syndrome) (MIM 302060), J Inherit Metab Dis, 
22 (1999) 555-567. 
[181] B.J. Ma, W.A. Taylor, V.W. Dolinsky, G.M. Hatch, Acylation of monolysocardiolipin in 
rat heart, J Lipid Res, 40 (1999) 1837-1845. 
[182] W.A. Taylor, G.M. Hatch, Purification and characterization of monolysocardiolipin 
acyltransferase from pig liver mitochondria, J Biol Chem, 278 (2003) 12716-12721. 
[183] M. Danos, W.A. Taylor, G.M. Hatch, Mitochondrial monolysocardiolipin acyltransferase 
is elevated in the surviving population of H9c2 cardiac myoblast cells exposed to 2-
deoxyglucose-induced apoptosis, Biochem Cell Biol, 86 (2008) 11-20. 
[184] M.M. Wright, A.G. Howe, V. Zaremberg, Cell membranes and apoptosis: role of 
cardiolipin, phosphatidylcholine, and anticancer lipid analogues, Biochem Cell Biol, 82 (2004) 
18-26. 
[185] Y. Zhao, Y.Q. Chen, S. Li, R.J. Konrad, G. Cao, The microsomal cardiolipin remodeling 
enzyme acyl-CoA lysocardiolipin acyltransferase is an acyltransferase of multiple anionic 
lysophospholipids, J Lipid Res, 50 (2009) 945-956. 
[186] K.J. Ayre, A.J. Hulbert, Dietary fatty acid profile influences the composition of skeletal 
muscle phospholipids in rats, J Nutr, 126 (1996) 653-662. 
[187] M. Foot, T.F. Cruz, M.T. Clandinin, Influence of dietary fat on the lipid composition of rat 
brain synaptosomal and microsomal membranes, Biochemical Journal, 208 (1982) 631-640. 
[188] A. Igal, N.T. de Gomez Dumm, Dietary n-3 fatty acids influence the lipid composition and 
physical properties of liver microsomal membranes in diabetic rats, Prostaglandins, leukotrienes, 
and essential fatty acids, 56 (1997) 245-252. 
[189] M. Aoun, C. Feillet-Coudray, G. Fouret, B. Chabi, D. Crouzier, C. Ferreri, C. 
Chatgilialoglu, C. Wrutniak-Cabello, J.P. Cristol, M.A. Carbonneau, C. Coudray, Rat liver 
mitochondrial membrane characteristics and mitochondrial functions are more profoundly 
altered by dietary lipid quantity than by dietary lipid quality: effect of different nutritional lipid 
patterns, The British journal of nutrition, 107 (2012) 647-659. 
[190] T. Kamada, T. Yamashita, Y. Baba, M. Kai, S. Setoyama, Y. Chuman, S. Otsuji, Dietary 
sardine oil increases erythrocyte membrane fluidity in diabetic patients, Diabetes, 35 (1986) 604-
611. 
[191] J.E. Swanson, J.E. Kinsella, Dietary n-3 polyunsaturated fatty acids: modification of rat 
cardiac lipids and fatty acid composition, J Nutr, 116 (1986) 514-523. 
[192] S. Pepe, N. Tsuchiya, E.G. Lakatta, R.G. Hansford, PUFA and aging modulate cardiac 
mitochondrial membrane lipid composition and Ca2+ activation of PDH, The American journal 
of physiology, 276 (1999) H149-158. 
[193] S. Yamaoka, R. Urade, M. Kito, Mitochondrial function in rats is affected by modification 
of membrane phospholipids with dietary sardine oil, J Nutr, 118 (1988) 290-296. 
 136 
[194] L. Cosson, A. Toutain, G. Simard, W. Kulik, G. Matyas, A. Guichet, H. Blasco, Z. 
Maakaroun-Vermesse, M.C. Vaillant, C. Le Caignec, A. Chantepie, F. Labarthe, Barth syndrome 
in a female patient, Molecular genetics and metabolism, 106 (2012) 115-120. 
[195] L.C. Ades, A.K. Gedeon, M.J. Wilson, M. Latham, M.W. Partington, J.C. Mulley, J. 
Nelson, K. Lui, D.O. Sillence, Barth syndrome: clinical features and confirmation of gene 
localisation to distal Xq28, American journal of medical genetics, 45 (1993) 327-334. 
[196] J. Christodoulou, R.R. McInnes, V. Jay, G. Wilson, L.E. Becker, D.C. Lehotay, B.A. Platt, 
P.J. Bridge, B.H. Robinson, J.T. Clarke, Barth syndrome: clinical observations and genetic 
linkage studies, American journal of medical genetics, 50 (1994) 255-264. 
[197] A.K. Gedeon, M.J. Wilson, A.C. Colley, D.O. Sillence, J.C. Mulley, X linked fatal 
infantile cardiomyopathy maps to Xq28 and is possibly allelic to Barth syndrome, Journal of 
medical genetics, 32 (1995) 383-388. 
[198] R.I. Kelley, J.P. Cheatham, B.J. Clark, M.A. Nigro, B.R. Powell, G.W. Sherwood, J.T. 
Sladky, W.P. Swisher, X-linked dilated cardiomyopathy with neutropenia, growth retardation, 
and 3-methylglutaconic aciduria, The Journal of pediatrics, 119 (1991) 738-747. 
[199] T. Ino, W.G. Sherwood, E. Cutz, L.N. Benson, V. Rose, R.M. Freedom, Dilated 
cardiomyopathy with neutropenia, short stature, and abnormal carnitine metabolism, The Journal 
of pediatrics, 113 (1988) 511-514. 
[200] C. Rigaud, A.S. Lebre, R. Touraine, B. Beaupain, C. Ottolenghi, A. Chabli, H. Ansquer, H. 
Ozsahin, S. Di Filippo, P. De Lonlay, B. Borm, F. Rivier, M.C. Vaillant, M. Mathieu-Dramard, 
A. Goldenberg, G. Viot, P. Charron, M. Rio, D. Bonnet, J. Donadieu, Natural history of Barth 
syndrome: a national cohort study of 22 patients, Orphanet journal of rare diseases, 8 (2013) 70. 
[201] W. Kulik, H. van Lenthe, F.S. Stet, R.H. Houtkooper, H. Kemp, J.E. Stone, C.G. Steward, 
R.J. Wanders, F.M. Vaz, Bloodspot assay using HPLC-tandem mass spectrometry for detection 
of Barth syndrome, Clinical chemistry, 54 (2008) 371-378. 
[202] S.L. Clarke, A. Bowron, I.L. Gonzalez, S.J. Groves, R. Newbury-Ecob, N. Clayton, R.P. 
Martin, B. Tsai-Goodman, V. Garratt, M. Ashworth, V.M. Bowen, K.R. McCurdy, M.K. Damin, 
C.T. Spencer, M.J. Toth, R.I. Kelley, C.G. Steward, Barth syndrome, Orphanet journal of rare 
diseases, 8 (2013) 23. 
[203] P.A. Bolhuis, G.W. Hensels, T.J. Hulsebos, F. Baas, P.G. Barth, Mapping of the locus for 
X-linked cardioskeletal myopathy with neutropenia and abnormal mitochondria (Barth 
syndrome) to Xq28, American journal of human genetics, 48 (1991) 481-485. 
[204] F. Valianpour, V. Mitsakos, D. Schlemmer, J.A. Towbin, J.M. Taylor, P.G. Ekert, D.R. 
Thorburn, A. Munnich, R.J. Wanders, P.G. Barth, F.M. Vaz, Monolysocardiolipins accumulate 
in Barth syndrome but do not lead to enhanced apoptosis, J Lipid Res, 46 (2005) 1182-1195. 
[205] I.L. Gonzalez, Barth syndrome: TAZ gene mutations, mRNAs, and evolution, American 
Journal of Medical Genetics Part A, 134A (2005) 409-414. 
[206] J.J. Bissler, M. Tsoras, H.H. Goring, P. Hug, G. Chuck, E. Tombragel, C. McGraw, J. 
Schlotman, M.A. Ralston, G. Hug, Infantile dilated X-linked cardiomyopathy, G4.5 mutations, 
altered lipids, and ultrastructural malformations of mitochondria in heart, liver, and skeletal 
muscle, Laboratory investigation; a journal of technical methods and pathology, 82 (2002) 335-
344. 
[207] F.M. Vaz, R.H. Houtkooper, F. Valianpour, P.G. Barth, R.J. Wanders, Only one splice 
variant of the human TAZ gene encodes a functional protein with a role in cardiolipin 
metabolism, J Biol Chem, 278 (2003) 43089-43094. 
 137 
[208] T.J. Montine, M.D. Neely, J.F. Quinn, M.F. Beal, W.R. Markesbery, L.J. Roberts, J.D. 
Morrow, Lipid peroxidation in aging brain and Alzheimer's disease, Free radical biology & 
medicine, 33 (2002) 620-626. 
[209] D.L. Marcus, C. Thomas, C. Rodriguez, K. Simberkoff, J.S. Tsai, J.A. Strafaci, M.L. 
Freedman, Increased Peroxidation and Reduced Antioxidant Enzyme Activity in Alzheimer's 
Disease, Experimental Neurology, 150 (1998) 40-44. 
[210] L.M. Sayre, D.A. Zelasko, P.L. Harris, G. Perry, R.G. Salomon, M.A. Smith, 4-
Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's 
disease, J Neurochem, 68 (1997) 2092-2097. 
[211] W.R. Markesbery, M.A. Lovell, Four-Hydroxynonenal, a Product of Lipid Peroxidation, is 
Increased in the Brain in Alzheimer’s Disease, Neurobiology of Aging, 19 (1998) 33-36. 
[212] S. Pope, J.M. Land, S.J. Heales, Oxidative stress and mitochondrial dysfunction in 
neurodegeneration; cardiolipin a critical target?, Biochim Biophys Acta, 1777 (2008) 794-799. 
[213] P. Jenner, D.T. Dexter, J. Sian, A.H. Schapira, C.D. Marsden, Oxidative stress as a cause 
of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings 
and Queens Parkinson's Disease Research Group, Annals of neurology, 32 Suppl (1992) S82-87. 
[214] M.F. Beal, Mitochondria, oxidative damage, and inflammation in Parkinson's disease, Ann 
N Y Acad Sci, 991 (2003) 120-131. 
[215] A.W. Linnane, S. Marzuki, T. Ozawa, M. Tanaka, Mitochondrial DNA mutations as an 
important contributor to ageing and degenerative diseases, Lancet, 1 (1989) 642-645. 
[216] G. Petrosillo, F.M. Ruggiero, G. Paradies, Role of reactive oxygen species and cardiolipin 
in the release of cytochrome c from mitochondria, FASEB journal : official publication of the 
Federation of American Societies for Experimental Biology, 17 (2003) 2202-2208. 
[217] V.E. Kagan, V.A. Tyurin, J. Jiang, Y.Y. Tyurina, V.B. Ritov, A.A. Amoscato, A.N. 
Osipov, N.A. Belikova, A.A. Kapralov, V. Kini, Vlasova, II, Q. Zhao, M. Zou, P. Di, D.A. 
Svistunenko, I.V. Kurnikov, G.G. Borisenko, Cytochrome c acts as a cardiolipin oxygenase 
required for release of proapoptotic factors, Nat Chem Biol, 1 (2005) 223-232. 
[218] T. Sen, N. Sen, G. Tripathi, U. Chatterjee, S. Chakrabarti, Lipid peroxidation associated 
cardiolipin loss and membrane depolarization in rat brain mitochondria, Neurochemistry 
international, 49 (2006) 20-27. 
[219] C.E. Ellis, E.J. Murphy, D.C. Mitchell, M.Y. Golovko, F. Scaglia, G.C. Barcelo-Coblijn, 
R.L. Nussbaum, Mitochondrial lipid abnormality and electron transport chain impairment in 
mice lacking alpha-synuclein, Molecular and cellular biology, 25 (2005) 10190-10201. 
[220] N.B. Cole, D.D. Murphy, T. Grider, S. Rueter, D. Brasaemle, R.L. Nussbaum, Lipid 
droplet binding and oligomerization properties of the Parkinson's disease protein alpha-
synuclein, J Biol Chem, 277 (2002) 6344-6352. 
[221] K. Nakamura, V.M. Nemani, F. Azarbal, G. Skibinski, J.M. Levy, K. Egami, L. 
Munishkina, J. Zhang, B. Gardner, J. Wakabayashi, H. Sesaki, Y. Cheng, S. Finkbeiner, R.L. 
Nussbaum, E. Masliah, R.H. Edwards, Direct membrane association drives mitochondrial fission 
by the Parkinson disease-associated protein alpha-synuclein, J Biol Chem, 286 (2011) 20710-
20726. 
[222] M. Robotta, H.R. Gerding, A. Vogel, K. Hauser, S. Schildknecht, C. Karreman, M. Leist, 
V. Subramaniam, M. Drescher, Alpha-Synuclein Binds to the Inner Membrane of Mitochondria 
in an α-Helical Conformation, ChemBioChem, 15 (2014) 2499-2502. 
 138 
[223] I.G. Zigoneanu, Y.J. Yang, A.S. Krois, E. Haque, G.J. Pielak, Interaction of alpha-
synuclein with vesicles that mimic mitochondrial membranes, Biochim Biophys Acta, 1818 
(2012) 512-519. 
[224] H. Bayir, A.A. Kapralov, J. Jiang, Z. Huang, Y.Y. Tyurina, V.A. Tyurin, Q. Zhao, N.A. 
Belikova, Vlasova, II, A. Maeda, J. Zhu, H.M. Na, P.G. Mastroberardino, L.J. Sparvero, A.A. 
Amoscato, C.T. Chu, J.T. Greenamyre, V.E. Kagan, Peroxidase mechanism of lipid-dependent 
cross-linking of synuclein with cytochrome C: protection against apoptosis versus delayed 
oxidative stress in Parkinson disease, J Biol Chem, 284 (2009) 15951-15969. 
[225] G.C. Sparagna, A.J. Chicco, R.C. Murphy, M.R. Bristow, C.A. Johnson, M.L. Rees, M.L. 
Maxey, S.A. McCune, R.L. Moore, Loss of cardiac tetralinoleoyl cardiolipin in human and 
experimental heart failure, J Lipid Res, 48 (2007) 1559-1570. 
[226] K.C. Chatfield, G.C. Sparagna, C.C. Sucharov, S.D. Miyamoto, J.E. Grudis, R.D. Sobus, J. 
Hijmans, B.L. Stauffer, Dysregulation of cardiolipin biosynthesis in pediatric heart failure, 
Journal of molecular and cellular cardiology, 74 (2014) 251-259. 
[227] X. Liu, B. Ye, S. Miller, H. Yuan, H. Zhang, L. Tian, J. Nie, R. Imae, H. Arai, Y. Li, Z. 
Cheng, Y. Shi, Ablation of ALCAT1 mitigates hypertrophic cardiomyopathy through effects on 
oxidative stress and mitophagy, Molecular and cellular biology, 32 (2012) 4493-4504. 
[228] J. Li, X. Liu, H. Wang, W. Zhang, D.C. Chan, Y. Shi, Lysocardiolipin acyltransferase 1 
(ALCAT1) controls mitochondrial DNA fidelity and biogenesis through modulation of MFN2 
expression, Proc Natl Acad Sci U S A, 109 (2012) 6975-6980. 
[229] M.A. Kiebish, X. Han, H. Cheng, J.H. Chuang, T.N. Seyfried, Cardiolipin and electron 
transport chain abnormalities in mouse brain tumor mitochondria: lipidomic evidence supporting 
the Warburg theory of cancer, J Lipid Res, 49 (2008) 2545-2556. 
[230] L.C. Huysentruyt, L.M. Shelton, T.N. Seyfried, Influence of methotrexate and cisplatin on 
tumor progression and survival in the VM mouse model of systemic metastatic cancer, 
International Journal of Cancer, 126 (2010) 65-72. 
[231] A. Sapandowski, M. Stope, K. Evert, M. Evert, U. Zimmermann, D. Peter, I. Päge, M. 
Burchardt, L. Schild, Cardiolipin composition correlates with prostate cancer cell proliferation, 
Molecular and Cellular Biochemistry, 410 (2015) 175-185. 
[232] L.C. Huysentruyt, P. Mukherjee, D. Banerjee, L.M. Shelton, T.N. Seyfried, Metastatic 
cancer cells with macrophage properties: Evidence from a new murine tumor model, 
International Journal of Cancer, 123 (2008) 73-84. 
[233] M.A. Kiebish, X. Han, H. Cheng, J.H. Chuang, T.N. Seyfried, Brain Mitochondrial Lipid 
Abnormalities in Mice Susceptible to Spontaneous Gliomas, Lipids, 43 (2008) 951-959. 
[234] D. Acehan, A. Malhotra, Y. Xu, M. Ren, D.L. Stokes, M. Schlame, Cardiolipin affects the 
supramolecular organization of ATP synthase in mitochondria, Biophysical journal, 100 (2011) 
2184-2192. 
[235] B. Gomez, Jr., N.C. Robinson, Quantitative determination of cardiolipin in mitochondrial 
electron transferring complexes by silicic acid high-performance liquid chromatography, Anal 
Biochem, 267 (1999) 212-216. 
[236] O. Warburg, On the origin of cancer cells, Science (New York, N.Y.), 123 (1956) 309-314. 
[237] H. Cheng, D.J. Mancuso, X. Jiang, S. Guan, J. Yang, K. Yang, G. Sun, R.W. Gross, X. 
Han, Shotgun lipidomics reveals the temporally dependent, highly diversified cardiolipin profile 
in the mammalian brain: temporally coordinated postnatal diversification of cardiolipin 
molecular species with neuronal remodeling, Biochemistry, 47 (2008) 5869-5880. 
 139 
[238] M.A. Kiebish, X. Han, H. Cheng, A. Lunceford, C.F. Clarke, H. Moon, J.H. Chuang, T.N. 
Seyfried, Lipidomic analysis and electron transport chain activities in C57BL/6J mouse brain 
mitochondria, J Neurochem, 106 (2008) 299-312. 
[239] E.M. Beckman, S.A. Porcelli, C.T. Morita, S.M. Behar, S.T. Furlong, M.B. Brenner, 
Recognition of a lipid antigen by GDI-restricted [alpha][beta]+ T cells, Nature, 372 (1994) 691-
694. 
[240] M. Tsuji, Glycolipids and phospholipids as natural CD1d-binding NKT cell ligands, 
Cellular and Molecular Life Sciences CMLS, 63 (2006) 1889-1898. 
[241] D. Cox, L. Fox, R. Tian, W. Bardet, M. Skaley, D. Mojsilovic, J. Gumperz, W. 
Hildebrand, Determination of Cellular Lipids Bound to Human CD1d Molecules, PLoS ONE, 4 
(2009) e5325. 
[242] M. Dieude, H. Striegl, A.J. Tyznik, J. Wang, S.M. Behar, C.A. Piccirillo, J.S. Levine, 
D.M. Zajonc, J. Rauch, Cardiolipin binds to CD1d and stimulates CD1d-restricted gammadelta T 
cells in the normal murine repertoire, Journal of immunology (Baltimore, Md. : 1950), 186 
(2011) 4771-4781. 
[243] K. Balasubramanian, A. Maeda, J.S. Lee, D. Mohammadyani, H.H. Dar, J.F. Jiang, C.M. 
St Croix, S. Watkins, V.A. Tyurin, Y.Y. Tyurina, K. Kloditz, A. Polimova, V.I. Kapralova, Z. 
Xiong, P. Ray, J. Klein-Seetharaman, R.K. Mallampalli, H. Bayir, B. Fadeel, V.E. Kagan, 
Dichotomous roles for externalized cardiolipin in extracellular signaling: Promotion of 
phagocytosis and attenuation of innate immunity, Science signaling, 8 (2015) ra95. 
[244] M. Sorice, A. Circella, I.M. Cristea, T. Garofalo, L. Di Renzo, C. Alessandri, G. Valesini, 
M.D. Esposti, Cardiolipin and its metabolites move from mitochondria to other cellular 
membranes during death receptor-mediated apoptosis, Cell death and differentiation, 11 (2004) 
1133-1145. 
[245] D. Bloemberg, Examining the Role of Apoptotic Cell Signalling and Mitochondrial Fisson 
During Skeletal Muscle Differentiation, in, vol. MSc, University of Waterloo, 2012, pp. 95. 
[246] M.M. Bradford, A rapid and sensitive method for the quantitation of microgram quantities 
of protein utilizing the principle of protein-dye binding, Anal Biochem, 72 (1976) 248-254. 
[247] I. Dimauro, T. Pearson, D. Caporossi, M.J. Jackson, A simple protocol for the subcellular 
fractionation of skeletal muscle cells and tissue, BMC research notes, 5 (2012) 513. 
[248] M.R. Wieckowski, C. Giorgi, M. Lebiedzinska, J. Duszynski, P. Pinton, Isolation of 
mitochondria-associated membranes and mitochondria from animal tissues and cells, Nat Protoc, 
4 (2009) 1582-1590. 
[249] J. Folch, M. Lees, G.H. Sloane Stanley, A simple method for the isolation and purification 
of total lipides from animal tissues, J Biol Chem, 226 (1957) 497-509. 
[250] E.G. Bligh, W.J. Dyer, A rapid method of total lipid extraction and purification, Canadian 
journal of biochemistry and physiology, 37 (1959) 911-917. 
[251] A.H. Metherel, A.Y. Taha, H. Izadi, K.D. Stark, The application of ultrasound energy to 
increase lipid extraction throughput of solid matrix samples (flaxseed), Prostaglandins, 
leukotrienes, and essential fatty acids, 81 (2009) 417-423. 
[252] S. Afshordel, S. Hagl, D. Werner, N. Rohner, D. Kogel, N.G. Bazan, G.P. Eckert, Omega-
3 polyunsaturated fatty acids improve mitochondrial dysfunction in brain aging--impact of Bcl-2 
and NPD-1 like metabolites, Prostaglandins, leukotrienes, and essential fatty acids, 92 (2015) 23-
31. 
 140 
[253] S. Hagl, A. Kocher, C. Schiborr, S.H. Eckert, I. Ciobanu, M. Birringer, H. El-Askary, A. 
Helal, M.T. Khayyal, J. Frank, W.E. Muller, G.P. Eckert, Rice bran extract protects from 
mitochondrial dysfunction in guinea pig brains, Pharmacological research, 76 (2013) 17-27. 
[254] G. Krumschnabel, M. Fontana-Ayoub, Z. Sumbalova, J. Heidler, K. Gauper, M. Fasching, 
E. Gnaiger, Simultaneous high-resolution measurement of mitochondrial respiration and 
hydrogen peroxide production, Methods in molecular biology (Clifton, N.J.), 1264 (2015) 245-
261. 
[255] L. Lin, A.H. Metherel, P.J. Jones, R.P. Bazinet, Fatty acid amide hydrolase (FAAH) 
regulates hypercapnia/ischemia-induced increases in n-acylethanolamines in mouse brain, J 
Neurochem, 142 (2017) 662-671. 
[256] L. Lin, H. Yang, P.J. Jones, Quantitative analysis of multiple fatty acid ethanolamides 
using ultra-performance liquid chromatography-tandem mass spectrometry, Prostaglandins, 
leukotrienes, and essential fatty acids, 87 (2012) 189-195. 
[257] J. Yang, T. Huang, F. Petralia, Q. Long, B. Zhang, C. Argmann, Y. Zhao, C.V. Mobbs, 
E.E. Schadt, J. Zhu, Z. Tu, G.C. The, Synchronized age-related gene expression changes across 
multiple tissues in human and the link to complex diseases, Scientific reports, 5 (2015) 15145. 
[258] R.M. Bradley, E.B. Mardian, K.A. Moes, R.E. Duncan, Acute Fasting Induces Expression 
of Acylglycerophosphate Acyltransferase (AGPAT) Enzymes in Murine Liver, Heart, and Brain, 
Lipids, 52 (2017) 457-461. 
[259] M. Kaczocha, S. Vivieca, J. Sun, S.T. Glaser, D.G. Deutsch, Fatty Acid-binding Proteins 
Transport N-Acylethanolamines to Nuclear Receptors and Are Targets of Endocannabinoid 
Transport Inhibitors, The Journal of biological chemistry, 287 (2012) 3415-3424. 
[260] H.S. Hansen, T.A. Diep, N-acylethanolamines, anandamide and food intake, Biochem 
Pharmacol, 78 (2009) 553-560. 
[261] M. Schlame, M. Ren, Y. Xu, M.L. Greenberg, I. Haller, Molecular symmetry in 
mitochondrial cardiolipins, Chemistry and physics of lipids, 138 (2005) 38-49. 
[262] R.M. Bradley, K.D. Stark, R.E. Duncan, Influence of tissue, diet, and enzymatic 
remodeling on cardiolipin fatty acyl profile, Molecular nutrition & food research, 60 (2016) 
1804-1818. 
[263] Y. Xu, M. Condell, H. Plesken, I. Edelman-Novemsky, J. Ma, M. Ren, M. Schlame, A 
Drosophila model of Barth syndrome, Proc Natl Acad Sci U S A, 103 (2006) 11584-11588. 
[264] G. Paradies, G. Petrosillo, F.M. Ruggiero, Cardiolipin-dependent decrease of cytochrome c 
oxidase activity in heart mitochondria from hypothyroid rats, Biochim Biophys Acta, 1319 
(1997) 5-8. 
[265] G. Paradies, F.M. Ruggiero, G. Petrosillo, E. Quagliariello, Alterations in carnitine-
acylcarnitine translocase activity and in phospholipid composition in heart mitochondria from 
hypothyroid rats, Biochim Biophys Acta, 1362 (1997) 193-200. 
[266] B. O'Rourke, D.K. Reibel, Effects of adrenoceptor blockade on cardiac hypertrophy and 
myocardial phospholipids, Proceedings of the Society for Experimental Biology and Medicine. 
Society for Experimental Biology and Medicine (New York, N.Y.), 200 (1992) 95-100. 
[267] D.K. Reibel, B. O'Rourke, K.A. Foster, H. Hutchinson, C.E. Uboh, R.L. Kent, Altered 
phospholipid metabolism in pressure-overload hypertrophied hearts, American Journal of 
Physiology-Heart and Circulatory Physiology, 250 (1986) H1-H6. 
[268] R. Gredilla, M. Lopez Torres, M. Portero-Otin, R. Pamplona, G. Barja, Influence of hyper- 
and hypothyroidism on lipid peroxidation, unsaturation of phospholipids, glutathione system and 
 141 
oxidative damage to nuclear and mitochondrial DNA in mice skeletal muscle, Mol Cell 
Biochem, 221 (2001) 41-48. 
[269] G. Paradies, F.M. Ruggiero, Effect of hyperthyroidism on the transport of pyruvate in rat-
heart mitochondria, Biochim Biophys Acta, 935 (1988) 79-86. 
[270] G. Paradies, F.M. Ruggiero, G. Petrosillo, E. Quagliariello, Enhanced cytochrome oxidase 
activity and modification of lipids in heart mitochondria from hyperthyroid rats, Biochim 
Biophys Acta, 1225 (1994) 165-170. 
[271] G. Paradies, F.M. Ruggiero, G. Petrosillo, E. Quagliariello, Stimulation of carnitine 
acylcarnitine translocase activity in heart mitochondria from hyperthyroid rats, FEBS Lett, 397 
(1996) 260-262. 
[272] S.B. Vik, G. Georgevich, R.A. Capaldi, Diphosphatidylglycerol is required for optimal 
activity of beef heart cytochrome c oxidase, Proc Natl Acad Sci U S A, 78 (1981) 1456-1460. 
[273] C. Arnarez, S.J. Marrink, X. Periole, Identification of cardiolipin binding sites on 
cytochrome c oxidase at the entrance of proton channels, Scientific reports, 3 (2013) 1263. 
[274] B. Gomez, Jr., N.C. Robinson, Phospholipase digestion of bound cardiolipin reversibly 
inactivates bovine cytochrome bc1, Biochemistry, 38 (1999) 9031-9038. 
[275] Z. Beleznai, V. Jancsik, Role of cardiolipin in the functioning of mitochondrial L-glycerol-
3-phosphate dehydrogenase, Biochemical and biophysical research communications, 159 (1989) 
132-139. 
[276] K.S. Eble, W.B. Coleman, R.R. Hantgan, C.C. Cunningham, Tightly associated cardiolipin 
in the bovine heart mitochondrial ATP synthase as analyzed by 31P nuclear magnetic resonance 
spectroscopy, J Biol Chem, 265 (1990) 19434-19440. 
[277] S.M. Claypool, Y. Oktay, P. Boontheung, J.A. Loo, C.M. Koehler, Cardiolipin defines the 
interactome of the major ADP/ATP carrier protein of the mitochondrial inner membrane, J Cell 
Biol, 182 (2008) 937-950. 
[278] A.J. Chicco, G.C. Sparagna, Role of cardiolipin alterations in mitochondrial dysfunction 
and disease, American Journal of Physiology-Cell Physiology, 292 (2007) C33-C44. 
[279] L.T. Rael, G.W. Thomas, M.L. Craun, C.G. Curtis, R. Bar-Or, D. Bar-Or, Lipid 
peroxidation and the thiobarbituric acid assay: standardization of the assay when using saturated 
and unsaturated fatty acids, Journal of biochemistry and molecular biology, 37 (2004) 749-752. 
[280] A.M. Almeida, C.R. Bertoncini, J. Borecky, N.C. Souza-Pinto, A.E. Vercesi, 
Mitochondrial DNA damage associated with lipid peroxidation of the mitochondrial membrane 
induced by Fe2+-citrate, Anais da Academia Brasileira de Ciencias, 78 (2006) 505-514. 
[281] A.M. Hruszkewycz, Evidence for mitochondrial DNA damage by lipid peroxidation, 
Biochemical and biophysical research communications, 153 (1988) 191-197. 
[282] E. Murillo-Rodriguez, K. Guzman, G. Arankowsky-Sandoval, M. Salas-Crisostomo, R. 
Jimenez-Moreno, O. Arias-Carrion, Evidence that activation of nuclear peroxisome proliferator-
activated receptor alpha (PPARalpha) modulates sleep homeostasis in rats, Brain research 
bulletin, 127 (2016) 156-163. 
[283] O. Sasso, G. Moreno-Sanz, C. Martucci, N. Realini, M. Dionisi, L. Mengatto, A. Duranti, 
G. Tarozzo, G. Tarzia, M. Mor, R. Bertorelli, A. Reggiani, D. Piomelli, Antinociceptive effects 
of the N-acylethanolamine acid amidase inhibitor ARN077 in rodent pain models, PAIN®, 154 
(2013) 350-360. 
[284] C. Solorzano, C. Zhu, N. Battista, G. Astarita, A. Lodola, S. Rivara, M. Mor, R. Russo, M. 
Maccarrone, F. Antonietti, A. Duranti, A. Tontini, S. Cuzzocrea, G. Tarzia, D. Piomelli, 
Selective <em>N</em>-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key 
 142 
role for endogenous palmitoylethanolamide in inflammation, Proceedings of the National 
Academy of Sciences, 106 (2009) 20966-20971. 
[285] S.S. Lee, W.Y. Chan, C.K. Lo, D.C. Wan, D.S. Tsang, W.T. Cheung, Requirement of 
PPARalpha in maintaining phospholipid and triacylglycerol homeostasis during energy 
deprivation, J Lipid Res, 45 (2004) 2025-2037. 
[286] B. Lu, Y.J. Jiang, Y. Zhou, F.Y. Xu, G.M. Hatch, P.C. Choy, Cloning and characterization 
of murine 1-acyl-sn-glycerol 3-phosphate acyltransferases and their regulation by PPARalpha in 
murine heart, The Biochemical journal, 385 (2005) 469-477. 
[287] Y.J. Jiang, B. Lu, F.Y. Xu, J. Gartshore, W.A. Taylor, A.J. Halayko, F.J. Gonzalez, J. 
Takasaki, P.C. Choy, G.M. Hatch, Stimulation of cardiac cardiolipin biosynthesis by PPARalpha 
activation, J Lipid Res, 45 (2004) 244-252. 
[288] G.P. Ahern, Activation of TRPV1 by the Satiety Factor Oleoylethanolamide, Journal of 
Biological Chemistry, 278 (2003) 30429-30434. 
[289] L. Pecze, W. Blum, T. Henzi, B. Schwaller, Endogenous TRPV1 stimulation leads to the 
activation of the inositol phospholipid pathway necessary for sustained Ca2+ oscillations, 
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1863 (2016) 2905-2915. 
[290] P. Movahed, B.A. Jonsson, B. Birnir, J.A. Wingstrand, T.D. Jorgensen, A. Ermund, O. 
Sterner, P.M. Zygmunt, E.D. Hogestatt, Endogenous unsaturated C18 N-acylethanolamines are 
vanilloid receptor (TRPV1) agonists, J Biol Chem, 280 (2005) 38496-38504. 
[291] D.J. Liput, E. Tsakalozou, D.C. Hammell, K.S. Paudel, K. Nixon, A.L. Stinchcomb, 
Quantification of anandamide, oleoylethanolamide and palmitoylethanolamide in rodent brain 
tissue using high performance liquid chromatography–electrospray mass spectroscopy, Journal 
of Pharmaceutical Analysis, 4 (2014) 234-241. 
[292] T. Ishida, S. Nishiumi, T. Tanahashi, A. Yamasaki, A. Yamazaki, T. Akashi, I. Miki, Y. 
Kondo, J. Inoue, S. Kawauchi, T. Azuma, M. Yoshida, S. Mizuno, Linoleoyl ethanolamide 
reduces lipopolysaccharide-induced inflammation in macrophages and ameliorates 2,4-
dinitrofluorobenzene-induced contact dermatitis in mice, European journal of pharmacology, 699 
(2013) 6-13. 
[293] B. Aryal, V.A. Rao, Deficiency in Cardiolipin Reduces Doxorubicin-Induced Oxidative 
Stress and Mitochondrial Damage in Human B-Lymphocytes, PLoS One, 11 (2016) e0158376. 
[294] F. Piscitelli, Chapter 9 - Endocannabinoidomics: “Omics” Approaches Applied to 
Endocannabinoids and Endocannabinoid-Like Mediators A2 - Marzo, Vincenzo Di, in: J. Wang 
(Ed.) The Endocannabinoidome, Academic Press, Boston, 2015, pp. 137-152. 
[295] M. Degn, K.L. Lambertsen, G. Petersen, M. Meldgaard, A. Artmann, B.H. Clausen, S.H. 
Hansen, B. Finsen, H.S. Hansen, T.M. Lund, Changes in brain levels of N‐acylethanolamines 
and 2‐arachidonoylglycerol in focal cerebral ischemia in mice, Journal of neurochemistry, 103 
(2007) 1907-1916. 
[296] M.A. Karwad, T. Macpherson, B. Wang, E. Theophilidou, S. Sarmad, D.A. Barrett, M. 
Larvin, K.L. Wright, J.N. Lund, S.E. O'Sullivan, Oleoylethanolamine and palmitoylethanolamine 
modulate intestinal permeability in vitro via TRPV1 and PPARalpha, FASEB journal : official 
publication of the Federation of American Societies for Experimental Biology, 31 (2017) 469-
481. 
[297] J.D. Brown, E. Karimian Azari, J.E. Ayala, Oleoylethanolamide: A fat ally in the fight 
against obesity, Physiology & behavior, 176 (2017) 50-58. 
 143 
[298] A. Romano, R. Coccurello, G. Giacovazzo, G. Bedse, A. Moles, S. Gaetani, 
Oleoylethanolamide: A Novel Potential Pharmacological Alternative to Cannabinoid Antagonists 
for the Control of Appetite, BioMed Research International, 2014 (2014) 203425. 
[299] M. Alhouayek, P. Bottemanne, K.V. Subramanian, D.M. Lambert, A. Makriyannis, P.D. 
Cani, G.G. Muccioli, N-Acylethanolamine-hydrolyzing acid amidase inhibition increases colon 
N-palmitoylethanolamine levels and counteracts murine colitis, FASEB journal : official 
publication of the Federation of American Societies for Experimental Biology, 29 (2015) 650-
661. 
[300] P. Garg, R.S. Duncan, S. Kaja, P. Koulen, Intracellular mechanisms of N-
acylethanolamine-mediated neuroprotection in a rat model of stroke, Neuroscience, 166 (2010) 
252-262. 
[301] T. Bandiera, S. Ponzano, D. Piomelli, Advances in the discovery of N-acylethanolamine 
acid amidase inhibitors, Pharmacological research, 86 (2014) 11-17. 
[302] R. Schiffmann, J.B. Kopp, I.H. Austin, et al., Enzyme replacement therapy in fabry 
disease: A randomized controlled trial, JAMA, 285 (2001) 2743-2749. 
[303] C. Angelini, C. Semplicini, Enzyme replacement therapy for Pompe disease, Current 
neurology and neuroscience reports, 12 (2012) 70-75. 
[304] H. Takahashi, Y. Hirai, M. Migita, Y. Seino, Y. Fukuda, H. Sakuraba, R. Kase, T. 
Kobayashi, Y. Hashimoto, T. Shimada, Long-term systemic therapy of Fabry disease in a 
knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer, Proc Natl 
Acad Sci U S A, 99 (2002) 13777-13782. 
[305] J. Park, G.J. Murray, A. Limaye, J.M. Quirk, M.P. Gelderman, R.O. Brady, P. Qasba, 
Long-term correction of globotriaosylceramide storage in Fabry mice by recombinant adeno-
associated virus-mediated gene transfer, Proc Natl Acad Sci U S A, 100 (2003) 3450-3454. 
[306] S.C. Jung, I.P. Han, A. Limaye, R. Xu, M.P. Gelderman, P. Zerfas, K. Tirumalai, G.J. 
Murray, M.J. During, R.O. Brady, P. Qasba, Adeno-associated viral vector-mediated gene 
transfer results in long-term enzymatic and functional correction in multiple organs of Fabry 
mice, Proc Natl Acad Sci U S A, 98 (2001) 2676-2681. 
[307] C. Mah, K.O. Cresawn, T.J. Fraites, Jr., C.A. Pacak, M.A. Lewis, I. Zolotukhin, B.J. 
Byrne, Sustained correction of glycogen storage disease type II using adeno-associated virus 
serotype 1 vectors, Gene therapy, 12 (2005) 1405-1409. 
[308] T.J. Fraites, Jr., M.R. Schleissing, R.A. Shanely, G.A. Walter, D.A. Cloutier, I. Zolotukhin, 
D.F. Pauly, N. Raben, P.H. Plotz, S.K. Powers, P.D. Kessler, B.J. Byrne, Correction of the 
enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus 
vectors, Molecular therapy : the journal of the American Society of Gene Therapy, 5 (2002) 571-
578. 
[309] N. Ikon, F.F. Hsu, J. Shearer, T.M. Forte, R.O. Ryan, Evaluation of cardiolipin nanodisks 
as lipidreplacement therapy for Barth syndrome, Journal of biomedical research, (2017). 
[310] N. Ikon, B. Su, F.F. Hsu, T.M. Forte, R.O. Ryan, Exogenous cardiolipin localizes to 
mitochondria and prevents TAZ knockdown-induced apoptosis in myeloid progenitor cells, 
Biochemical and biophysical research communications, 464 (2015) 580-585. 
[311] J. Fu, G. Astarita, S. Gaetani, J. Kim, B.F. Cravatt, K. Mackie, D. Piomelli, Food intake 
regulates oleoylethanolamide formation and degradation in the proximal small intestine, J Biol 
Chem, 282 (2007) 1518-1528. 
[312] J.T. Wood, J.S. Williams, L. Pandarinathan, A. Courville, M.R. Keplinger, D.R. Janero, P. 
Vouros, A. Makriyannis, C.J. Lammi-Keefe, Comprehensive profiling of the human circulating 
 144 
endocannabinoid metabolome: clinical sampling and sample storage parameters, Clinical 
chemistry and laboratory medicine : CCLM / FESCC, 46 (2008) 1289-1295. 
[313] A.E. Roberts, C. Nixon, C.G. Steward, K. Gauvreau, M. Maisenbacher, M. Fletcher, J. 
Geva, B.J. Byrne, C.T. Spencer, The Barth Syndrome Registry: distinguishing disease 
characteristics and growth data from a longitudinal study, American journal of medical genetics. 
Part A, 158a (2012) 2726-2732. 
[314] R.M. Bradley, D. Bloemberg, J.J. Aristizabal Henao, A.S. Mitchell, V.A. Fajardo, C. 
Bellissimo, E.B. Mardian, E. Bombardier, M.F. Paré, K.A. Moes, K.D. Stark, A.R. Tupling, J. 
Quadrilatero, R.E. Duncan, Lpaatd/Agpat4 deficiency impairs maximal force contractility in 
soleus and alters fibre type in extensor digitorum longus muscle Biochimica et Biophysica Acta 
(BBA) - Molecular Cell Research, Submitted November 19 2017, (2017) Manuscript ID: 
BBAMCR-17-580  
[315] R.M. Bradley, R.E. Duncan, The lysophosphatidic acid acyltransferases 
(acylglycerophosphate acyltransferases) family: one reaction, five enzymes, many roles, Current 
opinion in lipidology, (2018). 
[316] A. Bowron, J. Honeychurch, M. Williams, B. Tsai-Goodman, N. Clayton, L. Jones, G.J. 
Shortland, S.A. Qureshi, S.J. Heales, C.G. Steward, Barth syndrome without tetralinoleoyl 
cardiolipin deficiency: a possible ameliorated phenotype, J Inherit Metab Dis, 38 (2015) 279-
286. 
[317] C. Powers, Y. Huang, A. Strauss, Z. Khuchua, Diminished Exercise Capacity and 
Mitochondrial bc1 Complex Deficiency in Tafazzin-Knockdown Mice, Frontiers in physiology, 
4 (2013) 74. 
[318] S. Reynolds, Successful management of Barth syndrome: a systematic review highlighting 
the importance of a flexible and multidisciplinary approach, Journal of multidisciplinary 
healthcare, 8 (2015) 345-358. 
[319] L. van Dussen, M. Biegstraaten, C.E. Hollak, M.G. Dijkgraaf, Cost-effectiveness of 
enzyme replacement therapy for type 1 Gaucher disease, Orphanet journal of rare diseases, 9 
(2014) 51. 
[320] S.M. Rombach, C.E. Hollak, G.E. Linthorst, M.G. Dijkgraaf, Cost-effectiveness of enzyme 
replacement therapy for Fabry disease, Orphanet journal of rare diseases, 8 (2013) 29. 
[321] A.H. Sam, V. Salem, M.A. Ghatei, Rimonabant: From RIO to Ban, Journal of Obesity, 
2011 (2011) 432607. 
[322] F. Pi-Sunyer, L.J. Aronne, H.M. Heshmati, J. Devin, J. Rosenstock, R.I.-N.A.S.G. f, Effect 
of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in 
overweight or obese patients: Rio-north america: a randomized controlled trial, JAMA, 295 
(2006) 761-775. 
[323] F.A. Moreira, J.A.S. Crippa, The psychiatric side-effects of rimonabant, Revista Brasileira 
de Psiquiatria, 31 (2009) 145-153. 
[324] F. Loría, S. Petrosino, L. Mestre, A. Spagnolo, F. Correa, M. Hernangómez, C. Guaza, 
V.D. Marzo, F. Docagne, Study of the regulation of the endocannabinoid system in a virus model 
of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide, European Journal of 
Neuroscience, 28 (2008) 633-641. 
[325] B. Eberlein, C. Eicke, H.W. Reinhardt, J. Ring, Adjuvant treatment of atopic eczema: 
assessment of an emollient containing N‐palmitoylethanolamine (ATOPA study), Journal of the 
European Academy of Dermatology and Venereology, 22 (2008) 73-82. 
 145 
[326] U. Indraccolo, F. Barbieri, Effect of palmitoylethanolamide&#x2013;polydatin 
combination on chronic pelvic pain associated with endometriosis: Preliminary observations, 
European Journal of Obstetrics and Gynecology and Reproductive Biology, 150  76-79. 
[327] N.Q. Phan, D. Siepmann, I. Gralow, S. Stander, Adjuvant topical therapy with a 
cannabinoid receptor agonist in facial postherpetic neuralgia, Journal der Deutschen 
Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 8 
(2010) 88-91. 
[328] R. Conigliaro, V. Drago, P.S. Foster, C. Schievano, V. Di Marzo, Use of 
palmitoylethanolamide in the entrapment neuropathy of the median in the wrist, Minerva medica, 
102 (2011) 141-147. 
[329] A. Fan, X. Wu, H. Wu, L. Li, R. Huang, Y. Zhu, Y. Qiu, J. Fu, J. Ren, C. Zhu, 
Atheroprotective Effect of Oleoylethanolamide (OEA) Targeting Oxidized LDL, PLOS ONE, 9 
(2014) e85337. 
[330] S. Reynolds, C.M. Kreider, R. Bendixen, A mixed-methods investigation of sensory 
response patterns in Barth syndrome: a clinical phenotype?, American journal of medical 
genetics. Part A, 158a (2012) 1647-1653. 
[331] S. Reynolds, C.M. Kreider, L.E. Meeley, R.M. Bendixen, Taste perception and sensory 
sensitivity: Relationship to feeding problems in boys with Barth Syndrome, The Journal of rare 
disorders, 3 (2015) 1-9. 
[332] L.C. Cadalbert, F.N. Ghaffar, D. Stevenson, S. Bryson, F.M. Vaz, E. Gottlieb, D. 
Strathdee, Mouse Tafazzin Is Required for Male Germ Cell Meiosis and Spermatogenesis, PLoS 
One, 10 (2015) e0131066. 
[333] C.K. Phoon, D. Acehan, M. Schlame, D.L. Stokes, I. Edelman-Novemsky, D. Yu, Y. Xu, 
N. Viswanathan, M. Ren, Tafazzin knockdown in mice leads to a developmental cardiomyopathy 
with early diastolic dysfunction preceding myocardial noncompaction, Journal of the American 
Heart Association, 1 (2012). 
[334] Y. Shi, Emerging roles of cardiolipin remodeling in mitochondrial dysfunction associated 
with diabetes, obesity, and cardiovascular diseases, Journal of biomedical research, 24 (2010) 6-
15. 
[335] C.M. Julienne, M. Tardieu, S. Chevalier, M. Pinault, P. Bougnoux, F. Labarthe, C. Couet, 
S. Servais, J.-F. Dumas, Cardiolipin content is involved in liver mitochondrial energy wasting 
associated with cancer-induced cachexia without the involvement of adenine nucleotide 
translocase, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1842 (2014) 
726-733. 
[336] G. Paradies, G. Petrosillo, V. Paradies, F.M. Ruggiero, Oxidative stress, mitochondrial 
bioenergetics, and cardiolipin in aging, Free radical biology & medicine, 48 (2010) 1286-1295. 
[337] E.J. Lesnefsky, Q. Chen, C.L. Hoppel, Mitochondrial Metabolism in Aging Heart, 
Circulation research, 118 (2016) 1593-1611. 
[338] H.H. Szeto, First-in-class cardiolipin-protective compound as a therapeutic agent to restore 





Appendix A: Schematic of determining relative protein concentrations in protein generated from 
the TnT Coupled Reticulocyte Lysate System 
 
 
Appendix Figure 1: Schematic to determine relative protein concentrations from reticulocyte 
lysates.  
1 - produce reticulocyte lysates
- load 1ul of each sample into a stain-free acrylamide gel, and electrophorese gel
2
- quantify total protein per lane
- normalize all samples to the sample in lane 1
- this will give normalization values
1 2 3 4 5 6
3












- load 1 ul of sample 1 in a stain-free acrylamide gel
- load increasing concentrations of BSA as well
- electrophorese, quantify total protein/lane of sample 1, 
  and quantify total protein content of BSA bands
 [total protein/lane of sample 1]
[total protein of 1ug BSA band]
4 Perform calculations:
First, to get protein concentration of sample 1:
Next, multiply the concentration of sample 1 (ug/ul) by the normalization factors that 
have been obtained in step  2 
this will give the concentration of sample 1 in ug/uL
-- This method will give relative protein concentrations between samples  --
Method: Determining relative protein concentrations 
betweeen reticulocyte lysate samples
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Appendix Figure 3: Nucleotide alignment of long and short Hrasls1 transcript variants. 
Hrasls1_1SA      ---------------------------TGCTGGGAGAA---------------------- 
Hrasls1_1L       GAATCCGGGGATCCCATGCCTGAGGCGTGCTTGGAGGATTTGGGTGGCGGGGAGGGCGCG 
Hrasls1_1SB      ------------------------------------------------------------ 
                                                                              
 
Hrasls1_1SA      ------------------------------------------------------------ 
Hrasls1_1L       GGTCTGGGCCGAGCTCCAAAGACCAGGGGTAGGCGCCAGGGACCCCAGGATGCAGTCTGG 
Hrasls1_1SB      ------------------------------------------------------------ 
                                                                              
 
Hrasls1_1SA      ------------------------AGAAACCAA--------------GCAGGCACTG--- 
Hrasls1_1L       CAGGCGCGCGCCAGGAACCCGCGGAGGGATCAGAGGTGGCGCGGCGCGCGGACGCTGGCG 
Hrasls1_1SB      ---------------------------GATCAGAGGTGGCGCGGCGCGCGGACGCTGGCG 
                                             * **               ** * * ***    
 
Hrasls1_1SA      -----------------GGCTG----GAACTGAGCTGTGAGC---------AGGCGATTT 
Hrasls1_1L       TTGACGCAGCGGAGGGAGGCTGTGGTGGCCTTGGCTGTGGCCTTGGCCTCAGGGCGATGC 
Hrasls1_1SB      TTGACGCAGCGGAGGGAGGCTGTGGTGGCCTTGGCTGTGGCCTTGGCCTCAGGGCGATGC 
                                  *****    *  **  ******  *          ******   
 
Hrasls1_1SA      GTGT-------------GTCTGTTA---------CAGCCAGCTTGAGGG----------- 
Hrasls1_1L       GGATGGAGTCACCCAGGGTCTGCTAGCGGCACCGCAGCGAGCCCGTGGAGAACCCGGGAA 
Hrasls1_1SB      GGATGGAGTCACCCAGGGTCTGCTAGCGGCACCGCAGCGAGCCCGTGGAGAACCCGGGAA 
                 *  *             ***** **         **** ***  * **             
 
Hrasls1_1SA      ------------CTTCAGTG---TCAGGTGACCAGTCTCCA------AGATGGCGGTAAA 
Hrasls1_1L       GCCCGTCACTGCCTCCAGGGCACTAAGACAACCCAGCTTGAGC----AGATGGCGGTAAA 
Hrasls1_1SB      GCCCGTCACTGCCTCCAGGGCACTAAGACAACCCAGCTTGAGCAGGGAGATGGCGGTAAA 
                             ** *** *   * **   ***   **  *      ************* 
 
Hrasls1_1SA      TGATTGCTTCAGTCTGACCTATCCTCACAACCCACACCCAGGAGACTTGATTGAAGTGTT 
Hrasls1_1L       TGATTGCTTCAGTCTGACCTATCCTCACAACCCACACCCAGGAGACTTGATTGAAGTGTT 
Hrasls1_1SB      TGATTGCTTCAGTCTGACCTATCCTCACAACCCACACCCAGGAGACTTGATTGAAGTGTT 
                 ************************************************************ 
 
Hrasls1_1SA      CCGTCCTTGCTATCAGCACTGGGCACTGTACTTGGGTGATGGCTACGTGATCAACATTGC 
Hrasls1_1L       CCGTCCTTGCTATCAGCACTGGGCACTGTACTTGGGTGATGGCTACGTGATCAACATTGC 
Hrasls1_1SB      CCGTCCTTGCTATCAGCACTGGGCACTGTACTTGGGTGATGGCTACGTGATCAACATTGC 
                 ************************************************************ 
 
Hrasls1_1SA      ACCTATAGATGGCATTCGCTCATCATTTACAAGTGCTAAGTCCGTGTTCAGCACAAAGGC 
Hrasls1_1L       ACCTATAGATGGCATTCGCTCATCATTTACAAGTGCTAAGTCCGTGTTCAGCACAAAGGC 
Hrasls1_1SB      ACCTATAGATGGCATTCGCTCATCATTTACAAGTGCTAAGTCCGTGTTCAGCACAAAGGC 
                 ************************************************************ 
 
Hrasls1_1SA      CTTGGTGAAAATGCAGCTTTTGAAGGATGTTGTGGGAAATGACACATACAGAATAAATAA 
Hrasls1_1L       CTTGGTGAAAATGCAGCTTTTGAAGGATGTTGTGGGAAATGACACATACAGAATAAATAA 
Hrasls1_1SB      CTTGGTGAAAATGCAGCTTTTGAAGGATGTTGTGGGAAATGACACATACAGAATAAATAA 
                 ************************************************************ 
 
Hrasls1_1SA      CAAGTACGACACAACATACCCTCCTCTTCCTGTGGAGGAGGTGATACAACGGTCAGAGTT 
Hrasls1_1L       CAAGTACGACACAACATACCCTCCTCTTCCTGTGGAGGAGGTGATACAACGGTCAGAGTT 
Hrasls1_1SB      CAAGTACGACACAACATACCCTCCTCTTCCTGTGGAGGAGGTGATACAACGGTCAGAGTT 
                 ************************************************************ 
 
Hrasls1_1SA      CGCTATTGGGCAGGAAGTAGCCTATGACTTGCTGGTCAACAACTGTGAGCATTTTGTAAC 
Hrasls1_1L       CGCTATTGGGCAGGAAGTAGCCTATGACTTGCTGGTCAACAACTGTGAGCATTTTGTAAC 
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Hrasls1_1SB      CGCTATTGGGCAGGAAGTAGCCTATGACTTGCTGGTCAACAACTGTGAGCATTTTGTAAC 
                 ************************************************************ 
 
Hrasls1_1SA      CTTGCTGCGCTATGGAGAAGGAGTGTCAGAGCAGGCCAACCGAGCAATCGGCACCATCGG 
Hrasls1_1L       CTTGCTGCGCTATGGAGAAGGAGTGTCAGAGCAGGCCAACCGAGCAATCGGCACCATCGG 
Hrasls1_1SB      CTTGCTGCGCTATGGAGAAGGAGTGTCAGAGCAGGCCAACCGAGCAATCGGCACCATCGG 
                 ************************************************************ 
 
Hrasls1_1SA      ATTGGTGGCAGCTGGTATTGATATCTTCACATTCCTCGGCTTGTTTCCCAAAAGACAAAG 
Hrasls1_1L       ATTGGTGGCAGCTGGTATTGATATCTTCACATTCCTCGGCTTGTTTCCCAAAAGACAAAG 
Hrasls1_1SB      ATTGGTGGCAGCTGGTATTGATATCTTCACATTCCTCGGCTTGTTTCCCAAAAGACAAAG 
                 ************************************************************ 
 
Hrasls1_1SA      AACGAAATATTAGCAGTTTATTGAAGAGATTGGAATGAAGAAATTTGTGAGGAGAAAAAA 
Hrasls1_1L       AACGAAATATTAGCAGTTTATTGAAGAGATTGGAATGAAGAAATTTGTGAGGAGAAAAAA 
Hrasls1_1SB      AACGAAATATTAGCAGTTTATTGAAGAGATTGGAATGAAGAAATTTGTGAGGAGAAAAAA 
                 ************************************************************ 
 
Hrasls1_1SA      AAATCCTAGGGTGAATACTTATTTTGAATGCATCATTATTGCTCATGGTCCCCATGATGG 
Hrasls1_1L       AAATCCTAGGGTGAATACTTATTTTGAATGCATCATTATTGCTCATGGTCCCCATGATGG 
Hrasls1_1SB      AAATCCTAGGGTGAATACTTATTTTGAATGCATCATTATTGCTCATGGTCCCCATGATGG 
                 ************************************************************ 
 
Hrasls1_1SA      ATGGCAGACTCTGTAATAAATTGCTTGCTGATTTTAATCTTATCATTGAGCCAAGAAAAG 
Hrasls1_1L       ATGGCAGACTCTGTAATAAATTGCTTGCTGATTTTAATCTTATCATTGAGCCAAGAAAAG 
Hrasls1_1SB      ATGGCAGACTCTGTAATAAATTGCTTGCTGATTTTAATCTTATCATTGAGCCAAGAAAAG 
                 ************************************************************ 
 
Hrasls1_1SA      TTTTTCCCAACTAGCAGAGATTTGCCGTGGCAGCTTGAACAAAATGCAATTGCCTTTTGA 
Hrasls1_1L       TTTTTCCCAACTAGCAGAGATTTGCCGTGGCAGCTTGAACAAAATGCAATTGCCTTTTGA 
Hrasls1_1SB      TTTTTCCCAACTAGCAGAGATTTGCCGTGGCAGCTTGAACAAAATGCAATTGCCTTTTGA 
                 ************************************************************ 
 
Hrasls1_1SA      TCGAGCCAGCTGAGGATCTTAACAGAACCAAGACCACATTTTATCTTCTGCTGTAAATAT 
Hrasls1_1L       TCGAGCCAGCTGAGGATCTTAACAGAACCAAGACCACATTTTATCTTCTGCTGTAAATAT 
Hrasls1_1SB      TCGAGCCAGCTGAGGATCTTAACAGAACCAAGACCACATTTTATCTTCTGCTGTAAATAT 
                 ************************************************************ 
 
Hrasls1_1SA      TGTTTTCCTTTTCCCTAAGGACAGCTGTTTTGCCAGAGGTGTGGAGAACCATTTGCATAC 
Hrasls1_1L       TGTTTTCCTTTTCCCTAAGGACAGCTGTTTTGCCAGAGGTGTGGAGAACCATTTGCATAC 
Hrasls1_1SB      TGTTTTCCTTTTCCCTAAGGACAGCTGTTTTGCCAGAGGTGTGGAGAACCATTTGCATAC 
                 ************************************************************ 
 
Hrasls1_1SA      ACTGCTGAGAGACAGTTGTTAGGGCCAACATCTAAATTCCTTTTGCTTTCTTTGTCAGAA 
Hrasls1_1L       ACTGCTGAGAGACAGTTGTTAGGGCCAACATCTAAATTCCTTTTGCTTTCTTTGTCAGAA 
Hrasls1_1SB      ACTGCTGAGAGACAGTTGTTAGGGCCAACATCTAAATTCCTTTTGCTTTCTTTGTCAGAA 
                 ************************************************************ 
 
Hrasls1_1SA      AAAGGAGCGTGAACATATCCAGTAGTTTGGATACATGGATATATATCCATGATATATCCA 
Hrasls1_1L       AAAGGAGCGTGAACATATCCAGTAGTTTGGATACATGGATATATATCCATGATATATCCA 
Hrasls1_1SB      AAAGGAGCGTGAACATATCCAGTAGTTTGGATACATGGATATATATCCATGATATATCCA 
                 ************************************************************ 
 
Hrasls1_1SA      AGTACTTAAGGATCTCTGCATGACAAAGCATTTGAGGTGGTACCCCCATATTGCTGCACC 
Hrasls1_1L       AGTACTTAAGGATCTCTGCATGACAAAGCATTTGAGGTGGTACCCCCATATTGCTGCACC 
Hrasls1_1SB      AGTACTTAAGGATCTCTGCATGACAAAGCATTTGAGGTGGTACCCCCATATTGCTGCACC 
                 ************************************************************ 
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Hrasls1_1SA      TGTGTGGGTGGAGCATGTAAGAAGGAGTGGGGGACTTTTGTGTGTGCATATGTATGGAAT 
Hrasls1_1L       TGTGTGGGTGGAGCATGTAAGAAGGAGTGGGGGACTTTTGTGTGTGCATATGTATGGAAT 
Hrasls1_1SB      TGTGTGGGTGGAGCATGTAAGAAGGAGTGGGGGACTTTTGTGTGTGCATATGTATGGAAT 
                 ************************************************************ 
 
Hrasls1_1SA      TCTTATGAATGGTGTGCATGTATAGGGACGGTCTTGGTCTCACCTTTTTTATTCTTATTT 
Hrasls1_1L       TCTTATGAATGGTGTGCATGTATAGGGACGGTCTTGGTCTCACCTTTTTTATTCTTATTT 
Hrasls1_1SB      TCTTATGAATGGTGTGCATGTATAGGGACGGTCTTGGTCTCACCTTTTTTATTCTTATTT 
                 ************************************************************ 
 
Hrasls1_1SA      TATTCTTATTCTTATTTTATTTTATAATTTATAAAAGGAGACAGGGTATGCTGTCCTTTA 
Hrasls1_1L       TATTCTTATTCTTATTTTATTTTATAATTTATAAAAGGAGACAGGGTATGCTGTCCTTTA 
Hrasls1_1SB      TATTCTTATTCTTATTTTATTTTATAATTTATAAAAGGAGACAGGGTATGCTGTCCTTTA 
                 ************************************************************ 
 
Hrasls1_1SA      TAGCTTATGGCAAACTAGCTAGCCTGTGGGCATCCAGAGAGTCTCCTGTCTCTGCCTCCA 
Hrasls1_1L       TAGCTTATGGCAAACTAGCTAGCCTGTGGGCATCCAGAGAGTCTCCTGTCTCTGCCTCCA 
Hrasls1_1SB      TAGCTTATGGCAAACTAGCTAGCCTGTGGGCATCCAGAGAGTCTCCTGTCTCTGCCTCCA 
                 ************************************************************ 
 
Hrasls1_1SA      TTTCACGGTAGGAGTTCTGGAGTTACCGAAGTGAACTAACAACCCAAGCTTTCTGTGGAC 
Hrasls1_1L       TTTCACGGTAGGAGTTCTGGAGTTACCGAAGTGAACTAACAACCCAAGCTTTCTGTGGAC 
Hrasls1_1SB      TTTCACGGTAGGAGTTCTGGAGTTACCGAAGTGAACTAACAACCCAAGCTTTCTGTGGAC 
                 ************************************************************ 
 
Hrasls1_1SA      TCTGGGGATCTGAGCTCAAGACATCATGCTTATGTTTAAGATGCTTTACCCACTGAGCCC 
Hrasls1_1L       TCTGGGGATCTGAGCTCAAGACATCATGCTTATGTTTAAGATGCTTTACCCACTGAGCCC 
Hrasls1_1SB      TCTGGGGATCTGAGCTCAAGACATCATGCTTATGTTTAAGATGCTTTACCCACTGAGCCC 
                 ************************************************************ 
 
Hrasls1_1SA      CTCTCCAATCTCTCTCTCTCTCTTTCTTTCTCTCTCTCTCTCCCTTGTACGTTCAGACCC 
Hrasls1_1L       CTCTCCAATCTCTCTCTCTCTCTTTCTTTCTCTCTCTCTCTCCCTTGTACGTTCAGACCC 
Hrasls1_1SB      CTCTCCAATCTCTCTCTCTCTCTTTCTTTCTCTCTCTCTCTCCCTTGTACGTTCAGACCC 
                 ************************************************************ 
 
Hrasls1_1SA      AGTGTTCAAGACTCAGTGATGAACAATGGGCTGTCGTTTTATTGATTTAAATGGATCCCT 
Hrasls1_1L       AGTGTTCAAGACTCAGTGATGAACAATGGGCTGTCGTTTTATTGATTTAAATGGATCCCT 
Hrasls1_1SB      AGTGTTCAAGACTCAGTGATGAACAATGGGCTGTCGTTTTATTGATTTAAATGGATCCCT 
                 ************************************************************ 
 
Hrasls1_1SA      CCACATTGTGTAGTAGCTCAGTGGTTTGACCTTTGGGGCTTGGCAAGCAATCATTAATAT 
Hrasls1_1L       CCACATTGTGTAGTAGCTCAGTGGTTTGACCTTTGGGGCTTGGCAAGCAATCATTAATAT 
Hrasls1_1SB      CCACATTGTGTAGTAGCTCAGTGGTTTGACCTTTGGGGCTTGGCAAGCAATCATTAATAT 
                 ************************************************************ 
 
Hrasls1_1SA      TAATGCAAAGAGCTATATTTAAAACACAAAATTCCTCATTCCTTTAAAGATGTGAACTGT 
Hrasls1_1L       TAATGCAAAGAGCTATATTTAAAACACAAAATTCCTCATTCCTTTAAAGATGTGAACTGT 
Hrasls1_1SB      TAATGCAAAGAGCTATATTTAAAACACAAAATTCCTCATTCCTTTAAAGATGTGAACTGT 
                 ************************************************************ 
 
Hrasls1_1SA      AAATCAAGGAATCCGCTTATTTTATTCTTTTATTTTACTGATTATCCGTTGAATTAAACT 
Hrasls1_1L       AAATCAAGGAATCCGCTTATTTTATTCTTTTATTTTACTGATTATCCGTTGAATTAAACT 
Hrasls1_1SB      AAATCAAGGAATCCGCTTATTTTATTCTTTTATTTTACTGATTATCCGTTGAATTAAACT 
                 ************************************************************ 
 
Hrasls1_1SA      CCTTCTTAATGCCATTTCTGCAGAATTCTTGATAGCAGGTCAGGAGAGGTGGGACGTTAG 
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Hrasls1_1L       CCTTCTTAATGCCATTTCTGCAGAATTCTTGATAGCAGGTCAGGAGAGGTGGGACGTTAG 
Hrasls1_1SB      CCTTCTTAATGCCATTTCTGCAGAATTCTTGATAGCAGGTCAGGAGAGGTGGGACGTTAG 
                 ************************************************************ 
 
Hrasls1_1SA      TCTTTCTACATGAAGGTAGTATAAGGGCATCATGACATTACCTCATAAACCACACAGCTA 
Hrasls1_1L       TCTTTCTACATGAAGGTAGTATAAGGGCATCATGACATTACCTCATAAACCACACAGCTA 
Hrasls1_1SB      TCTTTCTACATGAAGGTAGTATAAGGGCATCATGACATTACCTCATAAACCACACAGCTA 
                 ************************************************************ 
 
Hrasls1_1SA      GCCCGGCATCCTTTTGTGCCATTATCAAAAGCATGTCAATCAATAAGGAAAGAGTGCCAG 
Hrasls1_1L       GCCCGGCATCCTTTTGTGCCATTATCAAAAGCATGTCAATCAATAAGGAAAGAGTGCCAG 
Hrasls1_1SB      GCCCGGCATCCTTTTGTGCCATTATCAAAAGCATGTCAATCAATAAGGAAAGAGTGCCAG 
                 ************************************************************ 
 
Hrasls1_1SA      TGACCATGGGGATAGAACGTGATGGAGTATGGTAAAGTCAAGTGCACAAGACTCGGTGGA 
Hrasls1_1L       TGACCATGGGGATAGAACGTGATGGAGTATGGTAAAGTCAAGTGCACAAGACTCGGTGGA 
Hrasls1_1SB      TGACCATGGGGATAGAACGTGATGGAGTATGGTAAAGTCAAGTGCACAAGACTCGGTGGA 
                 ************************************************************ 
 
Hrasls1_1SA      AAGCTCAGACCTACTTAACTGATTTGACCTTGGTGCTGGAAACACTCACACTGATGAGGG 
Hrasls1_1L       AAGCTCAGACCTACTTAACTGATTTGACCTTGGTGCTGGAAACACTCACACTGATGAGGG 
Hrasls1_1SB      AAGCTCAGACCTACTTAACTGATTTGACCTTGGTGCTGGAAACACTCACACTGATGAGGG 
                 ************************************************************ 
 
Hrasls1_1SA      TAACAGTAATGTGAACAGAACTATGTGCTGCCACTCCCATCCAGACAGAGTCCCCTCTGT 
Hrasls1_1L       TAACAGTAATGTGAACAGAACTATGTGCTGCCACTCCCATCCAGACAGAGTCCCCTCTGT 
Hrasls1_1SB      TAACAGTAATGTGAACAGAACTATGTGCTGCCACTCCCATCCAGACAGAGTCCCCTCTGT 
                 ************************************************************ 
 
Hrasls1_1SA      CCCTTCTTTACTTTTCTAACAGGCCCTTCTTGTCCGAACCTCCAGACTCATTCTTTAGTT 
Hrasls1_1L       CCCTTCTTTACTTTTCTAACAGGCCCTTCTTGTCCGAACCTCCAGACTCATTCTTTAGTT 
Hrasls1_1SB      CCCTTCTTTACTTTTCTAACAGGCCCTTCTTGTCCGAACCTCCAGACTCATTCTTTAGTT 
                 ************************************************************ 
 
Hrasls1_1SA      GTCTCAGAAGGCACGAGGTTACTTTTATCCTGAATGCAGGTCTCTGTTCCCAAATAGTAA 
Hrasls1_1L       GTCTCAGAAGGCACGAGGTTACTTTTATCCTGAATGCAGGTCTCTGTTCCCAAATAGTAA 
Hrasls1_1SB      GTCTCAGAAGGCACGAGGTTACTTTTATCCTGAATGCAGGTCTCTGTTCCCAAATAGTAA 
                 ************************************************************ 
 
Hrasls1_1SA      AGAATATTCAGTTTTCTAGAAGTTTCCTATTAAGGTAAGGGCAGCTGCAGCCTCTGGGCT 
Hrasls1_1L       AGAATATTCAGTTTTCTAGAAGTTTCCTATTAAGGTAAGGGCAGCTGCAGCCTCTGGGCT 
Hrasls1_1SB      AGAATATTCAGTTTTCTAGAAGTTTCCTATTAAGGTAAGGGCAGCTGCAGCCTCTGGGCT 
                 ************************************************************ 
 
Hrasls1_1SA      ACTTTCCCCTGGTGTGCCACCTTCTCAATAAACTATATTTGCAGGGCATTTGTCTCTGGC 
Hrasls1_1L       ACTTTCCCCTGGTGTGCCACCTTCTCAATAAACTATATTTGCAGGGCATTTGTCTCTGGC 
Hrasls1_1SB      ACTTTCCCCTGGTGTGCCACCTTCTCAATAAACTATATTTGCAGGGCATTTGTCTCTGGC 
                 ************************************************************ 
 
Hrasls1_1SA      AGAATTACACCGCCTGTCAGGAAAGGGACTAGGACTGAGAACCAAATGCCTCTTAGGGAT 
Hrasls1_1L       AGAATTACACCGCCTGTCAGGAAAGGGACTAGGACTGAGAACCAAATGCCTCTTAGGGAT 
Hrasls1_1SB      AGAATTACACCGCCTGTCAGGAAAGGGACTAGGACTGAGAACCAAATGCCTCTTAGGGAT 
                 ************************************************************ 
 
Hrasls1_1SA      TCAAATGAAACCTTTCTAGAGGACTCTGACATCTCCACTCCAGAAGAAAAGCAAAATGTT 
Hrasls1_1L       TCAAATGAAACCTTTCTAGAGGACTCTGACATCTCCACTCCAGAAGAAAAGCAAAATGTT 
Hrasls1_1SB      TCAAATGAAACCTTTCTAGAGGACTCTGACATCTCCACTCCAGAAGAAAAGCAAAATGTT 
 152 
 
                 ************************************************************ 
 
Hrasls1_1SA      AAAAGGAAAACGTCAGAAATGCACTTTTTAATCCATGGGTTTATTTCCTTATCAGTTATG 
Hrasls1_1L       AAAAGGAAAACGTCAGAAATGCACTTTTTAATCCATGGGTTTATTTCCTTATCAGTTATG 
Hrasls1_1SB      AAAAGGAAAACGTCAGAAATGCACTTTTTAATCCATGGGTTTATTTCCTTATCAGTTATG 
                 ************************************************************ 
 
Hrasls1_1SA      TGAAGCTTTGGCAGCCTTGGTTTGCTGTAAACATGGCCAACCTTAAAATGGGCAGCCCTA 
Hrasls1_1L       TGAAGCTTTGGCAGCCTTGGTTTGCTGTAAACATGGCCAACCTTAAAATGGGCAGCCCTA 
Hrasls1_1SB      TGAAGCTTTGGCAGCCTTGGTTTGCTGTAAACATGGCCAACCTTAAAATGGGCAGCCCTA 
                 ************************************************************ 
 
Hrasls1_1SA      AATAGCTGTGGTTGTTTTCCTGCAGGTACTCAATACCCACACGTTCAATGCAACTTATAC 
Hrasls1_1L       AATAGCTGTGGTTGTTTTCCTGCAGGTACTCAATACCCACACGTTCAATGCAACTTATAC 
Hrasls1_1SB      AATAGCTGTGGTTGTTTTCCTGCAGGTACTCAATACCCACACGTTCAATGCAACTTATAC 
                 ************************************************************ 
 
Hrasls1_1SA      TTGGATCAGCTATTTCCCCAACACTATGAAATATTGTCTGGGCATATTTTCAGCAGTCAG 
Hrasls1_1L       TTGGATCAGCTATTTCCCCAACACTATGAAATATTGTCTGGGCATATTTTCAGCAGTCAG 
Hrasls1_1SB      TTGGATCAGCTATTTCCCCAACACTATGAAATATTGTCTGGGCATATTTTCAGCAGTCAG 
                 ************************************************************ 
 
Hrasls1_1SA      GAATGGAGTCCACTTCTATCATGTTTCAAAAAATGGAATGTAAAGATCACCTGCATCAAG 
Hrasls1_1L       GAATGGAGTCCACTTCTATCATGTTTCAAAAAATGGAATGTAAAGATCACCTGCATCAAG 
Hrasls1_1SB      GAATGGAGTCCACTTCTATCATGTTTCAAAAAATGGAATGTAAAGATCACCTGCATCAAG 
                 ************************************************************ 
 
Hrasls1_1SA      TGATAGGTTTTTGGTAATACAAGGAAAGAAATGTCTGTATTTTTATTGAATATGTACATA 
Hrasls1_1L       TGATAGGTTTTTGGTAATACAAGGAAAGAAATGTCTGTATTTTTATTGAATATGTACATA 
Hrasls1_1SB      TGATAGGTTTTTGGTAATACAAGGAAAGAAATGTCTGTATTTTTATTGAATATGTACATA 
                 ************************************************************ 
 
Hrasls1_1SA      TAACAAATAAAATATGCTATCTAAATGTCA 
Hrasls1_1L       TAACAAATAAAATATGCTATCTAAATGTCA 
Hrasls1_1SB      TAACAAATAAAATATGCTATCTAAATGTC- 
                 *****************************  
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Appendix Figure 4: Metabolic treatment of HEK-293 cells with [14C] palmitate and NAE 
does not significantly increase [14C]cardiolipin content. 
HEK-293 cells were treated for 48 hours with [14C] palmitate and 0.1, 1, or 10 µM of PEA, 
OEA, or SEA. Total lipids were harvested and phospholipids separated by TLC. Cellular [14C] 
cardiolipin content in HEK-293 cells were treated with (A) PEA, (B) OEA, or (C) SEA. Cellular 
[14C] phosphatidylcholine content in HEK-293 cells were treated with (D) PEA, (E) OEA, or (F) 
SEA. Cellular [14C] phosphatidylethanolamine content in HEK-293 cells were treated with (G) 





Appendix D: List of buffers and components 
• Lysis Buffer 1  
o 50 mM Tris, pH 8.0, 2.4 mM EDTA, 100 mM NaCl, 0.5% w/v SDS with 
proteinase K added at a concentration of 1.0 mg/mL 
• Lysis Buffer 2  
o 100 mM Tris-HCl, pH 7.0, 10mM NaCl 
• Buffer A  
o 100 mM Tris-HCl, pH 7.4, 5 mM NaCl, 3 mM MgCl2, with 1% protease inhibitor 
cocktail 
• Buffer B  
o 50 mM Tris-HCl, pH 6.8, 1 mM EDTA, and 0.5% Triton X-100 
• Laemmeli Buffer  
o 125 mM Tris-HCl, pH 6.8, 20% glycerol, 4% SDS, 10% 2-mercaptoethanol, and 
0.05% bromophenol blue 
• Tris-Buffered Saline with Tween (TBST)  
o 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% Tween-20 
• Buffer C  
o 250 mM Sucrose, 50 mM Tris-HCl, pH 7.4, 5 mM MgCl2 
• Buffer D  
o 20 mM HEPES pH 7.9, 1.5 mM MgCl2, 0.5M NaCl, 0.2 mM EDTA, 20% (v/v) 
glycerol, 1% Triton X-100 
• Buffer E 
o 225 mM mannitol, 75 mM sucrose, 0.5 mM EGTA, 2 mM MOPS, pH 7.4 
• Buffer F 
o 225 mM mannitol, 75 mM sucrose, 30 mM Tris-HCl, pH 7.4 
• Buffer G 
o 225 mM mannitol, 75 mM sucrose, 0.5% BSA (w/v), 0.5% EGTA, 30 mM Tris-
HCl, pH 7.4 
• Buffer H 
o 225 mM mannitol, 75 mM sucrose, 0.5% BSA (w/v), 30 mM Tris-HCl, pH 7.4 
• Buffer I  
o 250 mM mannitol, 5 mM HEPES, pH 7.4, 0.5 mM EGTA 
• Buffer J 
o 225 mM mannitol, 25 mM HEPES, pH 7.4, 1 mM EGTA, 30% Percoll (w/v) 
• Acyltransferase Reaction Buffer  
o 100 mM Tris, pH 7.0, 4 mg/mL BSA 
• Transacylase Reaction Buffer  
o 50 mM Tris-HCl, pH 8.0, 2 mM DTT, 0.1% Nonidet P-40 
• Native Binding Buffer  
o 50 mM NaH2PO4, pH 8.0, 0.5 M NaCl, 10 mM imidazole, pH 6.0, final solution 
adjusted to pH 8.0 
• Native Wash Buffer  
o 50 mM NaH2PO4, pH 8.0, 0.5 M NaCl, 20 mM imidazole, pH 6.0, final solution 
adjusted to pH 8.0 
• Native Elution Buffer  
 155 
o 50 mM NaH2PO4, pH 8.0, 0.5 M NaCl, 250 mM imidazole, pH 6.0, final solution 
adjusted to pH 8.0 
• MiR05 buffer  
o 0.5 mM EGTA, 3 mM MgCl2, 60 mM lactobionic acid, 20 mM taurine, 10 mM 
potassium dihydrogenphosphate, 20 mM HEPES, 110 mM sucrose, and 1g/L 
essential fatty acid free bovine serum albumin 
• Hank’s Buffered Salt Solution 
o 0.137M NaCl, 5.4 mM KCl, 0.25 mM Na2HPO4, 0.1g glucose, 0.44 mM KH2PO4, 
1.3 mM CaCl2, 1.0 mM MgSO4, 4.2 mM NaHCO3, final solution pH adjusted to 
7.1 
• Tyrode’s solution  
o 95% O2, 5% CO2; 121 mM NaCl2, 5 mM KCl, 24 mM NaHCO3, 1.8 mM CaCl2, 




Appendix E: CL in HEK-293 cells as expressed as a percentage of total cellular PL 
 
 
Appendix Figure 5: CL as a percentage of total cellular PL in HEK-293 cells overexpressing 
control or HRASLS1 
Endogenous cardiolipin content of HEK-293 cells overexpressing control or HRASLS1 as a 




Appendix E: Relative percent of fatty acid content in HEK-293 cells overexpressing control or HRASLS1 
 
 
Appendix Figure 6: HRASLS1 overexpression in HEK-293 cells does not significantly alter relative fatty acyl composition of 
cardiolipin versus controls. 
Relative proportion of individual fatty acids within cardiolipin from control or HRASLS1-overexpressing HEK-293 cells including 
SFA (A), MUFA (B), n-6 PUFA (C), and n-3 PUFA (D). Data are means ± S.E.M. n=8-10. 
